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Soft tissue sarcomas are rare tumours of mesenchymal origin characterised by high 
biomolecular complexity and heterogeneity. The clinical management of advanced 
diseases remains a major challenge which needs new therapeutic strategies. 
Mounting evidence supports that the heparanase/heparan sulfate proteoglycan system plays 
a key role in sustaining tumour progression and dissemination and preclinical studies 
suggest its potential relevance as a therapeutic target. 
To better understand the specific role of heparanase, we performed RNA interference in 
rhabdoid tumour and synovial sarcoma models, and assessed the functional effects of 
heparanase silencing. We tested both miRNA and siRNA targeting heparanase, but only 
siRNAs were able to silence mRNA and down-regulate the protein following transient 
transfection. The reduced expression and enzymatic activity of secreted heparanase 
observed upon siRNA transfection were consistent with a strong inhibition of cell 
migration and invasion capability. The expression of pro-angiogenic factors was also 
reduced both in rhabdoid tumour and synovial sarcoma cell lines. In contrast, we observed 
that heparanase localised in specific subcellular compartments was resistant to the siRNA 
effect. 
The clinical application of siRNA-based therapeutic strategies faces significant challenges, 
mainly due to siRNA in vivo poor stability and inefficient delivery. In this work, we 
evaluated the use of different nanodelivery systems aimed at overcoming these limitations. 
The first approach consisted of hybrid nanoparticles with a silica core and a pH-responsive 
hydrogel shell. These nanoparticles showed promising features, such as remarkable loading 
and efficient release of siRNA, endo-lysosomal escape and in vivo accumulation at the 
tumour site. Nevertheless, siRNA delivered through this approach did not inhibit 
heparanase expression. The second nanodelivery system was leukosome, a biomimetic 
nanoparticle with leukocyte proteins included in a phospholipidic bilayer. Leukosomes 
efficiently delivered siRNA into the cells avoiding the endo-lysosomal entrapment. 
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Moreover, these biomimetic nanoparticles mainly accumulated at the tumour primary and 
metastatic sites. Despite these promising features, also leukosomes were unable to deliver 
an active siRNA. 
Overall, these findings demonstrate that specific inhibition of heparanase by gene silencing 
is a potential therapeutic approach for soft tissue sarcoma treatment. However, the siRNA 
delivery systems tested in this work, although promising in terms of tumour and metastasis 
targeting, still need further improvement to be suitable for nucleic acid delivery.  
 
  
6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This study was conducted under the supervision of Drs. Cinzia Lanzi and Paola Perego at 
the Molecular Pharmacology Unit, headed by Dr. Nadia Zaffaroni, at the Department of 
Applied Research & Technological Development, Fondazione IRCCS Istituto Nazionale 
dei Tumori, Milano, Italy. 
Part of the project was carried out under the supervision of Drs. Ennio Tasciotti, 
Alessandro Parodi, Francesca Taraballi and Roberto Molinaro at the Center for Biomimetic 
Medicine, Houston Methodist Research Institute, Houston, TX, USA. 
 
Table of contents 
 
 
7 
 
 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
 
  
Table of contents 
 
 
8 
ABSTRACT .......................................................................................................................... 3 
TABLE OF CONTENTS ..................................................................................................... 7 
1. INTRODUCTION ...................................................................................................... 17 
1.1. Soft tissue sarcomas ......................................................................................... 18 
1.1.1. Synovial sarcoma ........................................................................................... 20 
1.1.1.1 Synovial sarcoma therapy .............................................................................. 24 
1.1.2. Rhabdoid tumours .......................................................................................... 26 
1.1.2.1 Rhabdoid tumour therapy ............................................................................... 28 
1.1.3. Sarcoma microenvironment targeting ............................................................ 32 
1.2. The heparanase/heparan sulfate proteoglycan system ................................. 34 
1.2.1. Heparanase ..................................................................................................... 37 
1.2.2. Heparanase role in cancer progression ........................................................... 40 
1.2.3. Heparanase/heparan sulfate axes as a therapeutic target................................ 43 
1.3. RNA interference approaches......................................................................... 48 
1.3.1. MicroRNA ..................................................................................................... 49 
1.3.2. Small interfering RNA ................................................................................... 51 
1.3.3. Delivery of RNA-interfering molecules......................................................... 53 
1.4. Nanoparticles-based tools for RNAi delivery ................................................ 54 
1.4.1. Hybrid nanogel particles ................................................................................ 59 
1.4.2. Leukosomes ................................................................................................... 61 
2. SCOPE OF THE THESIS .......................................................................................... 63 
3. MATERIALS AND METHODS ............................................................................... 66 
3.1. Cell lines and culture conditions .................................................................... 67 
3.2. Cell transfection and transient gene silencing ............................................... 68 
3.3. MiR-1258 and heparanase gene expression analysis .................................... 69 
3.3.1. RNA isolation ................................................................................................ 69 
3.3.2. Quantitative reverse transcriptase polymerase chain reaction ....................... 69 
3.4. Protein expression analysis ............................................................................. 71 
3.4.1. Protein extraction and quantification ............................................................. 71 
3.4.2. Nucleus/cytoplasm fractionation .................................................................... 72 
3.4.3. Gel electrophoresis and western blotting ....................................................... 72 
3.4.4. Antibody Arrays ............................................................................................. 73 
3.4.5. Enzyme-linked immunosorbent assays .......................................................... 74 
3.4.6. Immunofluorescence staining ........................................................................ 74 
3.5. Functional studies in vitro ............................................................................... 76 
Table of contents 
 
 
9 
3.5.1. Cell growth curves ......................................................................................... 76 
3.5.2. Soft agar colony assay .................................................................................... 76 
3.5.3. Cell migration assay ....................................................................................... 76 
3.5.4. Cell invasion assay ......................................................................................... 77 
3.6. Synthesis and characterisation of nanoparticles for RNAi delivery ........... 77 
3.6.1. Synthesis and characterisation of pH-responsive hybrid nanogel particles 
(HNP) 78 
3.6.2. Synthesis and characterisation of Leukosomes .............................................. 78 
3.6.3. Dynamic Light Scattering .............................................................................. 80 
3.6.4. Fourier transform infrared analysis ................................................................ 81 
3.6.5. Atomic force microscopy ............................................................................... 81 
3.6.6. Nanoparticles toxicity assay ........................................................................... 82 
3.6.7. Scanning electron microscopy ....................................................................... 82 
3.6.8. Flow cytometry measurements ...................................................................... 83 
3.6.9. Migration assay .............................................................................................. 83 
3.6.10. Transmission electron microscopy ................................................................. 84 
3.6.11. Hybrid nanogel particle-siRNA loading and release ..................................... 84 
3.6.12. Leukosome/liposome-siRNA loading ............................................................ 85 
3.6.13. Polyethylenimine/siRNA-nanoparticle complexes formation. ...................... 86 
3.6.14. SiRNA-nanoparticles trafficking ................................................................... 86 
3.6.15. Intravital microscopy ..................................................................................... 87 
3.6.16. Immunofluorescence of tumour sections ....................................................... 88 
3.6.17. Animal studies ................................................................................................ 88 
3.7. Statistical Analysis ........................................................................................... 89 
4. RESULTS .................................................................................................................... 90 
4.1. MiR-1258 transfection ..................................................................................... 91 
4.2. Anti-heparanase siRNA transfection ............................................................. 98 
4.2.1. Effects of siRNA on extracellular heparanase ............................................... 99 
4.2.2. Effects of siRNA on cell motility ................................................................ 101 
4.2.3. Effects of siRNA on cell proliferation and colony formation ...................... 106 
4.2.4. Effects of siRNA on intracellular heparanase .............................................. 107 
4.2.5. Effects of siRNA on angiogenic molecules ................................................. 111 
4.3. Nanoparticles as tools for RNAi delivery .................................................... 112 
4.3.1. Design and characterisation of Hybrid Nanogel Particles ........................... 112 
4.3.1.1. In vitro biological effects of HNPs .......................................................115 
Table of contents 
 
 
10 
4.3.1.2. In vitro HNP-delivery of siRNA ...........................................................119 
4.3.1.3. In vivo HNP-delivery of siRNA............................................................123 
4.3.2. Design and characterisation of leukosomes ................................................. 125 
4.3.2.1. In vitro biological effects of leukosomes ..............................................125 
4.3.2.2. In vitro leukosome-delivery of siRNA .................................................127 
4.3.2.3. In vivo leukosome-delivery of siRNA ..................................................132 
5. DISCUSSION ............................................................................................................ 135 
6. CONCLUSIONS & FUTURE PERSPECTIVES .................................................. 148 
7. REFERENCES.......................................................................................................... 151 
PUBLICATIONS ............................................................................................................. 181 
DECLARATION OF AUTHORSHIP ........................................................................... 184 
List of figures and tables 
 
 
11 
 
 
 
 
 
 
 
 
 
 
LIST OF FIGURES AND TABLES 
  
List of figures and tables 
 
 
12 
Figure 1.1. The SS18-SSX translocation. ........................................................................... 21 
Figure 1.2. SS18-SSX fusion protein. ................................................................................. 23 
Figure 1.3. Epigenetic antagonism between PRC2 and SWI/SNF chromatin remodeling 
complexes. .................................................................................................................... 28 
Figure 1.4. Pathways regulated by SWI/SNF complex. ...................................................... 31 
Figure 1.5. HSPGs role in cells. .......................................................................................... 36 
Figure 1.6. Heparanase crystal 3D view. ............................................................................ 38 
Figure 1.7. Heparanase processing. ..................................................................................... 39 
Figure 1.8. Schematic model of heparanase trafficking. ..................................................... 43 
Figure 1.9. Schematic representation of heparin derivatives. ............................................. 46 
Figure 1.10. Biological barriers........................................................................................... 56 
Figure 1.11. HNP. ............................................................................................................... 60 
Figure 1.12. Graphic representation of leukosome. ............................................................ 61 
Figure 1.13. Schematic representation of the assembly of leukosomes using 
NanoAssemblr. ............................................................................................................. 62 
 
Figure 3.1. Representative images of metastatic deposit in lungs from mice harbouring 
orthotopic A204 or CME-1 tumours. ............................................................................ 68 
Figure 3.2. Schematic representation of leukosomes/liposomes synthesis with 
NanoAssemblr. ............................................................................................................. 80 
 
Figure 4.1. Predicted target sequence of miR-1258 in the 3’-UTR of human heparanase 
mRNA. .......................................................................................................................... 92 
Figure 4.2. Transfection’s efficiency of A204 and CME-1 cells. ....................................... 92 
Figure 4.3. MiR-1258 mimic transfection in sarcoma cell lines. ........................................ 94 
Figure 4.4. Attempts to increase miR-1258 mimic efficacy. .............................................. 96 
Figure 4.5. siR04, siR05 and siR06 sequences and binding sites on the four different 
transcript variants of heparanase................................................................................... 97 
Figure 4.6. siRNAs transfection in sarcoma cell lines. ....................................................... 99 
Figure 4.7. Down-regulation of heparanase in the extracellular environment. ................. 101 
Figure 4.8. Effects of anti-heparanase siRNAs on migration in sarcoma cell lines. ......... 103 
Figure 4.9. Effects of anti-heparanase siRNAs on invasion in sarcoma cell lines. ........... 105 
Figure 4.10. Heparanase siRNAs effect on cell proliferation and colony formation. ....... 107 
Figure 4.11. Heparanase subcellular localisation. ............................................................. 108 
Figure 4.12. Heparanase subcellular localisation. ............................................................. 110 
List of figures and tables 
 
 
13 
Figure 4.13. Effects of siRNAs anti heparanase on angiogenic molecules in sarcoma cells.
 .................................................................................................................................... 112 
Figure 4.14. pH responsiveness of HNPs. ......................................................................... 115 
Figure 4.15. Biological effects of HNPs on A204 cells. ................................................... 117 
Figure 4.16. HNPs endo-lysosomal escape. ...................................................................... 119 
Figure 4.17. pH-driven loading and release of siRNA. ..................................................... 121 
Figure 4.18. Heparanase levels after siRNA transfection. ................................................ 123 
Figure 4.19. In vivo delivery of HNPs and siRNA............................................................ 124 
Figure 4.20. Biological effect of leukosoms on RT cells. ................................................. 127 
Figure 4.21. Leukosomes/siRNA trafficking. ................................................................... 129 
Figure 4.22. Heparanase mRNA levels after siRNA transfection with different 
nanoparticles. .............................................................................................................. 132 
Figure 4.23. In vivo delivery of leukosomes and siRNA. ................................................. 134 
 
Figure 5.1. HS mimetics mechanism of action. ................................................................ 139 
Figure 5.2. Exosome internalisation mechanisms. ............................................................ 145 
 
 
Table 1.1. Clinical trials of siRNAs locally administered. .................................................. 52 
Table 1.2. Clinical trials of siRNAs systemically administered. ......................................... 52 
 
Table 3.1. Employed antibodies. ......................................................................................... 73 
 
Table 4.1. SiR04, siR05 and sir06 binding sites. ................................................................ 97 
 
Abbreviations 
 
 
14 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
 
  
Abbreviations 
 
 
15 
AFM   Atomic force microscopy 
AT/RT  Atypical teratoid rhabdoid tumour 
BCA  Bicinchoninic acid 
BSA  Bovine serum albumin 
CHOL  Cholesterol 
Ct  Cycle threshold 
CTLA-4 Cytotoxic T cell lymphocyte-associated protein 4 
CXCL16 Chemokine (C-X-C motif) ligand 16 
Dh  Hydrodynamic diameters 
DLS  Dynamic light scattering 
DOPC  1,2-dioleoyl-sn-glycero-3-phosphocholine  
DPPC  Dipalmitoylphosphatidylcholine 
DSPC  1,2-Distearoyl-sn-glycero-3-phosphocholine 
ECM  Extracellular matrix 
ELISA  Enzyme-linked immunosorbent assays 
EZH2  Enhancer of zeste homolog 2 
FACS  Fluorescence activated cell sorting 
FBS  Fetal bovine serum  
FGF  Fibroblast growth factor 
FT-IR  Fourier transform infrared 
HATs  Histone acetyltransferases 
HDAC  Histone deacetylase 
HGF   Hepatocyte growth factor 
HMRI   Houston Methodist Research Institute 
HNP  Hybrid nanogel particle 
HPSE  Heparanase 
HS   Heparan-sulfate 
HSPGs Heparan sulfate proteoglycans 
IF   Immunofluorescence  
IVM  Intravital microscopy 
KBr  Potassium bromide 
KRT  Rhabdoid tumour of the kidney 
miRNA  MicroRNA 
MMP-9 Matrix metallopeptidase 9 
mRNA Messenger RNA 
MRT   Malignant rhabdoid tumour 
MTT   3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide 
N/P   Amino/phosphate 
Neg Ctr  Negative Control 
O/N  Overnight 
PB   Phosphate buffer 
PBS  Phosphate-buffered saline  
PD-1  Programmed death receptor 1 
PDEAEM Poly(diethylaminoethyl methacrylate) 
PDGF  Platelet-derived growth factor 
Abbreviations 
 
 
16 
PDI  Polydispersity index 
PDL-1  Programmed death receptor 1 ligand 
PEGMA Polyethylene glycol methacrylate 
PEI  Polyethylenimine 
PI   Propidium iodide 
PRC   Polycomb repressive complex 
pre-miRNA Precursor microRNA 
pri-miRNA Primary microRNA 
qRT-PCR  Quantitative reverse transcription polymerase chain reaction 
RISC  RNA-induced silencing complex 
RNAi   RNA interference 
RQ  Relative quantification  
RT  Rhabdoid tumour  
RTKs  Receptor tyrosine kinases 
SDS  Sodium dodecyl sulfate  
SEM  Scanning electron microscope 
siRNA  Small interfering RNA  
SMARCB1 SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
subfamily B member 
SRB  Sulforhodamine B  
SS  Synovial sarcoma 
STS  Soft tissue sarcoma  
SWI/SNF Switch/sucrose son-fermentable 
TBS  Tris-buffered saline 
TEGDMA Triethylene glycol dimethacrylate  
TEM   Transmission electron microscopy  
TF  Tissue Factor/Coagulation Factor III 
TLE  Thin layer evaporation 
uPA   Urokinase-type Plasminogen Activator  
VEGF  Vascular endothelial growth factor 
WGA  Wheat germ agglutinin 
  
Introduction 
 
 
17 
 
 
 
 
 
 
 
 
 
 
1.INTRODUCTION 
  
Introduction 
 
 
18 
1.1. Soft tissue sarcomas 
The word ‘sarcoma’ is derived from the Greek σάρξ (sárx, “flesh”) -ωμα (ōma, “process”). 
Soft tissue sarcomas (STSs) are rare malignancies accounting for 1% of all cancers in 
adults and nearly 10% in children and adolescents [Siegel R.L. et al., 2018]. STSs arise 
from the embryonic mesoderm tissue, usually from connective, muscle, adipose, neural, 
vascular, or lymphatic tissues [Gilbert N.F. et al., 2009]. The most common onset location 
of sarcoma is in the extremities (arms, legs, hands, or feet), but it can also occur in the 
trunk (chest, back, hips, shoulders or abdomen), in the retroperitoneum or in head and 
neck; the anatomic site of the primary disease is an important variable influencing 
treatment and outcome. STSs tend to invade surrounding tissues and give rise to metastases 
in 50% of patients, especially in lymph nodes and lungs, whereas tumours arising in the 
abdominal cavity commonly metastasise to the liver and peritoneum [Cormier J.N. and 
Pollock R.E., 2004]. STSs constitute a highly heterogeneous family of malignancies 
comprising more than 50 subtypes. They can be classified according to the 2013 World 
Health Organization Classification of Tumours of Soft Tissue and Bone in twelve main 
groups [Fletcher C.D., 2013]: 
(1) Adipocytic tumours 
(2) Fibroblastic/myofibroblastic tumours 
(3) The so-called fibrohistiocytic tumours 
(4) Smooth muscle tumours 
(5) Pericytic (perivascular) tumours 
(6) Skeletal muscle tumours 
(7) Vascular tumours 
(8) Gastrointestinal stromal tumours 
(9) Nerve sheath tumours 
(10) Chondro-osseous tumours 
Introduction 
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(11) Tumours of uncertain differentiation 
(12) Undifferentiated/unclassified sarcomas 
Depending on the biological behaviour, they are sub-categorised in: benign, intermediate 
locally aggressive, intermediate rarely metastasising, or malignant [Wei S. et al., 2017]. 
The aetiology of most STSs remains unknown. Genetic factors (i.e., neurofibromatosis, 
retinoblastoma, Li-Fraumeni syndrome, Gardner’s syndrome), environmental factors 
(exposure to environmental carcinogens such as dioxin and some herbicides, trauma, injury 
or previous ionising radiation exposure), and immunological factors such as 
immunosuppression after transplant surgery, have been identified as predisposing 
aetiological factors in STS development [Zahm S.H. and Fraumeni J.F. Jr., 1997; Thomas 
D.M. et al., 2012]. As in other malignancies, it is very unlikely that a single factor causes 
the disease, but a multifactorial aetiology is likely.  
Based on genetic alterations, STSs can be divided into two major categories: the first one 
characterised by the presence of specific chromosomal translocations or mutations and a 
near-diploid karyotype, more frequent in young patients; the second one, which accounts 
for about 50% of STS, exhibiting complex karyotypes with non-specific chromosomal 
rearrangements, but presenting frequent genetic gain or losses characteristic of unstable 
genome [de Alava E., 2007].  
Sarcoma specific translocations produce fusion genes that mainly encode aberrant 
transcription factors or transcription regulators, such as PAX3/7-FKHR in alveolar 
rhabdomyosarcomas, EWS-ETS in Ewing’s sarcoma and SS18-SSX in synovial sarcoma 
(SS). The encoded hybrid oncoproteins induce aberrant transcription of target genes, 
stimulating various intracellular signaling pathways and resulting in cell proliferation, 
evasion from growth inhibition, escape from senescence, apoptosis and immune response, 
induction of angiogenesis, invasion and metastasis [Mitelman F. et al., 2007]. 
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The experimental models used in this thesis included SS and rhabdoid tumour (RT), 
specifically, CME-1 SS cells and A204 RT cells.  
 
1.1.1. Synovial sarcoma 
SS is an aggressive tumour accounting for 10% to 20% of STSs, most prevalent in 
adolescent and young adults [Herzog C.E., 2005]. Despite its name, SS is unrelated to the 
synovial tissues. The disease arises in soft tissues of the extremities in 66% of cases, 
especially adjacent to large joints (thigh, knee, ankle, feet, and arms), but can occur 
anywhere in the body. SS is characterised by local invasiveness and propensity to 
metastasise, particularly to the lungs [Orbach D. et al., 2011]. The clinical behaviour varies 
from superficial indolent tumours to highly aggressive tumours that are capable of 
recurring locally or at distant sites years after surgical resection of the primary tumour. 
Two main morphological tumour subtypes have been identified, i.e., the biphasic and 
monophasic variants, although, in a few cases a poorly differentiated monophasic subtype 
has been reported [Begin L.R., 2003; Cascales P. et al., 2006; Rong R. et al., 2009]. The 
two subtypes are equally distributed in children, with 55% of monophasic subtypes and 
45% of biphasic subtypes, whereas the monophasic subtype is more frequent in adults 
(72%). The biphasic SS morphology has been interpreted as a manifestation of aberrant 
mesenchymal to epithelial transition associated with interference by SS18-SSX oncogenes 
on E-cadherin repression [Saito T. et al., 2006]. However, the histological monophasic or 
biphasic subtypes have no prognostic impact [Orbach D. et al., 2011]. Distinction in 
monophasic or biphasic SS subtypes is based on the presence of spindle cells or both 
spindle and epithelial glandular cells, respectively. Monophasic SSs are entirely composed 
of packed spindle cells with no epithelial differentiation. Biphasic SSs are characterised by 
epithelial cells bearing ovoid nuclei and abundant cytoplasm areas of glandular 
differentiation in a background of spindle cells. The poorly differentiated variant is the 
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rarest and more aggressive SS subtype and presents dense cellularity, numerous mitotic 
figures, and areas of necrosis [Haldar M. et al., 2008]. 
Genetically, 95% of SSs are characterised by the chromosomal translocation t(X;18) which 
involves the SSX1, SSX2 or rarely SSX4 genes, closely related genes from chromosome 
Xp11, and the SS18 gene from chromosome 18q11. The translocation results in the 
formation of a chimeric gene encoding a chromatin remodeling fusion protein, which is 
able to induce transcriptional dysregulation [Brett D. et al., 1997] (Figure 1.1). Multiple 
studies concur to establish that the SS18-SSX translocation plays a role in this cancer: 1) 
most cases exhibit the translocation as the only cytogenetic abnormality and other 
mutations are rarely present [Panagopoulos I. et al., 2001; Joseph C.G. et al., 2014], 2) the 
translocation is maintained in metastatic and advanced lesions [Panagopoulos I. et al., 
2001], 3) SS18-SSX knockdown causes SS cell death [Carmody Soni E.E. et al., 2014], 
and 4) the expression of the oncoprotein in immature myoblasts was shown to induce SS 
with 100% penetrance in a mouse model [Haldar M. et al., 2007]. This study strongly 
supports that the SS18-SSX translocation behaves as a driver in SSs. 
 
Figure 1.1. The SS18-SSX translocation. 
The SS translocation involving the SS18 transcriptional activator on chromosome 18 and the SSX 
transcriptional repressor located on the X chromosome produces the fusion genes SS18–SSX1, SS18–SSX2, 
and rarely SS18–SSX4. 
 
The crucial role for the fusion product in the pathogenesis of SS has been linked to its 
interference with the gene expression by epigenetic deregulation [Przybyl J. et al., 2012]. 
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The current view is that SS18-SSX fusion proteins acquire novel functional properties 
accounting for oncogenic transformation, although the mechanism of the oncogenic 
activity has not been completely elucidated yet. Two recent studies proposed that the 
activity of SS18-SSX fusion proteins is mediated by protein-protein interactions that alter 
genetic programs through chromatin remodeling. In particular, SS18-SSX protein has been 
suggested to be incorporated into SWItch/sucrose non-fermentable (SWI/SNF/BAF) 
complexes replacing wild type SS18 and expelling SWI/SNF-related matrix-associated 
actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1/BAF47). In 
this way, BAF complexes counteract polycomb repressive complex (PRC)2-mediated 
repression of transcription [McBride M.J. et al., 2018] (Figure 1.2, A). In addition, SS18-
SSX containing BAF complexes have been shown to interact with the histone demethylase 
KDM2B within the PRC1.1 and to aberrantly activate the transcription of target genes 
involved in sarcoma cell transformation [Banito A. et al., 2018] (Figure 1.2, B). As a 
result, the epigenetic antagonism between BAF complexes (transcription promoters) and 
PCR2 (repressive complexes) would be altered leading to an abnormal transcriptional 
pattern that drives malignant transformation. 
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Figure 1.2. SS18-SSX fusion protein. 
(A) Graphic representation of the interaction between SS18-SSX protein and BAF complexes and subsequent 
transcription activation [McBride M.J. et al., 2018]. (B) Graphic representation of the SWI/SNF activation 
mediated by SS18-SSX/KDM2B interaction, and subsequent aberrant transcription activation [Banito A. et 
al., 2018]. 
 
The fusion SS18-SSX genes are unique to SS and considered diagnostic markers for these 
tumours. Fluorescence in situ hybridisation and quantitative reverse transcription 
polymerase chain reaction (qRT-PCR) are used as diagnostic techniques to detect the 
chromosomal translocation and the fusion transcript, respectively [Takenaka S. et al., 
2008; Saito T., 2013]. 
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1.1.1.1 Synovial sarcoma therapy 
Commonly, the first approach to SSs involves complete surgical resection of the tumour, 
which may be preceded or followed by radiotherapy. Post-operative radiotherapy and local 
excision can control local recurrence [Shwartz D.L. et al., 2002]. For metastatic SSs, the 
conventional front-line chemotherapy regimen containing anthracyclines and alkylating 
agents, exhibits limited advantages because of toxicity and eventual progression of the 
disease [Lange S.E.S. et al., 2014]. Moreover, prolonged treatment may induce severe 
adverse consequences, such as cardiotoxicity, infertility, and late effects affecting growth 
and development as well as the onset of secondary malignancies [Sultan I. et al., 2009]. 
The probability of recurrence of SS is approximately 50%, usually within 2 years, but there 
are cases of recurrence up to 30 years after diagnosis. About 40% of the tumours display 
metastatic spread, most commonly to the lungs with regional lymph node involvement. 
Advanced stage at presentation, positive surgical resection margins, larger tumour size (>5 
cm) and non-extremity tumour site are all negative prognostic factors for SSs [Lewis J.J. et 
al., 2000]. The 5-year overall survival rate for the patients without metastases is about 80% 
whereas it is lower (10-25%) in case of metastatic disease [Wu Y. et al., 2017]. The poor 
prognosis for recurrent and metastatic SS highlights the need for new therapeutic 
approaches to improve treatment outcomes. 
Besides conventional chemotherapy, targeted therapy has been explored extensively for SS 
treatment in an attempt to hit tumour features essential for tumour growth and progression. 
Multiple receptor tyrosine kinase (RTK)-mediated signaling pathways are active in SS and 
are implicated in angiogenesis [e.g., vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), fibroblast growth factor (FGF) and their receptors] [El 
Beaino M. et al., 2017]. Therefore, agents against these factors are among the commonly 
investigated targeted therapeutics. Several anti-angiogenic therapies have been tested in 
clinical trials, including multi-RTKs inhibitors (i.e., pazopanib, sorafenib, sunitinib, 
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regorafenib, imatinib and gefitinib), and the monoclonal antibodies bevacizumab (anti-
VEGF) and olaratumab (anti-PDGFRα) [https://clinicaltrials.gov]. Among these, only 
pazopanib (votrient), a RTK inhibitor targeting VEGFR and PDGFR family members and 
c-kit, and olaratumab gained approval in 2012 and 2016, respectively, for the treatment of 
advanced STS, including SS, in patients who received prior chemotherapy [Desar I.M.E. et 
al., 2018].  
The insulin-like growth factor (IGF) system, which regulates downstream pathways 
involved in cell proliferation and apoptosis inhibition, is another target for SS therapy. In 
detail, IGF-II and the receptor IGF-1R have been found up-regulated in SSs due to IGF-II 
induction mediated by SS18-SSX fusion proteins. Moreover, IGF-1R over-expression has 
been associated with higher metastatic dissemination in SSs [Xie Y. et al., 1999; de Bruijn 
D. R. et al., 2006; Sun Y. et al., 2006]. Clinical trials of cixutumumab, an anti-IGF-1R 
monoclonal antibody, have been carried out and obtained stable disease as the best 
response in a few SS patients [https://clinicaltrials.gov]. 
The PI3K/Akt/mTOR signaling pathway, which promotes cell proliferation and anti-
apoptotic survival responses, is dysregulated in SS and associated with aggressive clinical 
behaviour [Setsu N. et al., 2013]. Inhibitors of mTOR, such as temsirolimus and 
everolimus, have been included in clinical trials for patients with advanced sarcoma, 
including SS [https://clinicaltrials.gov]. 
The WNT-β catenin signaling pathway is activated in a subset of SS and its inhibitors have 
been found to have anti-tumour effects in preclinical studies [Trautmann M. et al., 2014; 
Barham W. et al., 2013]. 
90
Y-OTSA 101, a radiolabeled monoclonal antibody directed 
against the WNT receptor FZD10, is under investigation in a clinical trial in patients with 
progressive advanced SS [Giraudet A.L. et al., 2018]. 
The Hedgehog pathway, a major regulator of stem cell maintenance, cell differentiation 
and proliferation, is aberrantly activated in a variety of human cancers including soft tissue 
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and bone sarcomas [Almazan-Moga A. et al., 2017; Kumar R.M. and Fuchs B., 2015]. GLI 
is a transcription factor that, activated by the Hedgehog signaling, induces target gene 
transcription; it is known that the inappropriate activation of Hedgehog signaling leads to 
the growth, proliferation, and invasion of tumour cells [Skoda A.M. et al., 2018]. 
Vismodegib, an inhibitor of this pathway, has been evaluated in combination with 
RO4929097, a Notch signaling pathway inhibitor, in a Phase II clinical trial in advance 
STS patients, including SS patients, and obtained a stable disease in about half of the 
patients [https://clinicaltrials.gov]. 
Since the fusion protein SS18-SSX is a peculiar feature of SS and acts as the disease 
driver, it is attractive for investigation of the possibility to develop a specific target 
therapy. Natarajan V. and colleagues evaluated the use of small molecules that bind the 
junction region of the SS18-SSX1 fusion protein by applying an in silico drug screening 
based on molecular docking. In this study, the authors identified a compound (FPTI) able 
to inhibit SS cell proliferation with some selectivity [Natarajan V. et al., 2018]. 
Other epigenetic regulators involved in cancer progression have been investigated as 
potential targets in preclinical and clinical studies; particular attention has been paid to 
histone deacetylases (HDACs) and the methyltransferase enhancer of zeste homolog 2 
(EZH2). The HDAC inhibitor vorinostat and the EZH2 inhibitor tazemetostat have been 
tested in clinical trials in STS patients. No objective responses were achieved but a stable 
disease was obtained as the best response [Desar I.M.E. et al., 2018]. 
One of the most promising new therapeutic approaches for SS involves the targeting of the 
tumour microenvironment and will be discussed in chapter 3.1.1. 
 
1.1.2. Rhabdoid tumours 
Rhabdoid tumour (RT) is a rare aggressive malignant tumour that may affect brain 
[Atypical teratoid rhabdoid tumour (AT/RT)], kidney [Rhabdoid tumour of the kidney 
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(KRT)], or extrarenal soft tissues [Malignant rhabdoid tumour (MRT)]. The most common 
soft tissues affected by MRT are liver, skin and lung, but it can arise almost in all soft 
tissues [Wu X. et al., 2008]. The incidence of RT is higher in children between 1 and 4 
years, although it can occur also in adults [Leong F.J. and Leong A.S., 1996]. Rhabdoid 
cells exhibit filamentous cytoplasmic inclusions, large nucleoli and eosinophilic 
cytoplasm. Histology of RT is characterised by heterogeneous morphology with neural, 
epithelial, mesenchymal, or ependymal patterns, making diagnosis difficult [Parham D.M. 
et al., 1994].  
All RTs present homozygous loss or expression mutations of the tumour suppressor 
SMARCB1/INI1/hSNF5/BAF47 gene [Versteege I. et al., 1998; Biegel J.A. et al., 1999]. 
Thereby, diagnosis is usually confirmed by loss of nuclear staining of SMARCB1 protein 
by immunohistochemistry. SMARCB1 is a core subunit of the SWI/SNF chromatin 
remodeling complex, the same epigenetic regulator of gene transcription implicated in SSs. 
The SWI/SNF complex remodels chromatin by regulating the positions of nucleosomes 
and reducing the density of DNA, therefore allowing gene transcription activation. 
Mutations of SMARCB1 are sufficient and necessary to cause cancer [Geller J.I. et al., 
 2015]. The SWI/SNF complex competes for chromatin binding with the PRC2, whose 
catalytic subunit EZH2 is a histone methyltransferase which carries out the trimethylation 
of histone 3 at lysine 27, inducing gene expression repression (Figure 1.3). The 
inactivation of SMARCB1 leads to an elevated expression of EZH2 and consequently the 
down-regulation of various tumour suppressors’ expression [Wilson B.G. et al., 2010]. 
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Figure 1.3. Epigenetic antagonism between PRC2 and SWI/SNF chromatin remodeling complexes.  
As catalytic subunit of the PRC2, EZH2 carries out the trimethylation of histone 3 at lysine 27 (H3K27Me3), 
leading to gene expression repression. PRC2 competes for binding to the chromatin with the SWI/SNF 
chromatin remodeling complex, which allows gene transcription activation. SMARCB1 is a component of 
the SWI/SNF complex. 
 
1.1.2.1 Rhabdoid tumour therapy 
RT is often diagnosed at high stage and patients present early metastases to lung, liver, and 
lymph nodes, leading to poor prognosis. Overall survival of RT patients at 5-years, is about 
30%, independently of the tumour site, and is lower in younger patients (about 9% for 
patients aged 0-5 months) [Sultan I. et al., 2010]. 
Commonly, the treatment for RT includes surgical resection of the tumour, chemotherapy 
and radiotherapy. Total resection of tumour is a favourable prognostic factor; however, it is 
not always feasible, particularly for AT/RT [Chi S.N. et al., 2009; Madigan C.E. et al., 
2007]. 
There is no gold standard therapy for RT due to the rarity of the disease and heterogeneity 
of origin site; in the past, RTs were treated on the basis of the tumour location (i.e., KRT as 
Wilms Tumour, AT/RT as medulloblastoma). Recently, the identification of common 
molecular features and the subsequent treatment of RTs as an independent entity improved 
the prognosis of patients. Chemotherapy regimen includes combinations of vinca alkaloids, 
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alkylating agents, platinum compounds and anthracyclines [Chi S.N. et al, 2009]. In some 
patients, the use of high-dose chemotherapy followed by autologous stem cell 
transplantation or, for AT/TR patients, the use of intrathecal chemotherapy (methotrexate, 
cytarabine, mafosfamide, and hydrocortisone) may lead to favourable outcome [Gilman 
A.L. et al., 2011; Koga Y. et al., 2009; Athale U.H. et al., 2009; Blaney S.M. et al., 2012]. 
Some studies have related radiotherapy treatment with improved clinical outcomes 
[Tekautz T.M. et al., 2005; Zhuge Y. et al., 2010]. Unfortunately, the long term side-
effects of all these treatments have a strong impact on children growth and development, 
affecting the quality of life. 
Several targeted therapeutics are currently under preclinical and clinical evaluation either 
alone or in combination with conventional chemotherapy. SMARCB1 loss causes altered 
activation of signaling pathways. Effector molecules of these pathways, such as CDKs, 
EZH2, Aurora kinase A, GLI1, HDACs and Wnt/β-catenin, have been investigated as 
therapeutic targets (Figure 1.4). 
For instance, GLI1, a member of Sonic-Hedgehog pathway involved in cell differentiation 
and oncogenesis, has been described as up-regulated in RT primary tumours [Kerl
a
 K. et 
al., 2013]. Inhibition of GLI1, through administration of arsenic trioxide, reduced MRT 
cells proliferation in vitro and tumour growth in a mouse xenograft model [Kerl K. et al., 
2014; Tang Y. et al., 2014]. Hedgehog signaling pathway inhibitors have entered a new 
ongoing clinical trial on brain tumour patients, including AT/RT, which proposes the 
evaluation of rational combination therapies based on tumour type and molecular 
characteristics of the diseases [https://clinicaltrials.gov]. 
In a preclinical study, promising results have been obtained with the inhibition of WNT by 
RNA interfering (RNAi) molecules, which resulted in strong reduction of AT/RT cell 
viability [Chakravadhanula M. et al., 2015]. 
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C-MYC is highly expressed in RTs. The mechanism by which the loss of SMARCB1 
induces MYC activity in RT cells has not been clarified. A recent study in AT/TR 
preclinical models demonstrated that MYC inhibition, obtained through transgenic 
expression of a MYC dominant negative or inhibition of MYC transcriptomic programs 
with the BET inhibitor JQ1, reduces tumour cell self-renewal, induces senescence, and 
inhibits tumour growth in vivo [Rosson G.B. et al., 1  8  Cheng S.W. et al., 1     
Alimova  . et al.,  2018]. 
Alisertib (MLN8237) is an inhibitor of Aurora A kinase, which regulates the formation and 
stability of the mitotic spindle; this compound has been tested in 4 paediatric AT/RT 
patients and, as single-agent, induced a strong and durable regression of the disease 
[Wetmore C. et al., 2015]. It was previously demonstrated that usually Aurora A is 
repressed by SMARCB1 and the use of MLN8054, a selective small-molecule inhibitor of 
Aurora A kinase, reduced cell proliferation, followed by apoptosis induction in vitro, and 
reduced tumour growth in xenograft models [Carol H. et al., 2011; Lee S. et al., 2011]. 
SMARCB1 loss can promote cell cycle progression resulting from up-regulation of the 
EZH2 pathway. Inhibitors of component of this pathway (CDK4/CDK6/CyclinD), which is 
involved in cell cycle progression via Rb phosphorylation, have already been tested in 
clinical trials for different malignancies. Among them, the CDK4/6 inhibitor ribociclib 
(LEE001) has been tested in paediatric MRT patients displaying acceptable safety and 
pharmacokinetics [https://clinicaltrials.gov]. In preclinical studies palbociclib (PD-
0332991), another CDK4/6 inhibitor, showed promising results in terms of anti-tumour 
activity in both in vitro and in vivo experiments [Geoerger B. et al., 2017; Hashizume R. et 
al., 2016]. 
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Figure 1.4. Pathways regulated by SWI/SNF complex. 
The SWI/SNF complex, with the core subunit SMARCB1, plays a critical role in regulating expression of 
genes implicated in key signalling pathways, such as the Hedgehog, WNT-β catenin, MYC, Aurora A kinase 
and E2F.  
 
As previously mentioned, SWI/SNF and PRC complexes have opposite functions at 
transcription levels and compete for binding to the chromatin. SMARCB1‐deficient 
tumours express higher levels of EZH2, whose transcription is directly repressed by 
SMARCB1 [Wilson B.G. et al., 2010]. Lack of SMARCB1 in RT leads to repression of 
gene transcription caused by aberrant H3K27me3 mediated by EZH2 and oncogenic 
dependence on this methyltransferase. The EZH2 inhibitor tazemetostat, has shown 
promising activity in an undergoing Phase I clinical trial in paediatric patients with 
SMARCB1-negative tumours [https://clinicaltrials.gov]. In preclinical in vivo studies, the 
use of tazemetostat showed anti-tumour activity in RT models [Kurmasheva R.T. et al., 
2017]. 
Introduction 
 
 
32 
The epigenetic status of chromatin is regulated also by histone acetyltransferases (HATs) 
and HDACs, which are often aberrantly expressed in RTs. HDAC inhibitors showed anti-
tumour effect in combination with chemotherapeutic agents and radiosensitisation in 
preclinical in vitro and in vivo studies [Kerl
b
 K. et al., 2013; Thiemann M. et al., 2012; 
Moreno N. and Kerl K., 2016]. HDAC inhibitors (i.e., Vorinostat and Valproic Acid) have 
also been used in clinical trials in paediatric AT/RT patients alone or in combination 
treatments showing high tolerability [Fouladi M. et al., 2010; Hummel T.R. et al., 2013; Su 
J.M. et al., 2011]. 
 
1.1.3. Sarcoma microenvironment targeting 
The reciprocal interaction of tumour with microenvironment, including stroma cells, 
extracellular matrix (ECM) and signaling molecules, such as growth factors, chemokines 
and cytokines, is indeed fundamental for tumour sustenance. In such cross-talk, CXCL12 
and its cell-surface receptor, CXCR4, are key factors promoting tumour growth and 
metastasis dissemination [Domanska U.M. et al., 2013]. AMD3100, a CXCR4 inhibitor, 
effectively suppressed tumour growth when used in combination with anti-angiogenic 
agents and/or ifosfamide in both in vitro and in vivo SS models [Wakamatsu T. et al., 
2014]. 
Immune-based therapies have been explored in SS and RT patients. The cancer-testis 
antigen NY-ESO-1, highly expressed in the majority (80%) of SS, is one of the most 
analysed immune-targets. Adoptive immunotherapy with CD8
+
 T cells, genetically 
engineered to recognise the NY-ESO-1 antigen, was shown to induce significant tumour 
regressions in 67% patients with metastatic SS [Robbins P.F. et al., 2011]. Another 
approach to target NY-ESO-1 is vaccination. The dendritic cell-targeting viral vector 
expressing the NY-ESO-1 gene CMB305 induced NY-ESO-1 specific T cell responses in 
SS patients and is currently in initial Phase I study [Pollack S.M., 2018]. On the other 
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hand, immune checkpoint inhibition by ipilimumab, a monoclonal antibody specific for 
cytotoxic T cell lymphocyte-associated protein 4 (CTLA-4), did not provide clinical 
benefit in a clinical trial for SS patients [Maki R.G. et al., 2013]. 
Immune checkpoint inhibitors targeting programmed death receptor 1 (PD-1) or its ligand 
(PDL-1), and CTLA-4 have raised interest in the treatment of RTs [Nemes K. and 
Frühwald M.C., 2018]; in particular, a Phase I/II clinical trial with the anti-PDL-1, 
atezolizumab, is ongoing in paediatric and young adult patients with solid tumours, 
including MRT [https://clinicaltrials.gov]. T cells, expressing chimeric CD-specific antigen 
receptors (CARs), which target tumour-associated antigens directly on the tumour cell 
surface, represent an additional immunotherapeutic approach of potential interest for RT. 
CAR-T cells have shown promising results in patients with haematological malignancies. 
It has been recently demonstrated that glypican 3-positive MRT cells in vitro are 
responsive to CAR-T cells [Li W. et al., 2017]. Paediatric patients with AT/RT exhibited 
good response to anti-tumour immunotherapy with autologous dendritic cell vaccination 
and three out of seven patients became long-term survivors [van Gool S.W. et al., 2016].  
 
Because of the heterogeneity and rarity of STSs, the treatment of these pathologies remains 
a major challenge. Despite the improvement of systemic treatments, including the use of 
targeted therapy and immunotherapy, patients with advanced or recurrent disease still have 
poor prognosis. In fact, chemotherapy gives low response rates in most STS subtypes with 
acute and long-term toxicities, particularly relevant in paediatric patients. Further treatment 
strategies will require a better understanding of the STS biomolecular complexity to 
elucidate mechanisms involved in tumour progression and to understand the interplay 
between the tumour and its microenvironment. Thus, innovative therapies should 
conceivably envision multi-targeted approaches able to counteract multiple pathways and 
the tumour-microenvironment reciprocal dependency. 
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The heparanase/HSPG system, which acts at the tumour-microenvironment interface, is an 
emerging therapeutic target in several pathological conditions and prominently in cancer 
[Secchi M.F. et al., 2015; Vlodavsky I. et al., 2016]. A few recent studies also support a 
potential relevance in sarcomas [Shafat I. et al., 2011; Cassinelli G. et al., 2013]. 
 
1.2. The heparanase/heparan sulfate proteoglycan system 
Heparanase is the only mammalian endo-β-D-glucuronidase cleaving heparan-sulfate (HS) 
side chains of heparan sulfate proteoglycans (HSPGs). HS is a glycosaminoglycan 
synthesised in the Golgi apparatus and composed of glucuronic acid and N-
acetylglucosamine disaccharide units. Owing to their flexibility, HS polysaccharides 
display high variability in conformation and orientation of functional groups that allows 
the binding to a variety of different proteins. HS is synthesized in a non-template driven 
process on specific serine residues located on a restricted group of core proteins, the 
HSPGs associated with the cell surface (i.e., syndecan and glypican) or the ECM (i.e., 
perlecan, agrin, and collagen XVIII). The chain is firstly synthesized as an N-acetylated 
polymer, which then undergoes a series of modifications, including sulfation, 
epimerisation and deacetylation. Variable modifications encode information for different 
functions. Extracellularly, HS are modified by two endosulfatases, Sulfatase 1 and 
Sulfatase 2, which selectively remove 6-O-sulfate groups from mature HS. Heparin is a 
more completely modified version of HS, displaying also a higher negative charge density. 
Alterations of the HS synthesis or modifications processes have been associated with 
several diseases, such as cancer, amyloid disease, infectious disease or inflammatory 
conditions [Gallagher J.T., 2001]. 
HSPGs are ubiquitous glycoproteins localised at the cell surface, basement membrane and 
ECM; in addition, they can translocate into the nucleus in a regulated manner [Kovalszky 
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I. et al., 2014]. On the basis of their main location, they have been divided in three main 
groups:  
1) membrane HSPGs (i.e., syndecans and glypicans); 
2) ECM HSPGs (i.e., agrin, perlecan, type XVIII collagen); 
3) intracellular secretory vesicle HSPG (i.e., serglycin in mast cells). 
HSPGs play a wide variety of structural, biochemical and regulatory functions under both 
physiological and pathological conditions. Membrane HSPGs are involved in cell-cell and 
cell-ECM interactions, favouring cell adhesion and motility. Moreover, they play a key 
role in cell signaling acting as co-ligands and co-receptors for growth factors, chemokines 
and cytokines. HSPGs are involved in receptors endocytosis, helping ligands uptake and 
receptors internalisation for degradation or recycling [Sarrazin S. et al., 2011]. HSPGs 
contribute to the organisation and homeostasis of ECM providing mechanical support. 
Furthermore, thanks to their structural heterogeneity, they are able to sequestrate a wide 
variety of HS-binding bioactive molecules, including growth factors, cytokines and 
enzymes in an inactive reservoir form, from which they can be released by HS degradation 
mediated by heparanase (Figure 1.5) [Dreyfuss J.L. et al., 2009]. 
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Figure 1.5. HSPGs role in cells. 
HSPGs act as co-receptors for growth factors and their receptors on the same cell (a) or on neighbouring cells 
(b). They transport and present chemokines at the cell surface (c-d). By cleaving HS on proteoglycans, 
heparanase leaves the core protein exposed to attack by proteases, leading to proteolytic shedding (e-f). Cell-
surface HSPGs are recycled or degraded in lysosomes after endocytosis (g-h). Moreover, HSPGs facilitate 
cell adhesion to the ECM (i) and form bridges to the cytoskeleton (j). Extracellular HSPGs are involved in 
the formation of matrices that form physiological barriers and concentrate bioactive molecules in the 
extracellular space (k-l). A specific HSPG, serglycin, carries heparin and is packaged into secretory granules 
of mast cells (m). Finally, HS chains are also found in the nucleus (n) [Bishop J.R. et al., 2007]. 
 
The cleavage activity of heparanase produces discrete HS fragments leading to ECM 
disassembly in processes requiring tissue remodeling such as inflammation, angiogenesis, 
and metastasis. Moreover, it induces the mobilisation of HS-binding molecules and, 
through the activation of protease-mediated processes, the release of soluble bioactive 
HSPG ectodomains [Manon-Jensen T. et al., 2010; Arvatz G. et al., 2011]. Preclinical 
studies have documented the pro-angiogenic and pro-metastatic activity of heparanase. 
Clinically, an association between heparanase levels and tumour progression or patient 
prognosis has been described in several different tumours types [Barash U. et al., 2010].  
Introduction 
 
 
37 
Heparanase pro-angiogenic activity is in part ascribed to its ability to release from the 
ECM HS-binding pro-angiogenic factors (e.g. VEGF, FGF, hepatocyte growth factor 
(HGF), PDGF, heparin-binding EGF-like, IL-8) involved in paracrine and/or autocrine 
stimulation of signaling pathways mediated by receptor tyrosine kinases (RTKs) (e.g. 
PDGFR, FGFR, c-Met, EGFR) [Vreys V. and David G., 2007]. Therefore, targeting the 
heparanase/HS axis may have an impact on signaling pathways that support tumour growth 
and survival.  
 
1.2.1. Heparanase 
Heparanase activity as HS endoglycosidase was described for the first time in murine 
models in 1975 [Hook M. et al., 1975; Ogren S. and Lindahl U., 1975] and the name 
“heparanase” was introduced   years later [Nakajima M. et al., 1 84]  the heparanase 
coding gene (HPSE1) was cloned in 1999 [Vlodavsky I. et al., 1999; Hulett M.D. et al., 
1999; Toyoshima M. and Nakajima M., 1999; Kussie P.H. et al., 1999] and, more recently, 
a model of the protein structure was obtained by X-ray crystallography (Figure 1.6). 
Heparanase 3D structure presents a characteristic (β/α)8 domain with two conserved acidic 
residues (Glu
225
 and Glu
343
) critical for the catalytic activity. The C-terminal domain is 
required for heparanase activity and regulates protein secretion [Wu L. et al., 2015]. 
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Figure 1.6. Heparanase crystal 3D view. 
Front (left) and side (right) views of heparanase. Subunits are coloured yellow (8 kDa) and blue (50 kDa). 
There are five sites of N-glycosylation coloured in green and red in the front view. The two catalytic residues 
are coloured in green and red in the side view [Wu L. et al., 2015]. 
 
Physiologically, expression of heparanase is restricted primarily to the placenta, the skin 
tissues and blood-borne cells, including platelets and activated cells of the immune system 
[Vreys V. and David G., 2007], whereas it is detected in almost all tumours, including 
sarcomas [Ilan N. et al., 2006; Masola V. et al., 2009; Shafat I. et al., 2011; Kazarin O. et 
al., 2014]. 
The heparanase gene is localised on chromosome 4q21.3, which encodes a precursor of 
543 amino acids (pre-proheparanase). The pre-proheparanase is processed into an inactive 
65 kDa precursor enzyme by the removal of the N-terminal signal peptide in the Golgi 
apparatus, where the proheparanase is glycosylated. Then the protein is secreted into the 
extracellular space, where it binds several membrane molecules, such as glycoproteins 
(e.g., HSPGs). The binding to these molecules favours the re-internalisation of the 
proenzyme by endocytosis and the storage into lysosomes. The activation of the enzyme is 
mediated by cathepsin L by the proteolytic cleavage and excision of a 6 kDa linker region. 
The resulting mature enzyme is a heterodimer consisting of non-covalently associated 8 
and 50 kDa protein subunits (Figure 1.7) [Vlodavsky I. et al., 2016].  
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Figure 1.7. Heparanase processing. 
Pre-proheparanase harbours 35 amino acids signal peptide (Met1–Ala35) which is removed in the Golgi 
apparatus. The protein is then glycosylated and secreted as a latent 65 kDa protein. Proteolytic processing 
occurring into lysosomes removes the linker domain (Ser110–Gln157), resulting in a heterodimer composed 
of 8 kDa (Gln36–Glu109) and 50 kDa (Lys158–Ile543) subunits. Stars represent glycosilation sites.  
 
Upon activation, heparanase can be secreted or can translocate into the nucleus. The 
mechanism underlying the nuclear transport of heparanase has not been elucidated yet, but 
three different hypotheses have been proposed: 1) two putative nuclear localisation signals 
could mediate its nuclear localisation [Schubert S.Y. et al., 2004]; 2) heparanase could use 
HS as vehicle [Schubert S.Y. et al., 2004]; or 3) heat shock protein 90 may function as a 
chaperone for nuclear translocation of heparanase [Nobuhisa T. et al., 2007]. 
The mature endoglycosidase stored in the lysosomes is secreted into the extracellular space 
in response to specific physiologic or pathologic stimuli that may vary among cell types 
and biological settings (e.g., inflammatory cytokines, fatty acids, protein kinase A and C) 
[Chen, G. et al., 2004; Shafat I. et al., 2006]. The acidic lysosomal environment provides 
optimal conditions for heparanase storage and enzymatic activity. In fact, it has been 
demonstrated that its enzymatic activity is optimal between pH 5.5 and 6.0 [Gilat D. et al., 
1995]. The acidic tumour microenvironment also favours heparanase activity. In fact, the 
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production of acidic metabolites (e.g. lactic acid) is caused by anaerobic glycolysis under 
hypoxic conditions [Cairns R.A. et al., 2011]; this condition may also explain the enhanced 
activity of other enzymes such as proteases, which together with heparanase can favour 
cancer progression [Mason S.D. and Joyce J.A., 2011]. Inside the nucleus, active 
heparanase has been shown to degrade HS side chains of nuclear HSPGs, leading to the 
regulation of gene expression. Heparanase can interfere with gene expression via different 
mechanisms: 1) enhancing HATs activity by the cleavage of syndecan-1 HS, which is a 
HAT inhibitor. The activation of HATs induces the transcription of genes driving tumour 
progression [e.g. VEGF, Matrix metallopeptidase 9 (MMP-9), HGF] [Purushothaman A. et 
al., 2011]; 2) directly interacting with the nucleic acid [Yang Y. et al., 2015]. 
Heparanase has both enzymatic and non-enzymatic functions. Enzymatic activity, exerted 
by the active 50 kDa molecule, induces the cleavage of HS and the subsequent release of 
HS-binding molecules stored onto the HSPGs and the remodeling of ECM and basement 
membrane; all together these phenomena contribute to facilitate cell motility in tumour 
progression critical processes such as angiogenesis and inflammation [Vlodavsky I. et al., 
2011]. Heparanase non-enzymatic activity is mediated by the binding to still not well 
defined receptors on the cell surface activating signaling cascades intracellularly, such as 
Akt, ERK, p38 and Src pathways, ultimately leading to up-regulation of pro-angiogenic 
factors, such as VEGF and HGF [Fux L. et al., 2009]. 
 
1.2.2. Heparanase role in cancer progression 
The available evidence supports a role for heparanase in cancer progression in a large 
number of malignancies. Aberrant heparanase activity and expression correlates with 
increased micro-vessel density, metastatic potential of tumour cells and patients reduced 
post-operative survival [Kelly T. et al., 2003; Vlodavsky I. and Friedmann Y., 2001; 
Sanderson R.D. et al., 2017]. By degrading HS, heparanase participates in ECM 
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remodeling and promotes the concomitant release of several HS binding molecules, 
allowing cell dissemination, promoting the establishment of a new vascular network that 
supports tumour growth and provides a gateway for invading metastatic cells. Also, the 
signaling capacity of heparanase, which is mediated by the binding to cell surface receptors 
and the activation of intracellular pathways, sustains tumour growth and invasion [Riaz A. 
et al., 2013]. Furthermore, heparanase ability to regulate gene expression supports the 
tumour’s aggressive behaviour by enhancing the transcription of pro-angiogenic and pro-
metastatic factors, such as VEGF, HGF and MMP-9 (Figure 1.8) [Sanderson R.D. et al., 
2017]. 
In multiple myeloma, it has been shown that heparanase also contributes to metastasis and 
angiogenesis by promoting syndecan-1 shedding; in fact, by cleaving HS on syndecan-1, 
heparanase leaves the core protein exposed to attack by proteases, among which MMP-9 is 
up-regulated by heparanase. Shedding syndecan-1 can bind specific receptors (i.e., VLA-4 
and VEGFR2) and stimulate invasion. Moreover, the cleavage and the release of syndecan-
1 extracellular domain in a soluble form acts as a paracrine signal co-factor that ensures 
tumour/stroma cell cross-talk thereby enhancing the activity of HS-binding growth factors 
[Ramani V.C. et al., 2013]. 
It is known that inflammation plays a role in the neoplastic process, fostering proliferation, 
survival and migration [Mantovani A. et al., 2008]. Heparanase is a key player in 
inflammation; indeed, HS remodeling may affect the inflammatory response at multiple 
levels, such as the release of different chemokines and cytokines in the extracellular space, 
the promotion of leukocyte binding to the endothelium and transmigration through EMC 
and basement membrane, and the activation of macrophages through modulation of toll-
like receptors signaling pathway [Goldberg R. et al., 2013; Meirovitz A. et al., 2013; 
Hermano E. et al., 2014; Vlodavsky I. et al., 2016]. Also non-enzymatic activity of 
heparanase sustains inflammation by the activation of intracellular signaling pathways and 
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the promotion of cell-adhesion [Riaz A. et al., 2013]. During inflammation, heparanase 
expression increases in lymphocytes and its secretion contributes to the enhanced 
vascularisation and cell invasion characteristic of tumour-associated inflammation 
[Meirovitz A. et al., 2013]. 
Heparanase has been proposed to participate in autophagy, known to sustain tumour cell 
survival by providing metabolites obtained from the recycling of proteins and damaged 
organelles. This phenomenon contributes to provide growth advantages under stress 
conditions as well as resistance to chemotherapy [Rosenfeldt M.T. and Ryan K.M., 2011]. 
In the autophagocytic process, autophagosomes fuse with lysosomes, where the 
intracellular material can be degraded for recycling. Lysosomal-stored heparanase has been 
implicated in the autophagy process. The enzyme colocalises with the autophagy marker 
LC3-II (associated with autophagosomes) and its expression correlates with autophagy 
extent. The mechanism underlying autophagy induction by heparanase has not been 
clarified yet, but likely involves mTOR1, whose expression is inversely correlated with 
heparanase level (Figure 1.8) [Sanderson R.D. et al., 2017]. Up-regulation of heparanase 
and increased autophagy have been related with chemotherapy resistance [Shteingauz A. et 
al., 2015]. 
Besides, heparanase has been shown to participate in the biogenesis, composition and 
secretion of tumour-derived exosomes (Figure 1.8). These vesicles are considered 
important for the communication between neighbouring cells and for long-distance cell 
communication. By delivering proteins and nucleic acids, they are believed to play a role 
in tumour progression. Heparanase, which can also be a cargo of exosomes and be released 
at distant sites, has been implicated in the establishment of the metastatic niche [Thompson 
C.A. et al., 2013]. 
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Figure 1.8. Schematic model of heparanase trafficking.  
(1) The proheparanase is secreted in the extracellular spaces after synthesis. Here, it interacts with HSPGs, 
such as syndecan-1, and the complex is endocytosed. (2) Endosomes fuse with lysosomes, with the 
subsequent acidification and induction of heparanase cleavage by cathepsin-L. (3) In lysosomes heparanase 
participates in the formation of autophagosome. (4) Active heparanase translocates into the nucleus where it 
modulates gene transcription. (5) Active heparanase can be secreted in the extracellular space. (6) 
Heparanase modulates the formation and the release of exosomes and (7) it can be anchored to syndecan on 
exosome surfaces; heparanase, HPSE [Masola V. et al., 2018]. 
 
1.2.3. Heparanase/heparan sulfate axes as a therapeutic target 
The support provided by heparanase/HSPG to several aspects of malignancy makes this 
system an attractive target for therapeutic intervention. The heparanase/HSPG system 
represents an intriguing nodal point for targeting tumour growth, angiogenesis, metastatic 
spread and drug resistance [Vlodavsky I. et al., 2016; Couchman J.R. et al., 2016; 
Sanderson R.D. et al., 2017; Lanzi C. et al., 2017]. Moreover, heparanase is over-expressed 
in essentially all tumours examined, including bladder, brain, breast, colon, liver, ovarian, 
pancreatic and haematological malignancies in addition to sarcomas [Ilan N. et al., 2006; 
Cassinelli
a
 G. et al., 2016]. Interestingly, knock-out mice develop normally and exhibit no 
apparent anatomical or functional deficiencies and heparanase is the only mammalian 
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endoglycosidase able to cleave HS [Zcharia E. et al., 2009; Vlodavsky I. et al., 2012]. 
Taken together, these observations make heparanase a desirable target for cancer therapy. 
So far, various approaches have been developed to achieve heparanase blockade: 
1) Heparin derivatives bind heparanase as competitive substrate inhibitors, thus 
preventing access to the enzyme catalytic site. Heparin, that is a specialised form of HS 
produced exclusively by mast cells, was the first discovered heparanase substrate and it 
has been employed to inhibit heparanase enzymatic activity [Yahalom J. et al., 1984]. 
Unfortunately, due to thrombocytopenia and bleeding side effects, heparin cannot be 
administered at high concentrations or for prolonged treatments; so intensive synthesis 
studies have been conducted to obtain analogues with reduced anti-coagulant activity 
and increased heparanase affinity [Casu B. et al., 2008]. To reduce the unwanted 
anticoagulant activity of heparin, derivatives have been obtained through chemical 
modifications including oversulfation or partial desulfation, selective alteration of the 
residues that are involved in the biding to the antithrombin, or the development of low 
molecular weight heparin derivatives. Heparin derivatives act not only as heparanase 
inhibitors and HS mimetics preventing the binding of bioactive molecules to HS in the 
ECM and at the cell surface [Lanzi C. and Cassinelli G., 2018]. PI-88 (muparfostat) is 
a phosphosulfomannoligosaccharide (a mixture of highly sulfated oligosaccharides) 
non-cleavable by the endo-β-D-glucuronidase. It inhibits heparanase activity and 
competes with HS for the binding of angiogenic and growth factors [Parish C.R. et al., 
1999]. PI-88 was the first HS mimetic to enter clinical trials and it is currently under 
Phase II investigation for various cancer types [https://clinicaltrials.gov]. A Phase III 
trial in patients with hepatocellular carcinoma was prematurely terminated because the 
drug failed to reach the fixed disease-free survival endpoint. Recent evidence however 
suggests a possible clinical benefit in subgroups of patients with worse prognosis [Liu 
C.J. et al., 2014]. Among the most promising second-generation PI-88 analogues, the 
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tetrasaccharide fully-sulfated PG545 (pixatimod) showed improved anti-tumour 
efficacy and reduced anti-coagulant activity, compared to PI-88 [Hammond E. et al., 
2012]; moreover, it exhibited a remarkable immunomodulatory activity in preclinical 
studies [Weissmann M. et al., 2018]. Currently, PG545 is undergoing a Phase I clinical 
trial in combination with the immunocheckpoint inhibitor nivolumab (anti-PD-1 
antibody) in patients with advanced solid tumours [https://clinicaltrials.gov]. SST0001 
(roneparstat) is a modified 100% N-acetylated and 25% glycol split heparin. N-
acetylation confers to SST0001 a non anti-coagulant feature, whereas the glycol 
splitting enhances heparanase affinity. SST0001 is the only heparanase inhibitor tested 
in sarcoma models so far. Early studies carried out in our laboratory demonstrated a 
down-regulation of angiogenesis-related factors, such as MMP-9, VEGF, and 
inhibition of cell invasion in sarcoma cells treated with the drug [Cassinelli G. et al., 
2013]. SST0001 exhibited in vivo anti-tumour activity in several solid and 
haematological tumour models. A synergistic interaction was observed when used in 
combination with anti-angiogenic drugs (i.e., bevacizumab or sunitinib) in a Ewing’s 
sarcoma model, and with the camptothecin irinotecan in a RT model [Shafat I. et al., 
2011; Cassinelli G. et al., 2013; Cassinelli
b
 G. et al., 2016]. In addition, SST0001 was 
shown to counteract the activation of several RTKs involved in the malignant 
phenotype of STS models [e.g., Epidermal growth factor receptor (EGFR), PDGFR, 
ERBB4 and IGF-1R] [Cassinelli
b
 G. et al., 2016]. In a recently completed Phase I 
clinical evaluation in advanced multiple myeloma patients, this drug showed an 
excellent safety profile and signals of activity [https://clinicaltrials.gov]. Another 
glycol-split low molecular weight heparin, M402 (necuparanib), which is N-sulfated, 
binds HS-binding molecules, including heparanase, with high affinity [Zhou H. et al., 
2011]. In preclinical studies, M402 showed an efficient anti-tumour and anti-metastatic 
activity in murine models of breast and pancreatic cancer [Zhou H., et al., 2011; Chu 
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C.L., et al., 2012]. A Phase II clinical trial in combination with gemcitabine and nab-
paclitaxel in patients with metastatic pancreatic cancer has been recently terminated 
due to insufficient level of efficacy despite promising preclinical activity 
[https://clinicaltrials.gov]. 
 
Figure 1.9. Schematic representation of heparin derivatives.  
Schematic representation of PI-88, PG545, SST0001 and M402. 
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2) Small molecules, of both natural and synthetic origin, have been identified as 
heparanase inhibitors and are undergoing preclinical investigation [Lanzi C. et al., 
2017]. Small molecules derivatives of benzalole and benzazolyl showed potent anti-
heparanase activity in preclinical STS models, resulting in the inhibition of invasion 
and decrease of pro-angiogenic factors (i.e., FGF-1 and 2, VEGF and MMP-9) [Madia 
V.N. et al., 2018; Messore A. et al., 2018]. The recently reported heparanase crystal 
structure is expected to be of great utility for the rational design of improved inhibitors. 
3) Monoclonal antibodies. Recently, Weissmann and collaborators developed two 
different anti-heparanase antibodies, one against the KKDC peptide, a 14-aminoacid 
sequence comprising the substrate-binding domain of heparanase, and the other against 
the full-length protein. In preclinical in vivo studies, they were both able to neutralise 
heparanase, decreasing its intracellular content, and they inhibited lymphoma tumour 
growth and metastasis in preclinical models [Weissmann M. et al., 2016]. 
4) Nucleic acid-based inhibitors. Several attempts have been carried out to silence 
heparanase expression using different RNA interfering molecules, including 
microRNAs (miRNAs), small interfering RNA (siRNAs) and short hairpin RNAs 
(shRNA). MiR-1258 has been shown to down-regulate heparanase by targeting the 3′ 
UTR as demonstrated by luciferase assay in brain metastatic breast cancer cells [Zhang 
L. et al., 2011]. It has been shown in different preclinical studies that the over-
expression of miR-1258 reduces in vitro invasion of cells, and the number of 
experimentally induced metastases in vivo [Liu H. et al., 2012; Shi J. et al., 2017; 
Zhang L. et al., 2011]. MiR-429 has been described to decrease the invasion ability of 
gastric cancer cells by targeting heparanase [Sheng N. et al., 2018]. Other RNAi-based 
systems, such as transient transfection of siRNAs, have been used to silence heparanase 
in different preclinical tumour models. Heparanase siRNA-mediated silencing resulted 
in the inhibition of migration and invasion in various cellular models [Mikami S. et al., 
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2008; Zheng L.D. et al., 2010; Fan L. et al., 2011; Dong W. et al., 2014] and stable 
transfection reduced the tumourigenesis of an in vivo model of hepatocellular cancer 
[Xiong Z. et al., 2012]. Another strategy was the stable transfection of shRNA 
targeting heparanase that induced the decrease of tumour invasiveness, metastasis and 
angiogenesis in a gastric cancer preclinical model [Zheng L.D. et al., 2009]. 
 
1.3. RNA interference approaches 
Conventional chemotherapy generally affects vital cellular processes such as DNA 
replication and cell division. For example, it blocks enzymes involved in replication and 
transcription, or interferes with the cytoskeleton. The main weaknesses of classical cancer 
therapy are the lack of specificity, the consequent occurrence of toxicity and drug 
resistance development. Even targeted therapies present limitations due to inadequate 
specificity and onset of drug resistance. 
The use of RNA-based approaches aimed at interfering with cellular translational 
processes should lead to the generation of therapeutics with advantages in terms of 
specificity and efficacy compared to standard approaches.  
RNAi was discovered in 1998 by the scientists Andrew Fire and Craig Mello in C. elegans 
and it earned them the Nobel Prize for Medicine in 2006 [Fire A. et al., 1998]. MiRNAs 
and siRNAs are small non-coding RNAs with important roles in gene regulation. In the last 
decades, they have been widely investigated as potential novel classes of therapeutic 
agents for the treatment of a wide range of disorders including cancer. RNA interfering 
molecules are able to silence gene expression at the post-transcriptional level by targeting 
messenger RNA (mRNA). In particular, a miRNA has multiple targets bound with 
incomplete complementarity, whereas a siRNA has one specific target at a homologue 
sequence.  
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1.3.1. MicroRNA 
MiRNAs are composed of approximately 19-25 nucleotides and are naturally occurring 
post-transcriptional gene regulatory elements. These evolutionary conserved sequences, 
derived from non-coding regions, have been found in numerous species and have been 
shown to take part in the regulation of almost all cellular processes including 
developmental timings, stem cell functions, cellular differentiation, proliferation, and cell 
death [Calin G.A. and Croce C.M. 2006]. To date, 1917 different miRNAs have been 
discovered in humans [http://www.mirbase.org, March, 27
th
 2019]. 
About half of miRNAs are transcribed from non-protein coding transcripts, while the rest 
are located principally in the introns of coding genes and are co-transcribed with their host 
genes; they can also be grouped in clusters transcribed as poly-cistronic primary transcripts 
[Kim W.N., 2005]. 
MiRNAs are initially transcribed in the nucleus by RNA polymerase II, or more rarely by 
RNA polymerase III, as long primary miRNAs (pri-miRNAs). The pri-miRNAs have the 
typical shape of hairpins and are then processed into precursor miRNAs (pre-miRNAs, ~70 
to 120 nucleotides) by Drosha, a RNase III enzyme which, with the DiGeorge syndrome 
critical region gene 8 (DGCR8 or Pasha), belongs to a multiprotein complex named 
Microprocessor. Next, exportin 5, which recognises the 2-nt overhanging at 3`end of pre-
miRNAs, mediates their transport into the cytoplasm where they are cleaved by another 
RNase III enzyme Dicer into miRNA duplexes. The transactivation response RNA binding 
protein binds Dicer and helps the entry of the nucleic acid into the RNA-induced silencing 
complex (R SC), where the duplexes are divided and the “guide strand” associates with 
catalytic argonaute proteins. The other strand, “passenger strand” is usually degraded or, 
more rarely, associates with argonaute proteins, acting as active miRNA itself. The “guide 
strand” drives the R SC to the target mRNA through sequence complementarity and 
induces its translational repression. Recently, it has been found that RISC, with miRNA 
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and its target mRNA, is stored in processing bodies (P-bodies). The subsequent gene 
silencing is mediated by translational repression, due to imperfect sequence pairing, or 
mRNA deadenylation and subsequent degradation [Bhaskaran M. and Mohan M., 2014]. 
Alteration in miRNAs expression or activity can contribute to several diseases including 
tumour initiation and cancer progression. Altered miRNA expression in tumours compared 
to normal tissues can be linked to specific clinical and biological features [Bartel D.P., 
2004]. Given that expression of certain miRNAs influence tumour treatment responses 
they can also be used as prognostic factors and biomolecules for patient treatment 
stratification. Since their discovery, miRNAs have, therefore, attracted interest as potential 
therapeutic targets as well as new therapeutic tools [Osada H. and Takahashi T., 2007; 
Oliveto S. et al., 2017]. The use of miRNAs offers the opportunity of simultaneously 
regulating a wide range of genes. Moreover, since they are naturally synthesised by cells, 
they display lower toxicity and immune response compared to other therapies [Chen Y. et 
al., 2015]. 
Several miRNA mimetics and antagonists have already been formulated and tested in 
preclinical studies for different diseases, including cancer. MiRNA-based therapeutics are 
designed to achieve miRNA inhibition or miRNA replacement depending on whether the 
miRNA provides a survival advantage to tumour cells or it behaves as a tumour 
suppressor. For the inhibition strategy, cells are transfected with a synthetic single-strand 
RNA, which acts as miRNA antagonists (i.e., antagomirs, locked nucleic acid, etc.) and 
inhibits the action of the endogenous miRNAs. For the replacement strategy, synthetic 
double strand miRNAs (i.e., miRNA mimics) are used to mimic the function of the 
endogenous miRNAs [Petrovic N. and Ergun S., 2018]. Two miRNAs have entered 
clinical trials. Miravirsen, a short locked nucleic acid directed against miR-122 has been 
developed by Santaris Pharma for the treatment of hepatitis C virus. It is administered by 
subcutaneous injection in Phase II clinical trials and no long-term safety issues were 
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developed by patients [van der Ree M.H. et al., 2016; Chakraborty C. and Das S., 2016]. A 
Phase I clinical study of a liposomal synthetic miR-34a mimic (MXR34) was carried out in 
patients with advanced solid tumours, but the trial was terminated because of a high 
incidence of adverse events [Beg M.S. et al., 2017]. In line with this, further efforts to 
devise proper formulation and precise delivery to cancer cells are required to avoid 
undesirable side effects. 
 
1.3.2. Small interfering RNA 
SiRNAs are short (19–30 nucleotides) double-strand RNAs capable of degrading mRNAs 
in the cytoplasm. The mechanism relies on the complementarity between a siRNA and its 
target mRNA, resulting in a specific inhibition of target translation [Torres-Martínez S. and 
Ruiz-Vázquez R.M., 2017]. 
SiRNAs can be introduced into cells using vectors allowing the expression of shRNA, 
which are exported by exportin 5 into the cytoplasm and then processed by Dicer into 
active siRNAs [Brummelkamp T.R. et al., 2002], or transfecting cells with synthetic 
siRNA duplexes. The concentration of siRNA transiently transfected is progressively 
decreased upon cell division and RNase mediated degradation [Bumcrot D. et al., 2006]. 
In the cytoplasm, long dsRNAs interact with Dicer that processes the strands into short 
(~20 to 30 nucleotides) double stranded oligonucleotides with 2-nt overhanging at the 
3`end. Then, siRNAs interact with argonaute proteins, which cleave the “passenger strand” 
while the “guide strand” remains associated with the R SC. Next, the siRNA guides the 
RISC to its target mRNA and, as siRNAs are designed to be perfectly complementary to 
the target, causes site-specific cleavage via argonautes [Lam J.K. et al., 2015]. 
In principle, therapeutic approaches based on siRNA can be delivered either locally or 
systemically. For local administration, siRNAs can be injected directly into the target 
tissue, for example via the intravitreal and intranasal routes. In this way, siRNAs have 
Introduction 
 
 
52 
higher bioavailability and reduced side effects [Whitehead K.A. et al., 2009]. There are 
several siRNAs locally administered for various diseases in clinical trials, including two 
siRNAs developed for cancer treatment [https://clinicaltrials.gov] (Table 1.1). 
Drug Target gene Disease Administration Status 
CEQ508 β-catenin FAP Oral Phase I/II, ongoing 
SIG12D KRAS PDAC Intratumour Phase II, ongoing 
Table 1.1. Clinical trials of siRNAs locally administered. 
Familial adenomatous polyposis (FAP), Kirsten rat sarcoma (KRAS), pancreatic ductal adenocarcinoma 
(PDAC).  
 
Systemic delivery of siRNA is the best option for targeting a specific mRNA in sites with 
limited accessibility. Currently, there are several systemically administered siRNAs under 
clinical trials and, among them, 6 are employed for treating neoplastic diseases (Table 1.2) 
[https://clinicaltrials.gov]. The systemic delivery of siRNAs encounters several limitations, 
such as dose-limiting toxicity, adverse effects due to off-target binding, and activation of 
an immune response [Nikam R.R. and Gore K.R., 2018]. 
Drug Target gene Disease Status 
CALAA-01 RRM2 Solid tumours Phase I, terminated 
Atu-027 PKN3 Solid tumours Phase II, ongoing 
ALN-VSP02 KSP/VEGF Solid tumours Phase I, completed 
TKM-PLK1 PLK-1 GI-NET/ACC Phase II, ongoing 
DCR-MYC MYC HCC Phase II, ongoing 
siRNA-EphA2 EphA2 Solid tumours Phase I, ongoing 
Table 1.2. Clinical trials of siRNAs systemically administered. 
M2 subunit of ribonucleases reductase (RRM2), protein kinase 3 (PKN3), kinesin spindle protein (KSP), 
polo-like kinase-1 (PLK-1), gastrointestinal neuroendocrine tumours (GI-NET), adrenocortical carcinoma 
(ACC), hepatocellular carcinoma (HCC), ephrin type-A receptor 2 (EphA2). 
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SiRNAs and miRNAs have similar physico-chemical properties and for in vivo 
administration encounter similar limitations due to the scarce stability and poor 
bioavailability of RNA; therefore, similar strategies can be employed in principle to 
improve their in vivo efficacy. 
 
1.3.3. Delivery of RNA-interfering molecules 
In the last two decades, RNA-based therapies have been explored widely for clinical 
translation; RNAi-based therapies, able to interfere with the expression of genes, are 
endowed with potential to expand availability of anti-tumour agents and improve the 
efficacy of current therapies when used in combination. In principle, the use of siRNA and 
miRNA to inhibit the aberrant expression of oncogenes should provide the advantage of 
enhanced specificity compared to chemotherapeutics. However, even though these RNA-
based therapies may have promising application in cancer treatment, there are some 
limitations that complicate their clinical application. For example, RNA molecules lack 
stability (half-life lower than 10 minutes), have poor bioavailability, may accumulate in 
off-target sites and activate immunoresponses [Juliano R.L., 2016]. 
The use of chemical modifications improved the stability of RNA therapeutics, reduced 
undesired off-target effects and maximised on-target pharmacological activities. 
Modifications of the sugar as well as the introduction of phosphorothioate linkages, 
changes of nucleosides with introduction of 5’-methylcytidine nucleotide have been made 
among others [Juliano R.L., 2016]. These structural modifications partially overcome 
RNase degradation and the activation of immune system response, improving the potency 
and pharmacological properties of RNAi drugs [Khvorova A. and Watts J.K., 2017]. Even 
so, the delivery of RNA molecules through the various biological barriers remains the main 
problem hindering the widespread development of RNA therapeutics. The negative charge 
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and the high molecular weight of RNA-based therapeutics are the main reasons why these 
molecules have no ability to cross cellular membranes [Dowdy S.F., 2017]. Moreover, 
molecules smaller than 10 nm in diameter would be susceptible to rapid renal clearance 
due to the glomerular pore size, which is approximately 8 nm [van de Water F.M. et al., 
2006]. 
In order to overcome these obstacles, sophisticated delivery technologies for nucleic acids 
are required. For RNA delivery, different strategies have been developed including 
physical, chemical, and viral approaches. The physical methods include needle injection, 
gene gun, electroporation, and hydrodynamic delivery [Mellot A.J. et al., 2013]. The 
chemical approaches include the use of nanoparticles, for instance, lipid-based material, 
cationic polymers, or peptide-based carriers [Zhang S. et al., 2007]. Finally, the most 
efficient delivery approach is based on transduction by using viral vectors that infect cells. 
Unfortunately, this system presents high immunogenicity and safety issues due to the risk 
for viral recombination [Schott J.W. et al., 2016; Kaczmarek J.C. et al., 2017].  
 
1.4. Nanoparticles-based tools for RNAi delivery 
In this thesis, we investigated the use of two delivery platforms both developed in Dr. 
Tasciotti’s laboratory at the Houston Methodist Research  nstitute (HMR ): 1) hybrid 
nanogel particles (HNPs), comprising a pH-responsive cross-linked hydrogel shell around 
a silica core [Khaled S.Z. et al., 2016]; 2) leukosomes, that are liposome-like nanoparticles 
formulated using membrane proteins extracted from purified circulating leukocytes and 
synthetic biocompatible phospholipids [Molinaro R. et al., 2016]. 
Nanoparticles are particles between 1 and 1000 nm size with different physico-chemical 
properties that have been widely exploited for the delivery of various payloads. Several 
therapeutic nanoparticle platforms, including liposomes, polymeric- and albumin-based 
nanoparticles have been FDA approved for cancer treatment. Various systems are currently 
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under clinical and preclinical investigation for the nanodelivery of chemotherapeutic 
agents, small molecules, short nucleic acids, immunotherapeutics for cancer treatment and 
other therapeutic applications. The FDA-approved nanoparticles are primarily liposomal 
formulations of chemotherapeutics (i.e., Doxil/Doxorubicin, Daunoxome/Daunorubicin, 
Marqibo/Vincristine sulphate, Onivyde/Irinotecan) and the albumin bound paclitaxel 
Abraxane. No RNAi-based nanotherapy has been approved for cancer treatment yet, but 
many types of nanoparticles are under investigation for nucleic acid delivery in preclinical 
and clinical studies [Bobo D. et al., 2016; Zhang P. et al., 2018]. The use of delivery 
systems provides the opportunity to enhance in vivo targeting properties, pharmacokinetics, 
half-life and bioavailability of nucleic acid therapeutics [Tatiparti K. et al., 2017]. 
A major challenge in nanoparticle delivery is to favour the transport of therapeutics across 
biological barriers while excluding foreign material out and allowing only selected 
molecules to cross. The nanoparticles have to overcome different hindrances at both the 
systemic and cellular level:  
1) Immune surveillance by the mononuclear phagocytic system. After administration, 
plasma proteins rapidly bind to nanoparticles in a process called opsonisation and 
phagocytic cells recognise and sequester them.  
2) Non-specific accumulation at undesired sites, such as liver, spleen and kidneys, 
contributing to side effects at healthy organs.  
3) Crossing of the biological barriers while preserving their cargo. Nanoparticles have to 
interact with vessel walls and extravasate to disease site. This phenomenon is facilitated by 
the enhanced permeability and retention effect typical of tumours, but it is limitated by the 
interstitial fluid pressure caused by poor lymphatic drainage, as well as extensive fibrosis 
and a dense extracellular matrix.  
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4) Penetration of target cell membranes escaping the endosomal compartment. Commonly, 
nanoparticles undergo active uptake and are internalised in endocytic vesicles that 
eventually fuse with lysosomes, causing the degradation of the payload. Finally, tumour 
cells can neutralise the effects of drug-delivering nanoparticles by activating multi drug 
resistance mechanisms, such as the expression of drug efflux pumps to reduce the 
sensitivity to treatments (Figure 1.9) [Blanco E. et al., 2015].  
 
Figure 1.10. Biological barriers. 
In the blood circulation, nanoparticles undergo opsonisation and subsequent degradation by immune cells. 
They can also be accumulated in excretory organs, such as the spleen, kidney and liver, contributing to non-
specific distribution of nanotherapeutics to non-specific targets. To reach their target tissue, nanoparticles 
must exit the blood vessels and extravasate in tumours. Next, they have to cross cell membrane and avoid 
endosomal entrapment. IFP, interstitial fluid pressure. [Blanco E. et al., 2015] 
 
The delivery of nucleic acids using nanocarriers can be achieved by passive or active 
targeting. The former one relies on the enhanced permeability and retention effect, i.e., the 
prolonged circulation of nanoparticles combined with the leaky vasculature that leads to an 
accumulation in the tumour site, in a non-selective way. The main weakness of this system 
is the off-target delivery to undesired tissues, potentially leading to toxicity and adverse 
side effects [Ngoune R. et al., 2016]. Conversely, an active transport can be mediated by 
the specific ligand-receptors interaction between nanoparticle’s surface and the target 
tissue. This relies on functionalisation of nanoparticles with specific ligands (e.g., 
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transferrin, folic acid). The active delivery minimises the non-specific off-target effects 
typical of passive targeting [Alavi M. and Hamidi M., 2019]. Among frequently used 
nanocarriers there are liposomes and polymers, whose properties can effectively be 
examined using in vitro and in vivo cellular models. 
Liposomes are spherical lipid-based nanovesicles usually composed of neutral or charged 
lipids, which are amphiphilic molecules containing a polar head group connected by a 
linker to a hydrophobic tail. When liposomes are prepared to deliver nucleic acids, the 
positive charge is necessary for the electrostatic interaction with their anionic phosphate 
groups [Wasungu L. and Hoekstra D., 2006]. Cell lines can be transfected with liposomal 
nanoparticles to achieve high transfection efficiency. The subsequent release of nucleic 
acids can occur mainly in two different ways: 1) fusion of liposomal and cellular 
membranes through the interaction between the cationic headgroups of liposomes and the 
anionic glycoproteins and/or proteoglycans of the cellular membrane or 2) the liposome 
can undergo receptor-mediated endocytosis. In the latter case, following cell uptake, 
liposomes are embedded into the endosomes, where the anionic lipids diffuse from the 
endosomal membrane to the cationic liposomes, thus buffering and destabilising the 
endosomal membrane itself. This so-called “flip-flop” mechanism results in the 
displacement of the nucleic acid which is released to the cytosol [Xu Y. and Szoka F.C. Jr., 
1996]. The main advantages of liposomes are their biocompatibility, biodegradability and 
low toxicity, due to the presence of naturally occurring materials. On the other hand, due to 
their positive charge, they may lead to non-specific interactions with serum proteins and 
cause cytotoxicity and haemolysis [Wasungu L. and Hoekstra D., 2006], as well as 
immune system triggering through the activation of toll-like receptors [Molinaro R. et al., 
2013]. 
Cationic polymers represent a valid alternative to liposomes with relatively high 
transfection efficiency, easy preparation procedures, good biodegradability, low toxicity 
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and high stability [Wagner E., 2014]. These polymers electrostatically bind to the anionic 
phosphate groups along the backbone of the nucleic acids. These interactions enable the 
packing of the nucleic acids in nanoparticles called polyplexes [Aied A. et al., 2013]. The 
use of polymers provides protection from enzymatic degradation and prevents 
disaggregation in the presence of serum proteins. The polyplexes enter the cell mainly by 
endocytosis; this mechanism and the ability to escape the endosomal compartment depend 
on polymer composition, size and surface potential [Buyens K. et al., 2010; Molinaro R. et 
al., 2013]. 
Among the most commonly used polymer, polyethylenimine (PEI) presents good 
transfection capacity, but has low biocompatibility. PEI is a cationic polymer with high 
number of amines that provides the polymer with high charge density, conferring unique 
features such as strong nucleic acid condensation with protection from enzymatic 
degradation, and buffer capacity through the “proton sponge effect”, which allows 
endosome disruption and escape of nanoparticles from the endo-lysosomal entrapment 
[Godbey W.T. et al., 2001]. PEI exists in two forms, i.e., linear and branched, and this 
feature affects complexation with the nucleic acids and transfection efficiency. Branched 
PEI presents a higher number of primary amines, allowing the formation of more stable 
complexes essential for the delivery of siRNA [Kwok A. and Hart S.L., 2011]. 
Transfection efficiency also depends on PEI molecular weight, with higher molecular 
weight enhancing transfection efficiency, but also significantly increasing cytotoxicity due 
to high charge density and lack of degradable linkages [Goyal R. et al., 2014]. A proper 
balance between molecular weight and branched/linear form is needed for successful RNA 
delivery. In order to overcome PEI cytotoxicity, a proposed strategy is to conjugate PEI 
with other molecules (i.e., cholesterol, polyethylene glycol) [Cavallaro G. et al., 2017] or 
other nanoparticles [Buchman Y.K. et al., 2013; Ewe A. et al., 2017]. 
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1.4.1. Hybrid nanogel particles 
Hydrogels are hydrophilic polymeric networks with 3D configuration with high liquid 
absorbing capacity. Hydrogels are similar to living tissues, by virtue of their high water 
content, their soft and rubbery consistency, and low interfacial tension with biological 
fluids [Ratner B.D. and Hoffman A.S., 1976]. For drug delivery, they are required to be 
biodegradable and biocompatible. As they can swell in an aqueous environment, the most 
common mechanism of payload release from hydrogels is passive diffusion, which can be 
further regulated by adjusting the polymer composition. Other mechanisms of release are: 
1) diffusion-controlled, 2) swelling-controlled, or 3) chemically-controlled. In this way, the 
drug is released in a specific predetermined temporal and/or spatial manner within the 
body. Moreover, the release form hydrogel-based delivery systems can be time-controlled 
or stimuli-induced, such as under specific physiopathological conditions (i.e., temperature, 
pH, etc.) [Hamidi M. et al., 2008]. The use of hydrogel nanoparticles is limited by their 
low structural integrity and poor mechanical stability. The mechanical properties of 
hydrogels can be improved by increasing the amount of crosslinking, although this can 
affect the responsiveness and biocompatibility [Yang J. et al., 2013; Buwalda S.J. et al., 
2014]. Hybrid systems can be used to overcome the limitations of hydrogels. As a matter 
of fact, a rigid inorganic core can stabilise the hydrogel without losing its environmental 
responsiveness and biocompatibility [Yang J. et al., 2013]. 
The nanoparticles used in this thesis (HNPs) have a silica core encased within a pH-
responsive hydrogel composed by poly(diethylaminoethyl methacrylate) (PDEAEM) 
crosslinked with polyethylene glycol methacrylate (PEGMA) and triethylene glycol 
dimethacrylate (TEGDMA) linkers [Khaled S.Z. et al., 2016] (Figure 1.10).  
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Figure 1.11. HNP. 
(A) Schematic representation of a HNP. (B) Scanning electron microscope (SEM) image of HNPs, (C) 
transmission electron microscopy (TEM) image of HNPs [Khaled S.Z. et al., 2016]. 
 
HNPs demonstrated the ability to buffer the acid microenvironment through the 
protonation of the tertiary amines exposed on the particle surface, thereby acquiring a 
positive surface charge and increasing their size. This mechanism, known as “proton 
sponge effect”, endorses the nanoparticles with the ability to escape endosomal 
compartment [Khaled S.Z. et al., 2016]. 
In a previous study, siRNA loaded onto HNPs was efficiently released in an acidic pH 
environment, escaping endosomal sequestration. These nanoparticles were shown to 
significantly decrease the expression of CXCR4 in a human breast cancer cell line both in 
vitro and in vivo; moreover, they accumulated preferentially at the tumour site after 
intravenous injection [Khaled S.Z. et al., 2016]. Based on the afore-mentioned properties 
of HNPs and combining them with the physiopathological features of STS models, we 
decided to investigate the delivery of siRNAs to the tumour tissue using HNPs. We 
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hypothesised that the enhanced angiogenesis and subsequent leaking vasculature of STSs 
would trigger the accumulation of HNPs to the tumour.  
 
1.4.2. Leukosomes 
Leukosomes, which are liposome-like nanovesicles enriched in leukocyte membrane 
proteins, were developed in Dr. Tasciotti’s laboratory and firstly described by Molinaro 
[Molinaro R. et al., 2016]. These nanoparticles, prepared using membrane proteins 
extracted from purified circulating leukocytes and synthetic biocompatible phospholipids, 
were formulated to target and treat local inflammation [Molinaro R. et al., 2016]. The 
leukosome surface contains several membrane-associated proteins of leukocytes: among 
them, integrins (e.g., LFA-1, Mac-1, VLA-4), which facilitate particles binding to inflamed 
endothelium, while self-tolerance biomarkers (e.g., CD47, CD45 and MHCI) allow 
prolonged circulation and biocompatibility (Figure 1.11) [Molinaro R. et al., 2016].  
 
Figure 1.12. Graphic representation of leukosome. 
(A) Leukocyte-derived membrane proteins. (B) Phospholipids and protein mixture. (C) Leukosome 
phospholipid bilayer with integrated proteins. Dipalmitoylphosphatidylcholine (DPPC), 1,2-Distearoyl-sn-
glycero-3-phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), Cholesterol (CHOL) 
[Molinaro R. et al., 2016]. 
 
Owing to their size and molecular composition, leukosomes can be considered similar to 
exosomes, which are also nanosized membrane vesicles composed by a bilayer of 
phospholipids with proteins [Arrighetti N. et al., 2018]. Exosomes are natural carriers of a 
wide variety of biological molecules, such as lipids, proteins, DNA, mRNA, non-coding 
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RNA and various metabolites [Valadi H. et al., 2007]. In addition, leukosomes can be 
manufactured using a microfluidic-based platform, named NanoAssemblr, which allows a 
standardisable, batch-to-batch consistent, scalable, and high-throughput assembly method 
(Figure 1.12) [Molinaro R. et al., 2018]. This approach represents a universal, versatile and 
scalable tool for the manufacturing of lipid-based nanoparticles. 
 
Figure 1.13. Schematic representation of the assembly of leukosomes using NanoAssemblr. 
The NanoAssemblr platform allows the simultaneous synthesis of liposome-like nanoaprticles and the 
incorporation of a nucleic acid within them. An aqueous phase containing nucleic acid and membrane 
proteins is injected with an organic phase containing lipids in a microfluidic chip. By controlling the flow 
rate ratio between the two phases, the total flow rate of the two streams, and the temperature, it is possible to 
tune the size and shape of nanoparticles [Molinaro R. et al., 2018]. 
 
Based on the afore-mentioned properties of leukosomes, we decided to investigate the 
delivery of siRNAs to the sarcoma tissue using leukosomes. We hypothesised that the pro-
inflammatory function of heparanase, facilitating leukocyte recruitment, can be exploited 
for targeting the inflamed tumour microenvironment and efficiently deliver the cargo to 
STSs. 
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Treatment of recurrent and metastatic STS remains a challenge. Despite a few recently 
approved molecular targeted and histology-driven therapies, survival rates are still largely 
unsatisfactory and prognosis is poor for most patients, underscoring the need for new 
therapeutic strategies. 
Advances in understanding the pathogenesis of sarcomas have evidenced a crucial role for 
the tumour microenvironment. As in other solid tumours, the complex interactions between 
tumour cells and components of the microenvironment are essential for sarcoma growth 
and dissemination, and influence the response to therapies. Accumulating evidence 
indicates that the heparanase/HSPG system plays a crucial role at the interface between 
tumour and stromal components, and highlights the implication of heparanase in critical 
processes of tumour biology (e.g., inflammation, growth, angiogenesis, metastasis, drug 
resistance). 
Several lines of evidence support heparanase as a suitable target for cancer treatment; first 
of all, its expression is increased in all cancer types examined and several studies have 
correlated heparanase overexpression with reduced survival. There is only one 
enzimatically active form of heparanase in humans that is expressed at very low levels in 
healthy tissues. Moreover, preclinical studies of heparanase overexpression or knockdown 
demonstrated the relevant role of heparanase in tumour progression. Finally, preclinical 
and early clinical data with HS mimetics confirmed the feasibility and safety of targeting 
heparanase for treatment of cancer patients. 
Understanding the effects of specific heparanase inhibition in various tumour contexts is 
important to optimise the use of inhibitors alone and in rational combinations. By 
neutralising mRNA molecules, RNAi allows specific and efficient gene silencing and, 
combined with nanodelivery systems, represents a promising approach potentially 
transferable to the therapeutic setting.  
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On the basis of these considerations, the ultimate goal of this study was to assess in vitro 
and in vivo effects of heparanase RNAi approaches, with potential therapeutic application, 
in different sarcoma models.  
Specific aims of the thesis work were to: 
1) Identify small RNAi molecules (i.e., miRNA or siRNA) down-regulating 
heparanase expression and examine in vitro their functional effects in sarcoma cell 
lines characterised by high expression of heparanase.  
2) a. Optimise a nanoparticle-based system to deliver heparanase RNAi molecules in 
vitro. 
b. Assess distribution and therapeutic efficacy of nanoparticle-delivered anti-
heparanase RNAi in in vivo sarcoma preclinical models.  
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3.MATERIALS AND METHODS 
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3.1. Cell lines and culture conditions 
The human RT cell line A204 was obtained from American Type Culture Collection. 
Previously listed as a rhabdomyosarcoma cell line, in 2002 it was found to harbour a 
mutation in the SMARCB1 (hSNF5/INI1) gene, causing the loss of the encoded protein, 
consistent with classification as a RT [Betz B.L. et al., 2002]. The human SS cell line 
CME-1 was obtained from a monophasic tumour containing the SS18-SSX2 translocation 
and established by immortalisation with SV40 [Renwick P.J. et al., 1995]. This cell line 
was already available in our Institute [Mancuso T. et al., 2000]. The human non small cell 
lung cancer cell line A549, the human breast cancer cell line MDA-MB-231 and the 
human umbilical vein endothelial cells (HUVEC) were obtained from American Type 
Culture Collection. All tumour cell lines were authenticated by short tandem repeat 
analysis using the AmpFLSTR Identifiler PCR Amplification Kit (Applied Biosystems, 
Thermo Fisher Scientific, Waltham, MA, USA). For A204 cell line, microsatellite 
information is available online, while for CME-1 cell line the identity was confirmed by 
comparing the microsatellite profile with the analysis performed when the cells were 
received. Cell line identities were further confirmed by western blot analysis detecting 
expression of the SS18-SSX2 fusion protein and the loss of SMARCB1 in CME-1 and 
A204 cells, respectively. Cells were kept in culture for no more than 20 passages and 
thawed from an authenticated frozen stock. A204, CME-1 and A549 cell lines were grown 
in RPMI-1640 medium (Lonza, Basel, Switzerland) supplemented with 10% fetal bovine 
serum (FBS) (Gibco, Thermo Fisher Scientific). MDA-MB-231 cell line was grown in 
DMEM-F12 medium (Lonza) supplemented with 5% FBS. HUVEC cell line was grown in 
EBM-2 medium (Lonza) supplemented with EGM-2 SingleQuots (Lonza). Cells were 
grown as monolayer, at 37 °C in a 5 % CO₂ atmosphere and routinely checked for 
mycoplasma contamination (MycoAlert Mycoplasma Detection Kit, Lonza). Previous 
characterisation of the cell lines performed in our laboratory showed that A204 and CME-1 
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cells grow as intramuscular tumour xenografts in SCID mice. Microscopic metastatic foci 
have been observed in the lungs of tumour bearing mice (Figure 3.1). 
 
Figure 3. 1. Representative images of metastatic deposits in lungs from mice harbouring orthotopic 
A204 or CME-1 tumours.  
The lungs lobes were formalin fixed and paraffin embedded. For A204, sections were subjected to 
immunohistochemistry with anti-Vimentin (of human origin) [unpublished]. For CME-1, sections were 
stained with hematoxylin and eosin [Cassinelli G. et al., 2018]. 
 
3.2. Cell transfection and transient gene silencing 
For transfection, A204 and CME-1 cells were plated into 6-well plates at a density of 2.5 x 
10
4
 cells/cm
2
 and 3 x 10
4
 cells/cm
2
, respectively. Transfection efficiency was preliminary 
evaluated using BLOCK-iT™ Alexa Fluor Red Fluorescent Control (Ambion). Twenty 
four h later, cells were transfected in RPMI-1640 medium without FBS, using 
Lipofectamine RNAiMAX (Thermo Fisher Scientific) as transfection reagent with various 
concentrations of selected miRNA (has-miR-1258 ID: MC13267, mirVana™, Ambion, 
Thermo Fisher Scientific, or ID: mi0006392, MiRIDAN, Dharmacon, Lafayette, CO, 
USA), siRNA (HPSE Silencer Select Validate siRNA, s21304/siR04, s21305/siR05 and 
s21306/siR06 Ambion) or negative control (mirVana™ miRNA mimic Negative Control 
#1, and Silencer Select Negative Control #2, Ambion). Cells were incubated with the 
transfection mix for 5 h and then the transfection medium was replaced with complete 
medium. Cells were harvested at different time points after transfection for further 
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analyses. The levels of miRNA upon transfection were checked by qRT-PCR. When 
required, transfected cells were reseeded for cell growth curves, colony formation assays, 
migration and invasion assays. 
 
3.3. MiR-1258 and heparanase gene expression analysis 
3.3.1. RNA isolation 
RNA was isolated using miRNeasy Mini Kit (Qiagen, Hilden, Germany) following 
manufacturer’s instructions. The miRNeasy Mini Kit enables purification of total RNA 
with efficient enrichment of miRNA and small RNAs. Absorbance at 260 nm (A260) and 
280 nm (A280) was detected using a NanoDrop 2000c (NanoDrop, Thermo Fisher 
Scientific) spectrophotometer. A260 was used to calculate RNA concentration. A260/A280 
was used as a first means of assessing RNA purity. After quantifying RNA samples, they 
were stored at -80 °C.  
 
3.3.2. Quantitative reverse transcriptase polymerase chain reaction  
Quantitative RT-PCR was applied to quantify miRNAs and transcripts levels. RNA was 
first reverse transcribed to cDNA; then cDNA was amplified. Reverse transcription was 
performed using 2 different kits: miScript II RT Kit (Qiagen), for total RNA including 
miRNAs, or High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) for 
mRNA. The reaction was carried out using 1 μg RNA in the presence of RNase inhibitors, 
in a Biometra thermocycler (Biometra GmbH, Göttingen, Germany) following the 
manufacturer’s instruction. Two negative controls where included to check for possible 
reagent contaminations (one sample without reverse transcriptase and one without RNA). 
Amplification of the synthesised cDNA was performed using PrimeTime qPCR assays: 
HPSE Hs.PT.58.15529804 and GAPDH Hs.PT.39a.22214836 (Integrated DNA 
Technologies, IDT, Coralville, Iowa), based on the TaqMan technology (Applied 
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Biosystems). Amplification of miRNA was performed using miScript Primer assays: 
Hs_miR-1258_1 MS00014315 and Hs_SNORD48_1 MS00007511 (Qiagen) using SYBR 
Green-based real-time PCR. Technical triplicate reactions were carried out on MicroAmp 
Optical 96-Well reaction plates (Applied Biosystems). For genes, each reaction volume (10 
μL) contained 2.5 μL cDNA, 5 μL master mix (TaqMan Universal PCR Master Mix, 
Applied Biosystems) and 0.5 μL of the specific assay  for miRNAs, each reaction volume 
(25 μL) contained 2.5 μL of reverse transcribed miRNA, 12.5 μL master mix (QuantiTect 
SYBR Green PCR, Qiagen), 2.5 μL miScript Universal Primer (Qiagen), 2.5 μL of specific 
assay and 5 μL nuclease-free water. Amplification reactions were performed using a 
7900HT Fast Real-Time PCR System (Applied Biosystems) equipped with Sequence 
Detection Systems 2.4 software (Applied Biosystems). Data analysis was performed by the 
use of RQ manager software (Applied Biosystems). 
Relative levels of heparanase and miR-1258 were determined through the relative 
quantification (RQ) method using the comparative cycle threshold (Ct) (ΔΔCt) assay 
configuration. Briefly, for each reaction a value of Ct was identified.  
ΔCt, ΔΔCt and RQ were then calculated as follow: 
 
ΔCt = Ct(target gene/miRNA) − Ct(reference gene/miRNA). 
ΔΔCt = ΔCt(target sample) − ΔCt(reference sample) 
RQ = 2
-ΔΔCT 
 
GAPDH and SNORD48 were used as reference gene or miRNA, respectively. For each 
time point, cells transfected with negative control were chosen as reference samples. 
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3.4. Protein expression analysis 
3.4.1. Protein extraction and quantification 
Protein lysates were prepared using a lysis buffer derived from the Laemmli buffer 
[Laemmli U.K., 1970] composed of 0.125 M Tris HCl pH 6.8 (Trizma hydrochloride, 
Sigma-Aldrich, Merck, Burlington, MA, USA), 5% sodium dodecyl sulfate (SDS, Lonza) 
and protease/phosphatase inhibitors (25 mM sodium fluoride, 10 μg/mL pepstatin A, 1 mM 
phenylmethylsulfonyl fluoride, 10 μg/mL trypsin inhibitor, 12.5 μg/mL leupeptin, 30 
μg/mL aprotinin, 1 mM sodium orthovanadate and 1 mM sodium molibdate), all purchased 
from Sigma-Aldrich. 
At the appropriate time, A204 and CME-1 cells were harvested after washing twice with 
ice-cold ‘v-PBS’ (phosphate-buffered saline, PBS, Lonza, containing 100 μM sodium 
orthovanadate), to inhibit the action of phosphatases. The lysis buffer was added to wells 
and cell detachment from plastic was completed on ice by using a cell scraper (Corning 
Inc, Corning, NY, USA). Lysed cells were collected in tubes that were then boiled for 5 
min and sonicated for 30 s with immersion probe at 10% amplitude, 400W/20kHz 
(Branson 450 Digital Sonifier, Emerson Electric Co, Ferguson, MO, USA). 
An aliquot of cell lysates was kept for quantification of protein concentration that was 
performed through the bicinchoninic acid (BCA) assay method (Pierce, Thermo Fisher 
Scientific) using a 562 nm-reading-spectrophotomer (Uvikon 930, NorthStar Scientific, 
Leeds, UK). This method is based on a colorimetric reaction produced by the interaction 
between BCA and cuprous ions, which in turn are generated by the reduction of cupric ions 
by proteins.  Briefly, a standard curve was prepared using a series of dilutions of known 
concentration of bovine serum albumin (BSA) and assayed alongside the unknown 
proteins. Protein concentrations were calculated by comparing OD readings with those 
obtained from the standard curve. Lysates were frozen and stored at -80 °C. 
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3.4.2. Nucleus/cytoplasm fractionation 
Fractionated protein lysates were prepared using a Nuclear Extraction Kit (Cayman 
Chemicals, Ann Arbor, M , USA) following manufacturer’s instruction. Briefly, cell lysis 
was obtained using a hypotonic buffer, followed by a spin recovery of cytoplasmic lysates. 
Next, pelleted nuclei were lysed in a ‘nuclear extraction buffer’. Samples were stored at -
80 °C. To test the efficiency of fractionation, HDAC1 and α-tubulin as nuclear and 
cytoplasmic protein markers were used in membrane immunodecoration. 
 
3.4.3. Gel electrophoresis and western blotting 
After total cell lysis or nucleus/cytoplasm separation, 20 µg samples were fractionated by 
SDS-polyacrylamide gel electrophoresis. Gradient NuPAGE gels (4-12%) were employed 
following the manufacturer’s procedures (Applied Biosystems). After gel fractionation, 
proteins were transferred on Hybond ECL nitrocellulose membranes (GE Healthcare, 
Chicago, IL, USA) using a wet transfer apparatus. The transfer was performed overnight 
(O/N) at constant 37 V, using a transfer buffer (10% Tris-glycine pH 8.3 and 20% 
methanol). Transfer efficacy was evaluated by Ponceau S staining (Sigma-Aldrich). 
Membranes were first washed with ‘Tris-buffered saline (TBS)-Tween’ (TBS containing 
0.1% Tween-20, Sigma-Aldrich), then incubated with a ‘blocking buffer’ (TBS-Tween 
containing 5% (w/v) dried skimmed milk (Merck)). Membranes were then incubated on 
rotation, O/N at 4°C, with primary antibodies (Table 3.1) dissolved in blocking buffer. 
After rinsing 3 times with TBS-Tween, membranes were incubated for 1 h with 
peroxidase-conjugated mouse or rabbit IgG secondary antibodies (NA9310 and NA9340, 
GE Healthcare) dissolved in blocking buffer. After washing 3 times with TBS-Tween and 
once with TBS, the binding of secondary antibodies to membranes was detected on 
autoradiography film by chemiluminescence (ECL, GE Healthcare). Briefly, oxidation of 
luminol, a chemiluminescent substrate, is catalysed by horseradish peroxidase. This 
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reaction forms excited intermediates that release photons which are captured by the X-ray 
film when they decay to a lower energy level. This reaction occurs in presence of 
enhancers that amplify the light intensity by about 1000 folds. 
All western blot analyses were repeated at least 3 times using independent biological 
samples. Band quantification was performed taking advantage of the ImageJ software 
[Abramoff M.D. et al., 2004], following the specific protocol for 1D gel quantification 
available on ImageJ website (http://rsb.info.nih.gov/ij/docs/menus/analyze.html#gels). 
I tested 5 anti-heparanase antibodies: HPA-1 (H-80): sc-25825, HPA-1 (E-10): sc-515935 
[Santa Cruz Biotechnology, Dallas, TX, USA], anti-heparanase 1: ab42817 [Abcam, 
Cambridge, UK], anti-heparanase 1:MBS178331 [MyBioSource, San Diego, CA, USA] 
and HPA-1 733 [obtained from Professor Vlodavsky I.]. For this thesis, HPA-1 (H-80): sc-
25825 was selected as the best option. 
Antibody Dilution Catalog. No. Company 
Heparanase 1:500 sc-25825 Santa Cruz 
HDAC1 1:1000 sc-10809 Santa Cruz 
α-tubulin 1:1000 T5168 Sigma-Aldrich 
Actin 1:3000 A2066 Sigma-Aldrich 
Table 3.1. List of the employed antibodies and their dilutions. 
 
3.4.4. Antibody Arrays 
Antibody Arrays were used to investigate the relative levels of multiple angiogenic factors 
in sarcoma cells, (Human Angiogenesis Array Kit, ARY007, R&D Systems, Minneapolis, 
MI, USA) following the manufacturer’s procedures. Briefly, A204 and CME-1 cells were 
lysed in 1% NP-40 lysis buffer and centrifuged at 14.000 g for 15 min. The supernatant 
was recovered and the BCA assay method was used to quantify the protein concentration. 
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One mg of proteins was applied to each array.  
 
3.4.5. Enzyme-linked immunosorbent assays 
Heparanase concentration in cell culture conditioned media of transfected cells was 
determined by solid phase sandwich enzyme-linked immunosorbent assays (ELISA) (CSB-
E09899H, Cusabio Technology LLC, Houston, TX, USA). To obtain conditioned medium, 
48 h after cell transfection, the supernatant was removed and replaced with RPMI-1640 
without FBS. Twenty-four h later, the conditioned medium was collected and stored at -80 
°C until use. To obtain cell lysates, A204 and CME-1 cells were detached with a scraper in 
PBS containing phosphatase and protease inhibitors (Halt™ Protease  nhibitor Cocktail 
(100X) 78430, Halt™ Phosphatase  nhibitor Cocktail (100X) 78428, Thermo Fisher 
Scientific), and stored O/N at -80 °C. After 2 freeze-thaw cycles, cells were centrifuged at 
5000 x g at 4 °C for 5 min. The supernatant was collected and assayed immediately. 
Samples from each experiment were tested in duplicate, according to the manufacturer's 
instructions. The coloured product generated by the enzyme activity was detected by a 
microplate reader set at 450 nm (iMark, Bio-Rad, Hercules, CA, USA). 
 
3.4.6. Immunofluorescence staining 
A204 and CME-1 cells were seeded at appropriate density in 6-well plates containing 3 
coverslips. After 24 h, cells were transfected with anti-heparanase siRNA or negative 
control. Forty-eight h later cells were rinsed in PBS and fixed in 3.7% formaldehyde 
dissolved in PBS for 15 min. After washing with PBS, cells were permeabilised with 1% 
bovine serum albumin (BSA, Sigma-Aldrich) in PBS (PBA) + 0.1% Triton X-100 
(Honeywell Fluka, Morris Plains, NJ, USA), for 5 min. After washing with PBA, cells 
were incubated with PBA for 1 h. Wells were then incubated at room temperature with a 
heparanase antibody at 8 µg/mL for 3 h. After 2 washes with PBA, cells were incubated 
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with an AlexaFluor 488-conjugated goat anti-rabbit antibody (Life Technologies, Thermo 
Fisher Scientific) at 4 µg/mL for 1 h. After washing with PBA, wells were incubated with 
2 µg/mL Hoechst 33342 (Sigma-Aldrich) for 1 min, to counterstain nuclei. Coverslips 
were then removed from wells and mounted on glass slides with ProLong Antifade 
Mountants (Thermo Fischer Scientific) and let dry O/N. Fluorescence imaging was 
performed using a fluorescence microscope equipped with a digital camera.  
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3.5. Functional studies in vitro 
3.5.1. Cell growth curves 
Cells were seeded in 12-well plates (A204 8 x 10
3
 cells/cm
2
; CME-1 7 x 10
3
 cells/cm
2
) 
and, after 24 h, transfected with anti-heparanase siRNA or negative control. Cells were 
counted daily, after harvesting with trypsin-EDTA (Gibco), with an automated cell counter 
(Beckman Coulter, Brea, CA, USA). All cell growth experiments were performed at least 3 
times. 
 
3.5.2. Soft agar colony assay 
A 5% agarose (low gelling temperature, Sigma-Aldrich) in Millipore water (Merck) was 
prepared and autoclaved at 120 °C for 30 min. For CME-1 cells, 1.5 mL base of 0.5% 
agarose was prepared by diluting the melt 5% agarose in pre-warmed medium at 37 °C, 
allowed to solidify in Petri dishes (9.6 cm²) for 1 h. A cell suspension in medium was 
added to agarose to obtain final 0.33% agarose which was poured on the 0.5% agarose 
layer and allowed to solidify at room temperature for 1 h. Since A204 cells tended to 
invade across the base, growing below as monolayer, the agarose concentrations were 
adjusted to 0.7% for the base and 0.46% for the cell containing upper layer. The plates 
were then incubated at 37 °C for 7-10 days. To highlight colonies, 0.5 mL of p-
iodonitrotetrazolium (1 mg/mL in saline solution) vital dye was added to the plates. The 
next day, colonies were counted under a magnificator. 
 
3.5.3. Cell migration assay  
A wound healing assay was performed to assess migration of both cell lines by examining 
the cell ability to close gaps in a monolayer. A204 and CME-1 cells were seeded in 6-wells 
plates 4.2 x 10
4
 cells/cm
2
. Twenty four h later, cells were transfected with anti-heparanase 
siRNA or negative control. Following additional 24 h, wounds were induced by scratching 
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the cell monolayer with a sterile 200 µl pipette tip. Images were captured by phase-contrast 
microscopy immediately following wound induction (0 h), and at 16, 24, 48 and 72 h post-
scratching. To quantify cellular migration across the width of the wound, the length of 40 
individual lines throughout the wound were measured at each time point. Experiments 
were performed in triplicate.  
 
3.5.4. Cell invasion assay 
The invasion ability of cells was determined using the Transwell permeable support (8.0 
μm Polycarbonate Membrane, 6.5 mm  nsert, Costar, Corning). Membranes were coated 
with 60 μL of 208 μg/mL Matrigel (Corning). Forty-eight h after transfection, cells were 
seeded in duplicate onto the upper chamber in FBS-free RPMI-1640 medium (4-6 x 10
5
 
cells/mL in a volume of 300 μL). The lower chamber contained 1 mL medium with FBS. 
The chambers were incubated at 37 °C for 24 h allowing cells to invade Matrigel and pass 
through the microporous membrane. Then, cells adherent to filters on the lower chamber 
side were fixed with 100% ethanol for 30 min and stained with 0.4% sulforhodamine B 
(SRB, Sigma-Aldrich) in 1% acetic acid at room temperature for 20 min. Filters were then 
washed with 1% acetic acid and left to dry for 24 h. Finally, cells in 10 random fields per 
chamber were counted at the microscope. Experiments were performed in triplicate. 
 
3.6. Synthesis and characterisation of nanoparticles for RNAi 
delivery  
Nanoparticles have been synthesised and characterised in Dr. Tasciotti’s laboratory, at the 
HMRI, by high qualified chemists. All the in vitro studies testing nanoparticles efficacy on 
A204 cells were performed at the HMR  in collaboration with Tasciotti’s team. 
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3.6.1. Synthesis and characterisation of pH-responsive hybrid nanogel 
particles (HNP) 
HNPs were fabricated and characterised by chemists from Dr. Tasciotti’s laboratory, 
through a novel one-pot synthesis approach, as previously described [Khaled S.Z. et al., 
2016]. In summary, this procedure is based on the free radical co-polymerisation of the 
cationic monomer 2-(diethylamino)ethyl methacrylate and the monomeric silica precursor 
vinyltrimethoxysilane in the presence of polyethylene glycol methacrylate, triethylene 
glycol dimethacrylatelinkers and Fluorescein-5-isothiocyanate (FITC) for the imaging 
purposes (Thermo Fisher Scientific). This procedure yielded the in-situ formation of a 
cross-linked PDEAEM hydrogel shell around the fluorescent silica core. To eliminate the 
surfactants and unreacted monomers, the particles were washed several times in repeated 
cycles of resuspension in acetone and water, and then centrifuged. The particles were then 
lyophilised and stored in a desiccator until use. 
 
3.6.2. Synthesis and characterisation of Leukosomes 
Leukosomes were already available in the laboratory of Dr. Tasciotti. They were fabricated 
and characterised by designated personnel, as previously described [Molinaro R. et al., 
2016]. Leukosomes were prepared using the thin layer evaporation (TLE) method. Briefly, 
DPPC or the fluorescent equivalent, DSPC, DOPC, and CHOL (Avanti Polar Lipids Inc. 
Alabaster, AL, USA) were dissolved in a chloroform:methanol mixture (3:1 v/v) at 5:1:3:1 
molar ratio, respectively, and the solvent was then evaporated through a rotary evaporator 
(BÜCHI Labortechnik AG, Switzerland) to form a thin film. Films were hydrated with 
membrane proteins from inflammatory cells (1:300 protein-to-lipid ratio) dispersed in PBS 
to assemble leukosomes by 3 cycles of heating at 45 °C and vortexing, 3 min each. 
Membrane proteins were obtained from T cells and macrophages of Balb/c mice. Briefly, 
Balb/c mice (4 weeks old) were used to isolate fresh infiltrating leukocytes after injecting 
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thioglycollate medium (2.5 mL) into the peritoneum, to induce inflammation. Four days 
later, animals were sacrificed and the peritoneum washed 3 times with cold PBS in order to 
collect the peritoneal lavage. Fluorescence activated cell sorting (FACS) was performed to 
purify T cells and macrophages, taking advantage of specific surface markers. A 
commercial kit (Qiagen) was used to isolate enriched membrane protein fractions. Finally, 
following to lipid suspension hydration with membrane proteins, the formulation was 
extruded 10 times through 200 nm pore-size cellulose acetate membranes at 45 °C in order 
to obtain unilamellar vesicles, which were then dialysed overnight through 1000 KDa 
membranes (Spectrum Laboratories, Inc. Rancho Dominguez, CA, USA) to eliminate raw 
material and unincorporated proteins. Final leukosome concentration was assessed by 
measuring the fluorescence of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(carboxyfluorescein) (ammonium salt) [Molinaro R. et al., 2016] and normalised to the one 
of control liposomes. 
Leukosomes and liposomes were also synthesised using the above mentioned microfluidic 
approach [Kastner E. et al., 2014; Kastner E. et al., 2015] as described in Molinaro R. et 
al., 2018. By using this system it was possible to simultaneously synthesise leukosomes 
and incorporate the siRNA within the nanoparticles. Briefly, an aqueous phase containing 
siRNA and membrane proteins and an organic phase containing lipids were injected in a 
Y-shaped inlet channel, one for each arm of the Y (Figure 3.2). Then, by controlling the 
flow rate ratio between the aqueous and organic phases, the total flow rate of the two 
streams, and the temperature, the leukosomes were produced with the desired size of about 
100 nm.  
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Figure 3.2 Schematic representation of leukosomes/liposomes synthesis with NanoAssemblr.  
https://www.precisionnanosystems.com 
 
Leukosomes were stored at 4 °C until use. For in vivo imaging, 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-(lissamine rhodamine B sulfonyl (Avanti Polar Lipids) was 
dissolved with the other lipids (0.1 v/v molar ratio) in chloroform before the hydration 
phase. 
 
3.6.3. Dynamic Light Scattering  
The hydrodynamic diameters (Dh), Zeta (ζ) Potential and polydispersity index (PDI) of 
HNPs, liposomes and leukosomes were characterised by dynamic light scattering (DLS) 
using a ZetaPALS Zeta Potential Analyzer with a Multi-Angle Particle Sizing Option 
installed (Brookhaven Instruments Corporation, Holtsville, NY, USA), operating with a 25 
mW laser at a wavelength of 660 nm. Typically, 2.5 mL suspensions of the HNPs in 
phosphate buffer (PB) with physiological ionic strength (100 mM) at a concentration of 0.1 
mg/mL were used for the characterisation at a temperature of 25 °C. Scattered light was 
detected at 90° to the incident beam. A 9 mM leukosome suspension was diluted in 
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bidistilled water at a final concentration of 100 µM and used for the characterisation at a 
temperature of 25 °C. Scattered light was detected at an angle of 15°. Seven measurements 
were performed with 20 runs each and the results averaged. 
 
3.6.4. Fourier transform infrared analysis 
Fourier transform infrared (FT-IR) spectra were obtained on a Nicolet 6700 spectrometer 
(Thermo Fisher Scientific) with a deuterated triglycine sulfate detector and potassium 
bromide (KBr) beam splitter. Typically, 64 scans were performed in the wave number 
range of 4000–600/cm, both forward and backward at 4 kHz, with a manual gain of one. 
Pellets of about 10 mg of HNPs and 200 mg KBr (spectroscopy grade) (Thermo Fisher 
Scientific) were pressed using a Carver laboratory press. Spectra were collected by 
transmitting IR light through the pellets.  
 
3.6.5. Atomic force microscopy  
Atomic force microscopy (AFM) images of HNPs were collected in the ScanAsyst mode 
on a Multimode (Bruker Corporation, Santa Barbara, CA, USA) microscope using single-
beam silicon cantilever probes (Bruker MLCT at a resonance frequency of 10 kHz, a 
nominal tip curvature radius of 10 nm, and a force constant of 0.04 N/m). All 
measurements were subjected to first-order flattening. Particle size was calculated using 
the Nanoscope 6.13R1 software (Digital Instruments, Tonawanda, NY, USA). Mean 
values from 40 random particles in 3 independent experiments are reported. Quantitative 
AFM force mapping analysis was performed to evaluate the relative elasticity of particles 
in order to obtain a complete elastic property map of heterogeneous samples. HNPs were 
kept in acidic (phosphate/citrate buffer solution) or alkaline buffer (phosphate 
buffer/NaOH buffer solution) before AFM analysis. Young’s modulus was calculated for 
six different samples corresponding to 512x512 force–separation curves obtained over a 
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10x10 μm area. Young’s modulus represents the ability of a material to withstand changes 
in length when under lengthwise tension or compression. Young’s modulus was calculated 
using the following equation  
 
where F − Fadh is the force on the cantilever relative to the adhesion force, R is the tip end 
radius, d − d0 is the deformation of the sample and E* is the reduced modulus [Maugis D., 
2013]. 
 
3.6.6. Nanoparticles toxicity assay 
A204 cells were seeded into a 96-well plate at 5 x 10
3
 cells/cm
2 
and treated for 72 h with 
increasing concentrations (0.01 - 10 ng particle/cell) of HNPs. Then, 3-(4,5-
dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich) was added 
to complete media at 5 mg/mL and plates were incubated for 4 h at 37 ° C. The water-
soluble tetrazolium dye is reduced in the mitochondria of viable cells and purple formazan 
crystals are formed and then solubilised with dimethyl sulfoxide. Cell viability is measured 
through OD reading at 570 nm.  
 
3.6.7. Scanning electron microscopy 
For SEM imaging, A204 cells were seeded on Silicon wafers chips (5x5 mm) at a density 
of 5 x 10
3
 cells per filter and treated with HNPs. After 15 min, A204 were fixed in 2.5% 
glutaraldehyde O/N (Sigma-Aldrich), then, dehydrated with increasing concentrations of 
ethanol, followed by incubation in a 50% alcohol-hexamethyldisilazane (Sigma-Aldrich) 
solution for 10 min, with a final incubation in pure hexamethyldisilazane for 5 min, to 
prepare for O/N drying in a desiccator. Specimens were mounted on SEM stubs (Ted Pella, 
Inc., Redding, CA, USA) using conductive adhesive tape (12 mm OD PELCO Tabs, Ted 
Pella, Inc.). Samples were sputter coated with a 10 nm layer of gold using a Plasma 
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Sciences CrC-150 Sputtering System (Torr International, Inc., New Windsor, NY, USA). 
SEM images were acquired under high vacuum, at 20.00 kV, spot size 5.0, using a FEI 
Quanta 400 FEG ESEM equipped with an ETD (SE) detector (Thermo Fisher Scientific). 
 
3.6.8. Flow cytometry measurements 
The entry of nanoparticles into A204 cells was measured by FACS. For these experiments, 
cells were seeded in 6-well plates (3 x 10
4
 cells/cm
2
) in 2 mL complete medium. After 24 
h, cells were washed and incubated with 0.01 - 0.1 - 1 ng/cell of nanoparticles freshly re-
suspended in sterile water, or with 100µM of Rhodamine-labeled leukosomes for 3 h. After 
incubation with nanoparticles, cells were washed and detached from the plates with 
trypsin. Finally, cells were fixed in ice-cold PBS with 2% paraformaldehyde. HNPs 
fluorescence was acquired using a BD FACS Forteza flow cytometer (BD Biosciences, 
Franklin Lakes, NJ, USA). At least, 10
4
 events/sample were acquired and analysed with 
FlowJo software (FlowJo LLC, Ashland, OR, USA). For cell cycle analysis, cells were 
fixed in 70% ethanol 24 h after transfection, stained in PBS containing 10 μg/mL 
propidium iodide (PI; Sigma-Aldrich), and RNase A (66 U/mL; Sigma-Aldrich) for 18 h, 
and analysed by BD Accuri™ C6 Cytometer (BD Biosciences)  104 events were acquired 
and analysed with the C6 Analysis Software (BD Biosciences). 
 
3.6.9. Migration assay 
A204 cells were seeded at 2 x 10
5
 cells/ml
 
in complete medium in the upper chamber (8 
µm pore size) of 24-well Transwell plates (Costar) and treated with 0.1 ng/cell of HNPs for 
3 h. Cells were then washed three times with PBS and serum-free media was added into 
the upper chamber while complete media was added into the lower chambers. After 24 and 
72 h of incubation at 37º C, cells were fixed with 100% ethanol for 30 min and stained 
with 0.4% SRB in 1% acetic acid at room temperature for 20 min. Filters were then 
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washed with 1% acetic acid and left to dry for 24 h. Finally, cells in 10 random fields per 
chamber were counted at the microscope. Experiments were performed in triplicate. 
 
3.6.10. Transmission electron microscopy 
For TEM, A204 cells were plated at 2x10
5
 cells per well in a 6-well plate. The cells were 
treated with 0.1 ng of HNPs per cell for 3 h, and then washed. At 3, 6, 12, 24, 48 and 72 h 
after treatment, the cells were fixed in a solution of 2% paraformaldehyde and 3% 
glutaraldehyde in PBS, pH 7.4 at room temperature for 1 h. After fixation, the samples 
were washed and treated with 0.1% cacodylate buffered tannic acid, oxidised with 1% 
buffered osmium tetroxide for 30 min, and stained with 1% uranyl acetate. The samples 
were dehydrated in increasing concentrations of ethanol, infiltrated and embedded in Poly-
bed 812 medium. The samples were then polymerised in a 60 °C oven for 2 days. Ultrathin 
sections were cut in Leica Ultracut microtome (Leica), stained with uranyl acetate and lead 
citrate in a Leica EM Stainer, and examined in a JEM 1010 TEM (JOEL, USA, Inc., 
Peabody, MA, USA) at an accelerating voltage of 80 kV. Digital images were obtained 
using the AMT Imaging System (Advanced Microscopy Techniques, Danvers, MA, USA) 
by HMRI personnel. 
 
3.6.11. Hybrid nanogel particle-siRNA loading and release 
A fluorescent siRNA (siGLO RISC-Free Control siRNA labeled with Dy547, Dharmacon) 
was used to determine the pH-mediated loading and release kinetics of the HNP system. 
Polyplexes were formed by mixing 25 pmol of Dy547-labeled siRNA with the HNPs at an 
amino/phosphate (N/P) ratio of 40 in PB solutions at a pH of 6 or 7.4. In a typical 
procedure, a 100 μL aliquot of 300 μg HNPs was mixed with a 100 μL aliquot of 0.3325 
μg (25 pmol) siRNA in PB solution. The mix was gently shaken at room temperature for 
15 min. The resulting mixture was left at room temperature for another 15 min. The 
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solution was then spun down at 21,000 g for 5 min. The loading was evaluated by 
analysing the fluorescence intensity of the supernatant with a spectrofluorimeter. The same 
procedure was used to load the functional anti-heparanase siRNA. To investigate the pH-
mediated release of siRNA, the siRNA-HNP complexes loaded at pH 7 were incubated in 
PB solution at pH 5, 6 or 7.4. The amount of siRNA released was monitored by evaluating 
Dy547 fluorescence intensity with a spectrofluorimeter. All the procedures were performed 
in a RNAse-free environment. 
 
3.6.12. Leukosome/liposome-siRNA loading  
Leukosomes were loaded with siRNA following two different protocols. The first one 
relies on the use of Exo-Fect (System Biosciences, Palo Alto, CA, USA), a novel nucleic 
acid transfection agent that enables the transfection of nucleic acids directly into isolated 
exosomes and exosome-like nanoparticles. Dy547-labeled siRNA or anti-heparanase 
siRNA were incubated with Exo-Fect and leukosomes following the manufacturer 
instructions. Briefly, Exo-Fect solution was combined with siRNA (15-100 pmol), 
leukosomes and sterile 1X PBS. The solution was then incubated at 37°C in a shaker for 10 
min and then placed on ice. The reaction was stopped by adding ExoQuick-TC reagent to 
the suspension and the tubes were placed on ice for 30 min. Finally, the samples were 
centrifuged at 13,000 rpm for 3 min to eliminate the unencapsulated siRNA and the pellet 
resuspended in sterile PBS. Encapsulation of siRNA was evaluated by analysing the 
fluorescence intensity of the siRNA loaded into leukosomes, with a spectrofluorimeter. 
The siRNA-leukosomes were immediately used to transfect cells. 
The second loading method was performed by exploiting the electrostatic interaction 
between the anionic phosphate groups of siRNA and the cationic nitrogen groups of 
choline, which constitutes the polar head of phospholipids. The siRNA was added directly 
into the lipid formulation during leukosomes assembly with NanoAssemblr as 
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aforementioned. A fluorescent siRNA (Dy547-labeled siRNA) was used to evaluate the 
loading of this class of molecules. Fifteen – 100 pmol siRNA were loaded into the 
leukosomes and, after ultracentrifugation, siRNA encapsulation was evaluated by 
analysing the fluorescence intensity of the loaded leukosomes, with a spectrofluorimeter. 
An aliquot of 0.7 8 μg (60 pmol) of anti-heparanase siRNA was used for loading into 
leukosomes used for functional studies. Encapsulation of anti-heparanase siRNA was 
evaluated using Quant-iT RiboGreen Assay (Thermo Fisher Scientific), a fluorescence-
based assay. Fluorescence generated by the binding of RiboGreen to double-stranded 
siRNA was measured using FLx-800 microplate reader (BIO-TEK Instruments, Winooski, 
VT, USA). Encapsulation efficiency was defined as the percent of siRNA initially added 
that was encapsulated in nanoparticles. All the procedures were performed in an RNAse 
free environment. 
 
3.6.13. Polyethylenimine/siRNA-nanoparticle complexes formation. 
Polyethylenimine (PEI) F25 (25 kDa)/siRNA complexes were prepared as previously 
described [Werth S. et al., 2006]. Briefly, the PEI/siRNA mass ratio was 5:1 
(corresponding to N/P ratio 38) in nuclease-free water. The mixed solution was vortexed 
and incubated for 30 min at room temperature. Then, the PEI/siRNA complexes were 
incubated with nanoparticles as follow: for silica nanoparticles, the desired amount of 
PEI/siRNA was added to particles in aqueous solution, vortexed and incubated for at least 
1 h at room temperature; for liposomes and leukosomes equal volumes of PEI/siRNA 
complexes and nanoparticles were added at a PEI/lipid mass ratio of 5, vortexed and 
incubated for at least 1 h at room temperature. 
 
3.6.14. SiRNA-nanoparticles trafficking 
A204 cells (2 × 10
4
) were seeded in 4-wells Nunc 177399 Lab-Tek Chamber Slide 
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(Thermo Fisher Scientific). The next day, cells were transfected with Dy547-labeled 
siRNA using the Lipofectamine RNAiMAX for 5 h, or treated with Dy547-labeled siRNA-
loaded HNPs or leukosomes for 3 h. After transfection, cells were washed twice with PBS 
and stained with LysoTracker Red DND-99 and Hoechst 33342 or, for later time point 
analysis, fresh culture medium was added. Twenty-four h later, live cells were stained with 
Wheat Germ Agglutinin (WGA) Alexa Fluor 633 conjugate or LysoTracker Red DND-99 
and Hoechst 33342 (Thermo Fisher Scientific) following the manufacturer’s instruction. 
All experiments were performed in 3 replicates. The cells were observed and the images 
were acquired with a Nikon fluorescence microscope (Nikon Corporation, Tokyo, Japan) 
using a 60X magnification lens. Images were analysed by using “N S elements” (Nikon) 
and “ mageJ” software. To evaluate fluorescence intensity, 3 different fields were acquired 
from each well. 
 
3.6.15. Intravital microscopy  
Intravital microscopy (IVM) was carried out as described in van de Ven A.L. et al., 2013. 
A total of 5 x10
6 of A204 cells, suspended in 100 μL of PBS, was injected intramuscularly 
into the right leg of male SCID mice. Calipers were used to measure tumour diameters. 
Tumour volume was calculated using the following formula: [Length x (width)
2
]/2. On day 
20, when the mean tumour volume reached 200 mm
3
, the mice were randomly assigned to 
2 groups (n = 3). Groups were treated via intravenous administration with either FITC-
labeled 1 mg HNPs, loaded with Dy547-labeled siRNA, or 1 mg rhodamine labeled 
leukosomes. Mice were maintained anesthetised by inhalation of 2% isoflurane throughout 
the experiment. Under deep anaesthesia, tumours were exposed with surgical dissection of 
the skin while an intact blood supply was maintained. Immediately after injection, images 
were acquired over 3 h from 200 μm Z-stacks using an upright Nikon A1R laser scanning 
confocal microscope (Nikon) equipped with a resonance scanner, motorised and heated 
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stage. All settings, including laser power, gain, offset, and pinhole diameter were 
maintained constant throughout each acquisitions. All images were analysed with NIS-
Elements AR 4.12.01 64-bit software (Nikon). The Z-stack with the highest fluorescent 
intensity was used for further analyses. The threshold was adjusted to eliminate 
autofluorescence and the same threshold was applied for all image analyses. The relative 
fluorescent intensity was measured using a region of interest constructed using 5 
concentric circles in the selected Z-stacks.  
 
3.6.16. Immunofluorescence of tumour sections 
Explanted mice tumours were washed twice with PBS, embedded in a cryomold in 
Optimal Cutting Temperature (O.C.T., Tissue-Tek O.C.T. Compound, Sakura Finetek, 
Alphen aan den Rijn, The Netherlands), and instantly frozen at −80 °C. Ten μm-thick 
slides were obtained by cutting tumour blocks with a cryostat at −20 °C. The slides were 
stored at −20 °C. Immunofluorescence (IF) staining was performed once cryo-sections 
were obtained. Briefly, slides were thawed and fixed in 4% paraformaldehyde followed by 
blocking with 5% BSA (Sigma-Aldrich) in PBS. After washing, they were incubated O/N 
at 4 °C with an anti-CD31 antibody (BD Biosciences) at 2 µg/mL. After O/N incubation, 
sections were washed and a secondary antibody (4 µg/mL Alexa Fluor 488) was added at 
room temperature for 1 h. Sections were then counterstained with 2 µg/mL Hoechst 33342 
for 1 min, mounted using ProLong Gold Antifade, and cover-slipped. Tumour sections 
were imaged using a Nikon A1 Confocal Imaging System. 
 
3.6.17. Animal studies 
Animal studies were performed in accordance with the guidelines of the Animal Welfare 
Act and the Guide for the Care and Use of Laboratory Animals based on approved 
protocols by HMRI Institutional Animal Care and Use Committee. Male SCID mice were 
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purchased from Charles River Laboratories and housed in specific pathogen-free 
conditions. 
 
3.7. Statistical Analysis 
All the numeric data are presented as mean values ± standard deviation from at least three 
independent experiments. Two-tailed Student's t test was chosen as statistical analysis and 
performed by Prism GraphPad software. P-values <0.05 were considered statistically 
significant. 
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4.1. MiR-1258 transfection 
As first RNAi approach to silence heparanase in sarcoma cells, a miR-1258 mimic was 
used in transient transfection experiments. MiR-1258 is an intronic miRNA transcribed in 
the antisense orientation to the gene of the zinc finger protein 385B, isoform 1. It maps on 
human chromosome 2 (GRCh38.p12, 179860836 – 179860908 – www.genome.ucsc.edu). 
MiR-1258 was previously described to target the 3' UTR of the human heparanase gene 
(Figure 4.1). Its expression was found inversely correlated with that of heparanase in breast 
cancer clinical specimens and brain metastatic breast cancer, characterised by heparanase 
over-expression, non small cell lung cancer and gastric cancer cell lines and tissues [Tang 
D. et al., 2013; Zhang L. et al., 2011; Liu H. et al., 2012; Shi J. et al., 2017]. 
Heparanase is up-regulated in sarcomas and its expression has been found correlated with 
tumour progression and poor prognosis in Ewing’s sarcoma and osteosarcoma [Shafat I. et 
al., 2007; Cassinelli G. et al., 2013; Kazarin O. et al., 2014; Kim H.S. et al., 2006]. Due to 
its pro-metastatic and pro-angiogenic functions, it is a promising target for sarcoma 
therapy. A204 and CME-1 cell lines represent optimal models for the study of heparanase 
inhibition, because they express high levels of heparanase and display a metastatic 
behaviour in vivo. 
First of all, the transfection’s efficiency of A204 and CME-1 sarcoma cells was evaluated 
by using a commercial fluorescent oligonucleotide (BLOCK-iT Alexa Fluor Red 
Fluorescent Control) and Lipofectamine RNAiMAX as transfection reagent. Both A204 
and CME-1 cells showed high transfection efficiency as shown by the comparison of light 
microscopy and fluorescence images (Figure 4.2). 
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Figure 4.1. Predicted target sequence of miR-1258 in the 3’-UTR of human heparanase mRNA. 
Alignment of miR-1258 with human heparanase 3’-UTR. Complementary sequence on heparanase mRNA is 
shown in red. The seed sequence on miR-1258 is underlined [Zhang L. et al., 2011]. 
 
Figure 4.2. Transfection’s efficiency of A204 and CME-1 cells. 
Efficiency of transfection in the human sarcoma cell lines, A204 and CME-1, as detected by a fluorescent 
oligonucleotide using a fluorescence microscope 24 h after transfection. 
 
The miR-1258 mimic or the negative control were then transiently transfected in the 
sarcoma cells to determine whether this miRNA functionally affected endogenous 
heparanase expression. Heparanase mRNA and protein levels were evaluated at different 
time points following transfection with miR-1258 mimic concentrations ranging from 5 to 
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50 nM. The qRT-PCR analysis showed high levels of miR-1258, which were maintained 
up to 14 days after transfection, in both cell lines (Figure 4.3, A). Heparanase mRNA 
levels were minimally affected by the miR-1258 mimic transfection (Figure 4.3, B). In 
fact, miR-1258 mimic induced, at the highest concentration of 50 nM, a mild down-
regulation of heparanase in A204 cells, particularly at late time points; CME-1 cells 
presented fluctuant heparanase levels. Western blot analysis of A204 and CME-1 cell 
lysates prepared 48 h to 14 days after transfection with 50 nM miR-1258 mimic showed 
that heparanase protein expression was not decreased by exogenous miR-1258 over-
expression (Figure 4.3, C). 
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Figure 4.3. MiR-1258 mimic transfection in sarcoma cell lines.  
Quantitative RT-PCR analysis of miR-1258 (A) and heparanase (B) in A204 and CME-1 cells. Expression 
levels are reported as Relative Quantification with respect to cells transfected with the negative control (RQ 
= 1). The columns represent the mean and standard deviation of 3 independent experiments. SNORD48 and 
GAPDH were used as housekeeping controls for miR-1258 and heparanase, respectively. Western blot 
analysis (C) of heparanase after transfection with 50 nM miR-1258 mimic or negative control. Actin was 
used as loading control. Relative Quantification, RQ; heparanase, HPSE; Negative control, Neg Ctr; miR-
1258 mimic, miR-1258. 
 
Further experiments, aimed at increasing the efficiency of heparanase silencing by miR-
1258 mimic, were conducted using A204 cells, because these cells displayed a mild 
reduction of heparanase mRNA levels in the previous experiments. Thus, A204 cells were 
subjected to two consecutive transfections with 50 nM miR-1258 mimic or negative 
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control, in order to induce a consistent and durable decrease of heparanase levels. Cells 
were transfected again 72 h after the first transfection. After 7 and 10 days, cells were 
collected to assess miR-1258 and heparanase levels. As shown by the bar graphs, a strong 
increase of miR-1258 was detected applying two rounds of transfection. In contrast, a mild 
reduction was observed for heparanase mRNA levels (Figure 4.4, A). 
Since lentiviral stable transfection of miR-1258 mimic was previously reported to induce 
heparanase silencing in brain metastatic breast cancer and non small cell lung cancer cells 
[Liu H. et al., 2012; Zhang L. et al., 2011], the miR-1258 mimic was also tested in cellular 
models similar to cells used in those studies to compare the efficacy of transient 
transfection. A549 non small cell lung cancer cells and MDA-MB-231 breast cancer cells 
were transfected with 50 nM miR-1258 mimic or negative control and qRT-PCR analysis 
was performed 72 h after transfection (Figure 4.4, B). In both cell lines, in spite of the rise 
of miR-1258 levels, heparanase mRNA expression was barely decreased. As a further 
control, a miR-1258 mimic produced by an alternative company and already tested by 
Zhang and collaborators [Zhang L. et al., 2011], was transfected in A204 cells and the 
effects were compared to those of a commercial anti-heparanase siRNA (siR06 - s21306, 
Thermo Fisher Scientific; Figure 4.5 and Table 4.1). Also the alternative miR-1258 mimic 
did not efficiently inhibit heparanase expression, whereas the siR06 reduced heparanase 
mRNA level more than 75% compared to cells transfected with negative control siRNA 
(Figure 4.4, C). 
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Figure 4.4. Attempts to increase miR-1258 mimic efficacy. 
(A) Quantitative RT-PCR analysis of miR-1258 and heparanase in A204 cells. (B) MiR-1258 mimic 
transfection in A549 and MDA-MB-231 cells. (C) Heparanase levels in A204 after alternative miR-1258 
mimic or siR06 transfection. Expression levels are reported as Relative Quantification with respect to cells 
transfected with the negative control (RQ = 1). The columns represent the mean and standard deviation 
obtained in 3 experiments. SNORD48 and GAPDH were used as housekeeping miRNA and gene for miR-
1258 and heparanase, respectively. Relative Quantification, RQ; heparanase, HPSE. 
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Figure 4.5. siR04, siR05 and siR06 sequences and binding sites on the four different transcript variants 
of heparanase.  
The lines represent the heparanase transcript variants whose exons are represented as black boxes. Each 
siRNA is shown as a coloured line in correspondence with the binding exons. 
Information available on www.thermofisher.com. Heparanase, HPSE. 
 
siRNA Location Clone ID siR04 - Exon  siR05 - Exon  siR06 - Exon  
NM_001199830.1  NP_001186759.1  6 9 11 
NM_001098540.2  NP_001092010.1  7 10 12 
NM_001166498.2  NP_001159970.1  8 9 11 
NM_006665.5  NP_006656.2  8 11 13 
Table 4.1. SiR04, siR05 and siR06 binding sites.  
The table shows the targeted heparanase’s exons for each siRNA in the fourth heparanase transcript variants. 
Information available on www.thermofisher.com. 
 
Taken together, these experiments indicated that transient transfection of miR-1258 mimic 
is not sufficient to inhibit heparanase expression in a stable and persistent way in the 
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examined models. For this reason, the following experiments were carried out using 
siRNA molecules to induce heparanase silencing, instead of miR-1258 mimic. 
 
4.2. Anti-heparanase siRNA transfection 
Preliminary experiments were performed to select an optimal siRNA concentration and 
specific siRNAs to be used in the next experiments. A204 and CME-1 cells were 
transfected with siR06 at 5, 25 and 50 nM. A 25 nM concentration was selected for further 
experiments because it was the lowest concentration able to silence heparanase for up to 7 
days (Figure 4.6, A). Two additional anti-heparanase siRNAs (siR04, siR05) targeting 
different heparanase mRNA sites were tested (Figure 4.5 and Table 4.1). Heparanase 
expression was evaluated by qRT-PCR at 5 different time points up to 14 days after 
transfection (Figure 4.6, B) and by western blot analyses after 72 h (Figure 4.6, C). All the 
siRNAs tested were able to down-regulate heparanase mRNA expression up to 14 days, 
but with siR05 the silencing effect was progressively lost, particularly in CME-1 cells. 
Also western blot analysis showed a better reduction of heparanase protein level after 
siR04 and siR06 transfection. Thus, siR04 and siR06 were selected for further 
experiments, being the most effective at heparanase protein modulation. 
Results 
 
 
99 
 
Figure 4.6. SiRNAs transfection in sarcoma cell lines. 
(A) Quantitative RT-PCR analysis of heparanase in A204 and CME-1 cells transfected with different 
concentrations of siR06. (B) Quantitative RT-PCR analysis of heparanase in A204 and CME-1 cells 
transfected with 25 nM siR04, siR05 and siR06. Expression levels are reported as Relative Quantification 
with respect to cells transfected with the negative control (RQ = 1). The columns represent the mean and 
standard deviation of 3 experiments. SNORD48 and GAPDH were used as housekeeping miRNA and gene 
for miR-1258 and heparanase, respectively. (C) Western blot analysis of heparanase 72 h after transfection 
with 25 nM siRNAs or negative control. Actin was used as loading control. Relative Quantification, RQ; 
Negative control, Neg Ctr; heparanase, HPSE. 
 
4.2.1. Effects of siRNA on extracellular heparanase 
To evaluate the functional effects of heparanase silencing, the enzymatic activity of the 
endoglycosidase was assessed in conditioned media from siRNA-transfected cells. In fact, 
heparanase is known to exert its enzymatic activity in the extracellular environment, 
through cleavage of heparan sulfate, and it is therefore secreted by the cells. Moreover, 
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because of the peculiar trafficking following its synthesis, it is present in the extracellular 
space also as inactive form (Figure 1.6, from Introduction). The amount of heparanase in 
the conditioned media was first measured through ELISA, at 72 h after cell transfection 
with negative control, siR04 or siR06 (Figure 4.7, A). The level of heparanase was 
significantly reduced in the conditioned media after siRNAs transfection of both A204 and 
CME-1 cells, as compared to negative control transfection. Then, heparanase activity was 
quantified by an enzymatic assay in serum-free conditioned media of the transfected 
sarcoma cells. Heparanase enzymatic activity, expressed as ng of heparan sulfate released 
from a heparan sulfate-coated plate per minute, was significantly reduced in both cell lines 
transfected with the siRNAs compared to cells transfected with negative control (Figure 
4.7, B).  
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Figure 4.7. Down-regulation of heparanase in the extracellular environment. 
(A) Heparanase concentration in conditioned media collected from human sarcoma cell lines 72 h after 
transfection with negative control, siR04 or siR06. (B) Heparanase enzymatic activity measured in 
conditioned media of A204 cells and CME-1 cells 72 h after transfection. The enzymatic activity is expressed 
as ng of heparan sulphate removed per minute. Data were normalised to the total amount of protein extracted 
from the cells. The results represent the mean ± standard deviation of 3 independent experiments performed 
in triplicate. Negative control, Neg Ctr; heparanase, HPSE; heparan sulphate, HS. 
 
4.2.2. Effects of siRNA on cell motility 
Since heparanase has been reported to exert pro-migrative and pro-invasive properties in 
several cancer cells, the effect of heparanase silencing on cell motility was examined in 
sarcoma cells. Confluent cells were transfected with either siRNAs or negative control and, 
after 5 h, the cells were subjected to wound healing. Pictures of the wound were taken at 
time 0 and 24 h, or 72 h, for CME-1 and A204 cells, respectively. Both siRNAs 
significantly inhibited the migration of A204 and CME-1 cells, as determined by the 
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measure of the migration distance. The migration distance of A204 negative control, siR04 
and siR06 was 135 ± 4, 70 ± 2, and 60 ± 4 µm, respectively. The migration distance of 
CME-1 was 150 ± 3, 85 ± 2, and 55 ± 3 µm, respectively (Figure 4.8). 
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Figure 4.8. Effects of anti-heparanase siRNAs on migration in sarcoma cell lines. 
Representative images of wound healing assay evaluated at 72 h for A204 (A) and  at 24 h for CME-1 (B) 
cells aftyer scratch. Cells were treated with negative control, siR04 or siR06. The migration distance (in µm) 
is represented in bar charts (C and D). Graphs depict the mean and standard deviation of three independent 
experiments. 
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To assess the effect of heparanase silencing on the cell invasion capability, cells were 
seeded in transwells 48 h after transfection with negative control or siRNAs. Twenty-four 
h later, cells that invaded the lower chamber passing through Matrigel were counted. As 
shown in Figure 4.9, Matrigel invasion was significantly inhibited by the two siRNAs in 
both cell lines. These results indicated that the down-regulation of heparanase expression 
inhibited migration and invasion ability of the human sarcoma cells. 
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Figure 4.9. Effects of anti-heparanase siRNAs on invasion in sarcoma cell lines. 
Representative images of transwell invasion assay of A204 (A) and CME-1 (B) cells treated with negative 
control, siR04 or siR06 at 72 h after transfection. Cells that invaded the Matrigel membrane of the Transwell 
were stained with SRB and counted under a microscope. In A204 cells the reduction of invasion was 31.8 % 
± 6.6 or 52.2 % ± 6.7 for cells transfected with siR04 or siR06, respectively, compared to negative control. In 
CME-1 cells the reduction of invasion was 37.1 % ± 8.3 or 60.3 % ± 7.7 for cells transfected with siR04 or 
siR06, respectively, compared to negative control. The percentage of invading cells is represented in bar 
charts (C and D), graphs depict the mean and standard deviation of three independent experiments. 
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4.2.3. Effects of siRNA on cell proliferation and colony formation 
To determine whether the observed effects of heparanase silencing were related to effects 
on cell growth and proliferation over the time frame of the migration and invasion 
experiments, cell proliferation assays were performed with transfected cells. After 
transfection with negative control or siRNAs, cells were counted over 6 consecutive days 
(Figure 4.10, A). These experiments showed that, actually, silencing of heparanase did not 
affect cell proliferation in adherent cells. 
A204 and CME-1 cell ability to form colonies in soft agar was also tested to examine if 
silencing resulted in decreased anchorage independent growth which is evaluated in a long-
term assay. SiR06 significantly reduced the colony number, especially in CME-1 cells; 
(Figure 4.10, B). 
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Figure 4.10. Heparanase siRNAs effect on cell proliferation and colony formation. 
(A) Cell proliferation assay of cell transfected with negative control, siR04 or siR06. Cells were counted at 
the cell counter over 6 consecutive days. (B) Colony formation assay in soft agar of A204 and CME-1 
transfected with negative control, siR04 or siR06. 
 
4.2.4. Effects of siRNA on intracellular heparanase 
On the basis of previous results, further experiments were carried out using only siR06, as 
it was the most efficient in heparanase silencing and simultaneously in counteracting 
tumour cells aggressiveness.  
Heparanase is localised intracellularly in the cytoplasm, mostly in lysosomes, and into the 
nucleus, but also secreted in the extracellular space. To examine the effect of RNAi on 
heparanase protein levels in intracellular compartments, cell lysates from negative control- 
and siR06-transfected sarcoma cells were subjected to subfractionation. Cytoplasmic and 
nuclear fractions were then analysed by western blotting for heparanase expression.  
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Heparanase exists in different forms, in fact, it is translated as a pre-proenzyme and, after 
the cleavage of the signal peptide, a latent pro-heparanase is generated (65 kDa). This 
inactive enzyme undergoes further proteolytic cleavage, mediated by cathepsin L, and the 
active heparanase is obtained as a noncovalent heterodimer (8 kDa + 50kDa).  
The pre-proheparanase form was highly sensitive to siRNA transfection and its reduction 
was evident in both cytoplasm and nucleus (red arrow in Figure 4.11). In contrast, latent 
heparanase level, sequestered into the nucleus, was not reduced by siRNA (blue arrow in 
Figure 4.11); also the level of cleaved form of the endoglycosidase was not affected by 
siRNAs transfection and it was mostly accumulated in the cytoplasm (green arrow in 
Figure 4.11). It is known from the literature that active heparanase is segregated in the 
lysosomes [Goldshmidt
b
 O. et al., 2002; Zester A. et al., 2004]. This finding obtained by 
western blot analysis suggested that heparanase when localised into the nucleus and into 
the lysosomes is stable and has a longer half-life time compared to heparanase free in the 
cytoplasm; for this reason it might be resistant to siRNA effect. 
 
Figure 4.11. Western blot analysis of heparanase subcellular localisation. 
Western blot analysis of subcellular localisation of heparanase in A204 and CME-1 cells transfected with 
negative control or siR06. Seventy-two h after transfection cells were lysated for nuclear/cytoplasm 
fractionation. HDAC1 and α-tubulin were used as loading control for nucleus and cytoplasm, respectively. 
Red arrows indicate the pre-proheparanase; blue arrows indicate the latent proheparanase; green arrows 
indicate the processed active heparanase. Heparanase, HPSE; Histone deacetylase 1, HDAC1; negative 
control, Neg Ctr. 
 
Results 
 
 
109 
The subcellular distribution of heparanase was also evaluated using IF microscopy in cells 
transfected with siR06 or the negative control. Heparanase was reduced in the cytoplasm of 
siR06 transfected cells, but not in the nucleus, confirming western blot results. It was also 
noticeable that heparanase accumulated in specific spots in the cytoplasm, likely 
corresponding to lysosomes, according to the study of Goldshmidt
b
, O. et al. (Figure 4.12). 
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Figure 4.12. Immunofluorescence analysis of heparanase subcellular localisation. 
Subcellular localisation of heparanase in A204 (A) and CME-1 (B) cells after transfection with negative 
control (Neg Ctr) and siR06. Seventy-two h after transfection cells were analysed by fluorescence 
microscopy. Bars represent 10 µm.  
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Overall, the observed effects of RNAi on intracellular and secreted heparanase indicated 
that pre-proheparanase was the most sensitive to the silencing, likely because it is the first 
one synthesised by the cells. After the synthesis, heparanase is commonly released in the 
extracellular space and this isoform was also affected by siRNA, as shown by ELISA. The 
latent proheparanase was found accumulated in the nuclei where it was protected and not 
affected by the silencing. Finally, heparanase processing occurs into the lysosomes [Zetser 
A. et al., 2004], where active endoglycosidase is sequestered and also in this compartment 
it was not sensitive to RNAi. It is conceivable that the segregation of heparanase in the 
nuclei or in the lysosomes increases the protein stability and consequently its half-life. 
 
4.2.5. Effects of siRNA on angiogenic molecules 
As mentioned above, heparanase plays an important role in tumour angiogenesis and 
invasion. Therefore, we examined the effect of heparanase silencing on angiogenesis-
related factors profile by using an antibody array system. Protein lysates obtained from 
transfected A204 or CME-1 cells were tested using a Human Angiogenesis Array Kit. In 
both cell lines, the down-regulation of heparanase induced a decline in the expression 
levels of bioactive molecules known to play a significant pro-angiogenic and pro-invasion 
role. In particular, the levels of Tissue Factor/Coagulation Factor III (TF), Chemokine (C-
X-C motif) ligand 16 (CXCL16) and CD26 were down-regulated in both A204 and CME-1 
cells (Figure 4.13).  
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Figure 4.13. Effects of siRNAs anti heparanase on angiogenic molecules in sarcoma cells. 
The levels of 55 angiogenesis related proteins were determined in A204 and CME-1 tumour cell lysates 
using a protein arrays after 72 h from the transfection. Every couple of filters probed with cell lysates 
treated with negative control or siR06 was taken from the same autoradiography film, as for each protein 
different exposure time was required. Negative control, Neg Ctr; uPA, Urokinase-type Plasminogen 
Activator. 
 
4.3. Nanoparticles as tools for RNAi delivery 
4.3.1. Design and characterisation of Hybrid Nanogel Particles  
The first delivery platform tested consisted of HNPs, originally synthesised to deliver RNA 
molecules into tumour cells. The nanoparticles for this project were synthesised and 
characterised by specialised personnel following the protocols of Khaled, who described 
HNPs for the first time in a paper published in Biomaterials [Khaled S.Z. et al., 2016]. I 
participated in the characterisation of HNPs and in vitro tests.  
These nanoparticles are characterised by a pH-responsive PDAEAM cross-linked hydrogel 
shell around a silica core (Figure 1.10). HNPs are known to be able to buffer and swell in 
acidic pH, thanks to the features of the hydrogel, however the properties of the HNPs need 
to be checked after each synthesis. Thus, DLS, ζ potential, and FT R analyses were used to 
evaluate size and surface charge, and to confirm the presence of the polymer of HNPs. The 
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synthesised nanoparticles had homogeneous solvated Dh (119 nm ± 6) and positive charge 
(5.3 mV ± 0.8) as measured at pH 7.4 in aqueous buffer, with PDI 0.168, a value which 
revealed an ideal homogeneity. Indeed, PDI values lower than 0.2 identify ideal 
homogeneity properties for nanoparticles. 
The vibrational modes and chemical signatures of HNPs, analysed through FTIR 
spectroscopy, showed the presence of a 10 nm PDAEAM shell around the silica core (data 
not shown). 
The pH-responsiveness was evaluated. Specifically, the ability of HNPs to buffer pH was 
demonstrated by a titration study in which 0.1 M HCl was gradually added to the HNPs in 
solvent (PB) or to HNPs-free solvent. Under these conditions, HNPs were found to 
increase the amount of acidic solution needed to reduce the pH of the buffer (Figure 4.14, 
A). 
To determine the ability of HNPs to change their size in response to pH variation, a 
suspension of 0.1 mg/mL HNPs was examined at different pH values using DLS. This 
analysis showed that the Dh of HNPs was inversely dependent on the environmental pH 
(Figure 4.14, B). The hydrogel buffering capability occurs through the protonation of the 
tertiary amines exposed on the nanoparticle surface, which results in swelling of the 
particles that became positively charged. In detail, the Dh of the HNPs increased from 117 
± 12 nm to 264 ±   nm as the environmental pH changed from 8 to 4. The ζ potential 
analysis showed that HNPs enhanced their positive charge as a consequence of shifting of 
the pH towards an acidic value, thereby confirming the protonation effect (Figure 4.14, C). 
Specifically, the particles charge increased from -9.1 ± 0.7 mV to 36.2 ± 2.5 mV as the 
environmental pH changed from 8 to 4. This phenomenon is known as “proton sponge 
effect” [Behr J.P., 1997] and it has been demonstrated to facilitate the escape of 
nanoparticles from endosomal vesicles [Pack D.W. et al., 2005]. 
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The nanoparticles were further characterised by AFM to validate the size of the particles 
measured with DLS and to investigate the surface changes in response to pH variations. 
The analysis of HNPs diluted in acidic or alkaline buffer confirmed the ability of HNPs to 
swell in acidic environment. The diameter of the particles in an acidic environment was 
63.8 nm ± 2.0, whereas in an alkaline environment was 48.8 nm ± 2.7. Viscoelastic 
properties of both acidic and alkaline HNPs were also investigated by calculating the 
Young’s modulus as a measure of the stiffness of the particles. The elastic modulus for 
acidic nanoparticles demonstrated an increase in stiffness when compared to alkaline 
particles (831 ± 25 kPa vs. 643 ± 16 kPa) (Figure 4.14, D). Overall, these analyses 
demonstrated the ability of HNPs to swell and acquire a positive charge, while buffering 
the surrounding environment through the protonation of the tertiary amines exposed on the 
particle surface.  
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Figure 4.14. pH responsiveness of HNPs. 
(A) The graph shows pH variation of phosphate buffer and phosphate buffer containing HNPs, after the 
gradual addition of 0.1 M HCl. (B) The line graph describes the size of the particles at different pH. (C) The 
line graph illustrates the surface charge of the system at different pH. (D) Representation of AFM topography 
maps and the corresponding Young’s modulus maps of HNPs at pH 4 and 8. Variation of the size and the 
Young’s modulus is represented in histograms on the right. 
 
4.3.1.1. In vitro biological effects of HNPs 
The human RT cell line A204 was used to evaluate the capability of HNPs to deliver 
siRNAs. First of all, the effects of the empty nanoparticles on cell viability were assessed. 
Cells were treated with HNPs at concentrations ranging from 0.01 to 10 ng/cell, and the 
cell viability was evaluated using the MTT assay after 72 h; it was observed that HNPs had 
a minimal effect on proliferation at concentrations ≤ 0.1 ng/cell (Figure 4.15, A). 
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The interaction of HNPs with the cell membrane and their internalisation were then 
examined. The surface interaction between particles and cell membrane was analysed by 
SEM after 15 min of treatment. HNPs displayed high affinity with the cell surface, 
resulting in membrane perturbations (Figure 4.15, B). The internalisation efficiency in 
A204 cells was evaluated by flow cytometry after cell exposure to fluorescent HNPs for 3 
h. The percentages of cells with internalised nanoparticles were 44.9 ± 3.0, 93.3 ±0.85 and 
42.0 ± 3.7 for cells treated with 0.01, 0.1 or 1 ng/cell, respectively (Figure 4.15, C). A 
concentration corresponding to 0.01 ng/cell was too low to achieve an optimal 
internalisation, whereas a concentration of 1 ng/cell was toxic and impaired viability. The 
intermediate concentration of 0.1 ng/cell was thereby used in further experiments. 
The effect of nanoparticles internalisation on cell cycle was analysed using flow 
cytometry. Treatment with HNPs induced a strong reduction of the G2/M phase and an 
accumulation of cells in the S phase (Figure 4.15, D).  
Furthermore, A204 cells displayed a significant slowing of migration capability 24 h after 
treatment with nanoparticles; this effect was reversible, because the cells fully resumed 
their ability to migrate 72 h after the nanoparticles uptake (Figure 4.15, E). These two 
effects might be linked with the intracellular accumulation of nanoparticles that interfere 
with the cytoskeleton functions, preventing cell division and motility. 
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Figure 4.15. Biological effects of HNPs on A204 cells. 
(A) Sensitivity of A204 cells to different concentrations of HNPs. The MTT assay was used to evaluate the 
cytotoxicity of HNPs on A204 cells exposed to increasing nanoparticles concentrations for 72 h. Untreated 
cells were used as control. The mean of at least three independent experiments is reported. (B) SEM analysis 
of A204 cells 15 min following particle treatment. Scale bars, 1 μm. (C) A204 cells where incubated with 
fluorescent nanoparticles for 3 h and then cells were harvested for flow cytometry. The percentage of cells 
with internalised fluorescent HNPs is represented in the graph. (D) Flow cytometric analysis of cell cycle 
profiles of A204 cells treated with HNPs. Cells were exposed to 0.1 ng/cell of nanoparticles for 3 h. After 24 
h cells were harvested, stained with propidium iodide, and analysed for perturbations in the cell cycle. The 
columns depict the percentage of cells in each cell cycle phase. (E) A204 cells ability to migrate towards a 
chemotactic gradient (serum). Cells were seeded on 8 µm cell culture insert following 3 h particle exposure 
(0.1 ng/cell). Migrated cells were counted after 24 and 72 h. 
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To reach its mRNA target, a siRNA must be released into the cytoplasm; therefore it is 
essential that nanoparticles escape the endo-lysosomal compartment. The capacity of 
HNPs to escape from the endo-lysosomal compartment was evaluated by fluorescence 
microscopy. The endo-lysosomal vesicles were stained with LysoTracker, a red-
fluorescent dye used for labeling and tracking acidic organelles in live cells. Fluorescent 
images were taken at different time points following treatment with FITC-labeled HNPs 
(0.1 ng/cell). HNPs displayed a partial colocalisation with LysoTracker after 3 h of 
exposure to nanoparticles, whereas they mainly colocalised with endo-lysosomal vesicles 
after 72 h (Figure 4.16, A). Given that around 50% (see Pearson’s correlation value) of 
nanoparticles were colocalised with acidic vesicles at 3 h, the remaining fraction was 
assumed to be cytoplasmic. The increase of Pearson’s correlation value at 72 h suggests 
the occurrence of re-internalisation of nanoparticles with time. 
The endo-lysosomal escape phenomenon was further investigated in endothelial HUVEC 
cells and a paper on this subject is currently under review at the journal Small. TEM 
analysis showed that the endo-lysosomal compartment was re-organised after nanoparticles 
internalisation. In detail, HNPs were shown to be incorporated into vesicles at 3 h and then 
they damaged the vesicle membranes and broke out from the endo-lysosomes. At later time 
points, (i.e., 24 and 72 h), TEM analysis showed the formation of multilamellar bodies 
around HNPs, likely an attempt to surround and sequester the particles (Figure 4.16, B).  
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Figure 4.16. HNPs endo-lysosomal escape. 
(A) Fluorescent microscope images showing the colocalisation of lysosomes and nanoparticles following a 3 
h treatment. Lysosomes are stained red (LysoTracker Red DND-99), HNPs are green (FITC) and nuclei are 
blue (Hoechst). Scale bars, 50 μm. (B) TEM images of HNPs compartmentalisation in endo-lysosomal 
vesicles in HUVEC cells at 3, 12, 24 and 72 h. Scale bar: 1 μm. 
 
4.3.1.2. In vitro HNP-delivery of siRNA 
Since siRNAs have negative charges on the phosphate backbone and HNPs have positive 
charges on the hydrogel surface in acidic pH, loading of siRNA is expected to be mediated 
by the electrostatic interaction between the positive charge of the hydrogel and the 
negative charge of the nucleic acid. The loading efficiency of the siRNA molecules was 
assessed at diverse pH conditions by spectrofluorimeter detection. The maximum 
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measured loading efficiency was nearly 95% at pH 6 whereas decreased at other pH 
values, being 59.5% at pH 5 and 19% at pH 7 (Figure 4.17, A). Therefore, the subsequent 
experiments were carried out loading the siRNA on HNPs at pH 6.  
For a siRNA to reach its target it is essential to have an efficient release from the carrier. A 
fluorescent siRNA release from HNPs was investigated in cell-free solutions at different 
pH representing physiologic (pH ~7), endosomal (pH ~6) or lysosomal (pH ~5) 
environments. After incubation, the cumulative siRNA released from the nanoparticle was 
measured over a period of 24 h. The release reached about 80% at pH 5, whereas the 
siRNA was mostly retained at pH 6 and 7 (Figure 4.17, B). Even if in acidic conditions the 
nanoparticles acquired a positive charge, the release of siRNA was higher at pH 5; it is 
conceivable that the shell, after swelling, had a broaden hydrogel net, allowing siRNA 
diffusion in the surrounding environment. In contrast, the siRNA was retained at higher pH 
even though siRNA had a lower electrostatic affinity for the hydrogel, probably because it 
was entrapped in the hydrogel structure that was tighter at pH 6 and 7, compared to pH 5 
(represented in Figure 4.17, C). 
To evaluate the capability of the HNPs to deliver siRNA into the cells, fluorescent 
microscopy analysis on A204 cells was performed 3 h after treatment with fluorescent 
siRNA-HNPs. This analysis showed that HNPs were able to deliver siRNA into the cells 
and about half of the nanoparticles still maintained the siRNA attached, as shown by the 
colocalisation of the red (Dy547-labeled siRNA) and the green (FITC-labeled HNPs) 
signals (Figure 4.17, D). 
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Figure 4.17. pH-driven siRNA/HNPs loading and release. 
(A) The graph shows siRNA loading efficiency at different pH. The histograms depict the percentage of 
loaded siRNA. (B) The graph shows the percentage of siRNA released at different pH. (C) Graphic 
representation of siRNA loading and release on HNPs. (D) Fluorescent microscopy analysis of intracellular 
delivery of Dy547-labeled siRNA (red) mediated by FITC-labeled HNPs (green) into A204 cells (WGA 
staining, fuchsia). Nuclei are blue (Hoechst). Scale bar 20 µm. Histogram represents the Pearson’s 
correlation value of the siRNA-HNPs colocalisation. 
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The ability of the HNPs to deliver active anti-heparanase siRNA was evaluated by treating 
the cells with siRNA-loaded HNPs compared to cells treated with scrambled siRNA-
loaded HNPs or empty HNPs, as negative controls. The expression level of the heparanase 
gene was analysed 72 h after treatment, using qRT-PCR (Figure 4.18, A). Despite the 
promising HNPs characteristics and delivery, heparanase silencing was not achieved by 
siRNA delivered through nanoparticles. 
In previous experiments it was demonstrated the ability of HNPs to load, release and 
efficiently deliver siRNAs into the cell cytoplasm, avoiding the endo-lysosomal 
compartment. Nevertheless, the system was not able to inhibit the expression of its target. 
One possibility is that the siRNA loaded onto the HNPs was not protected by the hydrogel 
from the environment and was released in an inactive form. Polyethylenimine (PEI) was 
then used to protect RNA during the loading on the silica core and the delivery to cells. 
PEI is a synthetic branched or linear polymer positively charged and able to buffer pH. The 
capability of PEI to protect siRNAs from degradation and to efficiently deliver siRNAs to 
the cell cytoplasm has already been described. [Jager M. et al., 2012]. The positive charges 
of PEI are responsible for the siRNA-PEI complex formation and favour cell 
internalisation. However, sometimes these complexes could lead to particles aggregation. 
In vivo administration of PEI causes toxicity due to the binding of free PEI with serum 
proteins and blood cells causing the formation of aggregates that interact with tissues or 
intracellular molecules inducing acute cell damage [Godbey W.T. et al., 2001]. To reduce 
PEI toxicity we conjugated the silica core with the siRNA-PEI complex, and tested these 
nanoparticles in A204 cells. Despite the ability of the sole PEI to deliver a functionally 
active siRNA, able to decrease heparanase mRNA, heparanase silencing was not achieved 
with PEI-silica nanoparticles as shown by qRT-PCR (Figure 4.18, B). Further studies have 
to be performed in order to optimise the transfection efficiency of the HNP/siRNA 
Results 
 
 
123 
complex in vitro. For this reason, we decided to test the biodistribution properties of those 
nanoparticles, but not their in vivo efficacy. 
 
Figure 4.18. Heparanase levels after nanoparticle-delivered siRNA. 
(A) Quantitative RT-PCR analysis of heparanase in A204 cells after transfection with negative control or 
anti-heparanase siRNA delivered with HNPs. (B) Quantitative RT-PCR analysis of heparanase in A204 cells 
after transfection with negative control or anti-heparanase siRNA delivered with PEI-silica or PEI alone. 
Expression levels are reported as Relative Quantification with respect to cells treated with empty 
nanoparticles (RQ = 1). The columns represent the mean and standard deviation of 3 experiments. GAPDH 
was used as housekeeping gene. HNPs loaded with negative control, Neg Ctr; HNPs loaded with anti-
heparanase siRNA, siHPSE; Relative Quantification, RQ. 
 
4.3.1.3. In vivo HNP-delivery of siRNA 
In parallel experiments, we evaluated the ability of HNPs to target the tumour and 
associated vessels in vivo. In particular, evaluation of nanoparticle delivery was performed 
in RT xenografts established by intra muscular injection of A204 cells previously used for 
in vitro studies. Mice harbouring A204 tumours were treated with FITC-labeled HNPs 
loaded with Dy547-labeled siRNA and followed for 2 h using intravital microscopy, IVM. 
An accumulation of HNPs at the tumour vasculature was observed. Moreover, the 
fluorescence of siRNA and HNPs overlapped, indicating the nucleic acid delivery in vivo 
(Figure 4.19, A). Explanted tumours were used for further IF analyses, which confirmed 
the presence of HNPs at the tumour site and stroma (Figure 4.19, B).  
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Figure 4.19. In vivo delivery of HNPs and siRNA. 
A) Representative IVM images of A204 tumour vessels at 2 h after HNPs administration. Green arrows 
indicate HNPs accumulated at the tumour vasculature. HNPs are green, siRNA is red, and vessels are white. 
Scale bar: 25 μm. B) Representative IF images of A204 tumour sections depicting the distribution of HNPs 
(green asterisks) into the vessels (CD31 staining, fuchsia), and released into the stroma (yellow asterisk) at 2 
h after nanoparticles administration. Scale bar: 100 μm.  
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4.3.2. Design and characterisation of leukosomes 
HNP-based approach mainly deals with exploiting a) polymers for siRNA complexation 
and b) passive targeting for tumour accumulation. As mentioned above, we explored a 
second approach, based on biomimetic liposome-like nanoparticles, called leukosomes 
(Figure 1.16). This approach relies on the encapsulation of siRNA into the aqueous core of 
leukosomes and on the accumulation of the siRNA/leukosome complex to the tumour site 
through an active targeting approach. 
Leukosomes were synthesised and characterised by specialised personnel. During my 
experience at the HMRI, I worked on the in vitro assays to test siRNA transfection 
efficiency. In a previous study, the leukosome synthesis method was shown to conserve the 
versatility and physico-chemical properties of liposomes, including the ability to load 
different compounds, while maintaining the structure of leukocyte membrane proteins, the 
ability to target inflammation and escape immune system clearance through the presence of 
proteins involved in adhesion (LFA-1, Mac-1, PSGL-1 and CD18), and self-tolerance 
(CD45 and CD47) [Molinaro R. et al., 2016]. Leukosomes synthesised for this thesis were 
122 ± 3.91 nm and charged -13.8 ± 2.71 mV, as measured by DLS and ζ potential 
analyses, with a low PDI 0.148 a value which revealed an ideal homogeneity. Indeed, PDI 
values lower than 0.2 identify ideal homogeneity properties for nanoparticles.  
 
4.3.2.1. In vitro biological effects of leukosomes 
The human RT cell line A204 was used to evaluate the ability of leukosomes to deliver 
siRNA into the cell cytoplasm. 
In preliminary experiments, the effect of empty leukosomes was assessed on cell viability. 
Cells were treated with these biomimetic nanoparticles at concentrations ranging from 0.5 
to 100 µM and the cell viability was evaluated with MTT assay after 72 h. At all tested 
concentrations, leukosomes were non-toxic for the cells (Figure 4.20, A). Further 
Results 
 
 
126 
experiments were carried out using 10 µM leukosomes, a concentration already used in the 
laboratory for in vitro studies. 
FACS analysis was applied to evaluate the internalisation of leukosomes and the effect on 
cell cycle. The internalisation efficiency of A204 cells was examined after cell exposure to 
rhodamine-labeled leukosomes (1-10 µM) for 3 h. The percentage of cells positive for 
rhodamine fluorescence was close to 80% for all the nanoparticle concentrations used 
(Figure 4.20, B). The treatment with leukosomes induced a mild effect on cell cycle with a 
slight increase of cells in S phase and decrease of those in G2/M phase (Figure 4.20, C).  
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Figure 4.20. Biological effects of leukosomes on RT cells. 
(A) The MTT assay was used to evaluate the cytotoxicity of leukosomes on A204 cells exposed for 72 h to 
increasing nanoparticles concentrations. The percent of viable cells was calculated by dividing absorbance at 
550 nm of treated cells by that of untreated cells and multiplied per 100. The mean of at least 3 independent 
experiments is reported. (B) A204 cells were exposed to rhodamine-labeled leukosomes for 3 h and then 
subjected to flow cytometry. Cells were treated with 1, 5 or 10 µM leukosomes for 3 h. The percentage of 
cells that had internalised nanoparticles is represented in the graph. (C) Flow cytometric analysis of the cell 
cycle profiles of A204 cells treated with leukosomes. After 24 h cells were harvested, stained with propidium 
iodide and analysed for perturbations in the cell cycle. The columns depict the percentage of cells in each 
phase.  
 
4.3.2.2. In vitro leukosome-delivery of siRNA 
Another series of preliminary experiments was performed to assess siRNA loading into 
leukosomes and its fate after delivery to the cells. The siRNA was loaded into leukosomes 
using Exo-Fect, a reagent able to transfect exosome-like vesicles with nucleic acids [Torri 
A. et al., 2017]. A Dy547-labeled siRNA was incubated with Exo-Fect and leukosomes; 
then the loading efficiency of the siRNA was evaluated by analysing the fluorescence 
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intensity of the encapsulated siRNA with a spectrofluorimeter. Loading efficiency was 
around 85% with siRNA amount ranging from 15 to 100 pmol (Figure 4.21, A). 
To possibly fulfil a therapeutic role, a siRNA has to be released into the cell cytoplasm, 
avoiding endo-lysosomal entrapment, a process depending on nanoparticle properties. 
Intracellular trafficking of siRNA-leukosomes was investigated by IF analysis, using 
Dy547-labeled siRNA, FITC-labeled leukosomes and LysoTracker to stain lysosomes. It 
was observed that most of the leukosomes rapidly fused with the cell plasma membrane, 
and the siRNA was subsequently released into the cytoplasm. Leukosome biology is 
similar to that of exosomes, and we hypothesised that they undergo the same mechanism of 
internalisation. It has been previously described that exosomes bind various cellular 
receptors of the recipient cell. After that, they may fuse with the cellular membrane or be 
endocytosed via phagocytosis, macropinocytosis or receptor-mediated endocytosis 
[McKelvey K.J. et al., 2015]. IF analysis demonstrated a similar behaviour for leukosomes. 
In fact, images taken at 3 and 24 h after treatment displayed an accumulation of green 
signal (FITC-labeled leukosomes) in correspondence of the cell membrane (Figure 4.21, 
B), and only a few particles were visible within the cells. This peculiar localisation was 
even more evident at 24 h. In addition, there was a negligible colocalisation of leukosomes 
with LysoTracker both at 3 and 24 h (Figure 4.21, C), indicating that leukosomes were able 
to avoid the endo-lysosomal compartment. The colocalisation between siRNA and 
leukosomes was low at 3 h and even lower at 24 h, suggesting that the siRNA was rapidly 
and mostly released, in a time dependent manner (Figure 4.21, D). Unexpectedly, the 
siRNA was partially colocalised with lysosomes, about 60% at 3 h and 40% at 24 h. To 
understand if this phenomenon was related to leukosome delivery, the fate of siRNA was 
evaluated after transfection with lipofectamine RNAiMAX. Also by this approach, a 
similar amount of siRNA was found colocalised with lysosomes (Figure 4.21, E and F). IF 
data were also used to calculate the amount of siRNA free in the cell cytoplasm. The 
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siRNA fraction colocalised with leukosomes or lysosomes was subtracted to total siRNA. 
The result indicated that the amount of siRNA available in the cytoplasm was slightly 
lower than 20% at 3 h and around 40% at 24 h (Figure 4.21, G). 
 
Figure 4.21. Leukosomes/siRNA trafficking. 
(A) The graph shows siRNA loading efficiency with different starting concentrations. (B) Fluorescent 
microscope images showing siRNA-leukosomes trafficking in A204 cells after a 3 h exposure. Lysosomes 
are white, leukosomes are green, siRNA is red and nuclei are blue. Scale bars, 50 μm. (C) Histogram depicts 
the Pearson’s correlation value regarding Leukosomes/lysosomes colocalisation. (D) Histogram depicts the 
Pearson’s correlation value regarding leukosomes/siRNA colocalisation. (E) Fluorescent microscope image 
showing the siRNA and the lysosomes following transfection with lipofectamine RNAiMAX. Lysosomes are 
white, siRNA is blue. (F) Histogram depicts the Pearson’s correlation value regarding siRNA/lysosomes 
colocalisation. (G) The graph shows the percentage of siRNA free in the cytoplasm. 
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After demonstrating the ability of leukosomes to load and deliver siRNA molecules into 
the cell cytoplasm, the efficacy of the anti-heparanase siR06, delivered through 
leukosomes, in targeting heparanase was investigated in A204 cells. Cells were treated 
with siR06-leukosomes, scramble siRNA-leukosomes, or empty leukosomes for 3 h. The 
expression level of heparanase mRNA was analysed using qRT-PCR 72 h after treatment 
(Figure 4.22, A, red bars). Heparanase silencing was not achieved by siRNA delivered 
through leukosomes.  
The following experiments were performed in the attempt to understand and overcome the 
lack of efficacy of the leukosome-siRNA complex. As leukosomes were negatively 
charged, we supposed that the repulsion between the negative charges of siRNA and 
nanoparticles was responsible for an incorrect siRNA loading. To overcome this possible 
limitation, leukosome formulation was modified to make the nanoparticles positively 
charged. The specific amount of the different phospholipids was changed to favour the 
interaction between the anionic phosphate groups of siRNA and the cationic nitrogen 
groups of the phospholipids. The newly synthesised leukosomes were 109.8 ± 2.4 nm and 
charge 16.2 ± 3.28 mV as measured by DLS and ζ potential, with a PD  0.151, In spite of 
this effort, heparanase silencing was not accomplished (Figure 4.22, A, green bars). 
To better understand the reason why leukosomes were not able to deliver active siRNA, 
DLS analyses of siRNA-leukosomes and empty leukosomes were compared. It was noticed 
that siRNA-loaded leukosomes were larger than empty nanoparticles and were negatively 
charged (siRNA-leukosomes: 216 ± 24.4 nm, -39.1 ± 4.29 mV). These data indicated that 
the siRNA was not encapsulated into the leukosomes core when transfected with Exo-Fect, 
but it was deposited onto their surface.  
To overcome this issue, we decided to fabricate leukosomes using the microfluidic-based 
platform (NanoAssemblr, Precision NanoSystem’s Technology) just acquired and set up in 
the Houston laboratory. With this device, the manufacture of nanoparticles occurs under 
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extremely controlled conditions and the mixing ratio, flow rate and lipid composition can 
be adjusted.  
For the synthesis, an ethanol solution containing the mixture of lipids and an aqueous 
solution containing siRNA and the leukocyte membrane proteins were injected into two 
separate channels of the NanoAssemblr and then the two solutions were mixed. During this 
process, the positive charges of the phospholipids interacted with the negative charges of 
the nucleic acid, allowing the encapsulation of siRNA into the leukosomes. This procedure 
led to the self-assembly of siRNA-leukosomes with a size of 127 ± 4.0 nm and a charge of 
1.36 ± 0.88 mV as measured by DLS and ζ potential, with a PD  0.121. Also with these 
new nanoparticles, heparanase silencing was not obtained (Figure 4.22, B, red bars). To 
exclude that the concurrent loading of siRNA and proteins into the NanoAssemblr might 
interfere with siRNA loading, siRNA-liposomes were fabricated with the same 
phospholipid formulation of leukosomes and tested in A204 cells. Even having eliminated 
proteins, siRNA-nanoparticles were not able to inhibit heparanase expression (Figure 4.22, 
B, green bars). 
As in preliminary experiments the delivery and the trafficking of siRNA-leukosomes were 
quite satisfying, we hypothesised that the siRNA was degraded or inactivated in some 
phase of the procedure, thereby being unable to target heparanase mRNA. 
In literature, PEI was conjugated with liposomes to reduce PEI toxicity and to achieve 
efficiently siRNA delivery [Ewe A. et al., 2017]. For this thesis, we conjugated both 
leukosomes and liposomes with siRNA-PEI complex, and tested these nanoparticles in 
A204 cells. Heparanase inhibition was obtained neither with PEI-liposomes nor with PEI-
leukosomes (Figure 4.22, C). 
Thus, despite the promising properties of leukosomes, in this thesis we demonstrated that 
the tested formulations of nanoparticles are not suitable for delivery of functional siRNA 
and that further optimisation of the encapsulation and release phases is required. 
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Figure 4.22. Heparanase mRNA levels after siRNA transfection with different nanoparticles. 
(A) Quantitative RT-PCR analysis after siRNA delivery with leukosomes and positively charged leukosomes 
(+) assembled by TLE. (B) Quantitative RT-PCR analysis after siRNA delivery with leukosomes and 
liposomes assembled with NanoAssemblr. (C) Quantitative RT-PCR analysis after siRNA delivery with 
leukosomes and liposomes conjugated with PEI. Expression levels are reported as Relative Quantification 
with respect to cells transfected with empty nanoparticles (RQ = 1). The columns represent the mean and 
standard deviation of three independent experiments. GAPDH was used as housekeeping control. 
Leukosome, leuko; liposome, lipo; NanoAssemblr, NA; negative control, Neg Ctr,; anti-heparanase siRNA, 
siHPSE; Relative Quantification, RQ. 
 
4.3.2.3. In vivo leukosome-delivery of siRNA 
In parallel, the ability of leukosomes to target the tumour and associated vessels was 
evaluated in an in vivo model. In vivo experiments were performed in the metastatic RT 
xenograft established by intramuscular injection of A204 cells. Mice harbouring A204 
tumours were treated with rhodamine-labeled empty leukosomes by intravenous 
administration and followed for 3 h using IVM. Leukosomes preferentially accumulated at 
the tumour site and were retained at least up to 3 h (Figure 4.23, A). It was also observed 
that leukosomes were able to target the lung metastasis, as assessed by confocal 
microscopy on a visible metastasis of explanted lungs, 3 h after leukosomes injection 
(Figure 4.23, B and C). 
The capability of leukosomes to deliver siRNA in vivo was also evaluated. FITC-labeled 
leukosomes loaded with Dy547-labeled siRNA where intravenously injected in mice 
harbouring A204 orthotopic tumours and followed for 3 h with IVM. The siRNA was 
maintained within nanoparticles for all the duration of the experiment (Figure 4.23, D) and 
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a fraction of siRNA-leukosomes was also able to extravasate outside the vessels (Figure 
4.23, E) as measured at the end of the experiment.  
Interestingly, it was observed that there were no empty leukosomes at early time points 
(i.e., from 0 to 30 min), and all the leukosomes were still carrying siRNA. After about 40 
min, empty particles were visible at the IVM microscope, meaning that some leukosomes 
were releasing the siRNA while still circulating in the vessels. 
The in vivo experiments demonstrated that leukosomes are able to target and accumulate at 
the tumour site; nonetheless a fraction of nanoparticles lost the cargo before extravasating 
from the vessels. 
Taken together, these results support that leukosomes formulation and synthesis require 
further refinement to be suitable for nucleic acid delivery. 
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Figure 4.23. In vivo delivery of leukosomes and siRNA. 
 (A) Representative IVM image of A204 tumour vessels at 3 h after leukosomes administration. Leukosomes 
are red, vessels appear green for auto-fluorescence. Scale bar: 20 μm. (B) Representative  F image of lung 
metastasis 3 h after leukosomes administration. (C) Picture of lung metastasis used for B. (D) Plot of the first 
3 h of leukosomes accumulation in A204 tumours. Error bars represent the standard deviation of 
measurements from at least 5 fields of views taken from 3 mice. E) Plot of leukosomes accumulation in lungs 
of A204 tumour bearing mice, 3 h after leukosomes administration. Error bars represent the standard 
deviation of measurements from at least 5 fields of views taken from 3 mice. 
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STSs are a heterogeneous group of over 50 histological subtypes of rare mesenchymal 
tumours, representing about 10% of tumours in paediatric age. Surgery, alone or in 
combination with chemotherapy and/or radiotherapy, is the best choice for local control 
whereas systemic treatment of advanced disease remains a challenge. In spite of the gold 
standard chemotherapy based on cytotoxic drugs, the prognosis for unresectable, recurrent 
or metastatic disease remains poor. Often, chemotherapy gives low response rates bringing 
acute and long term toxicity with it, which is particularly detrimental for children and 
adolescents. The high heterogeneity of sarcomas led to the current development of 
histology-driven, molecular targeted and immunomodulatory therapies also affecting the 
tumour stromal component [Noujaim J. et al., 2016]. The biomolecular complexity of 
sarcomas suggests that most of these tumours might not be dependent on a single 
targetable signaling pathway. Thus, innovative therapies should conceivably envision 
multi-targeted approaches and/or rational combination treatments, exploiting tumour 
dependence on its microenvironment as well. In this context, the heparanase/HSPG system 
plays a key role. In fact, the altered interplay between heparanase and its substrate HS in 
tumours disrupts the structural integrity of ECM and the homeostasis of several HS-
binding bioactive molecules, and influences cell adhesion and motility [Vlodavsky I. and 
Friedmann Y., 2001; Sanderson R.D. et al., 2017]. Thus, heparanase has been extensively 
investigated as a master regulator of cancer progression and a potential therapeutic target, 
although the multiple mechanisms of its involvement in different tumour processes have 
not been completely clarified [Vlodavsky I. et al., 2016; Couchman J.R. et al., 2016; 
Sanderson R.D. et al., 2017; Lanzi C. et al., 2017]. 
In this thesis work, we investigated the possibility to specifically down-regulate heparanase 
by RNAi approaches based on nanoparticle delivery, potentially exploitable therapeutically 
in STS models. In fact, previous studies carried out in our laboratory suggested that the 
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heparanase/HSPG system represents a promising therapeutic target in these tumours 
[Cassinelli G. et al., 2013; Cassinelli
b
 G. et al., 2016; Cassinelli G. et al., 2018]. 
The study was designed to inhibit heparanase expression in two human STS models, the 
rhabdoid tumour A204 and the synovial sarcoma CME-1, and to evaluate subsequent 
biochemical and biological effects. These cell lines were chosen because they both express 
high levels of heparanase and are well characterised by previous studies conducted in our 
laboratory [Cassinelli G. et al., 2013, Cassinelli
b
 G. et al., 2016, Cassinelli G. et al., 2018]. 
Moreover, both cell lines grow orthotopically, spontaneously disseminating to the lungs in 
SCID mice [(Figure 3.1.) unpublished data and Cassinelli G. et al., 2018], thereby 
providing the opportunity to investigate the effects of heparanase inhibition on tumour 
growth and distant dissemination. The RNAi approach, distinct from other heparanase 
targeting strategies under investigation, such as small molecules and antibodies, would in 
principle be able to reduce expression of intracellular and extracellular heparanase, as well 
as its enzymatic and non-enzymatic functions. Moreover, heparanase gene silencing, being 
a selective approach, in contrast with HS mimetics would allow gene function and 
biological effects to be linked. 
As a first approach, we evaluated the use of miR-1258 as an RNAi tool to down-regulate 
heparanase in the STS models. In fact, miR-1258 was previously found to correlate 
inversely with heparanase expression in clinical specimens of breast cancer and non small 
cell lung cancer [Tang D. et al., 2013; Liu H. et al., 2012]. In lung cancer, expression 
levels of miR-1258 and heparanase were significantly correlated to TNM staging and 
lymph node metastasis [Liu H. et al., 2012]. In breast cancer cell lines, miR-1258 levels 
correlated negatively with heparanase expression and enzymatic activity, as well as with 
the cell metastatic properties [Zhang L. et al., 2011]. Accordingly, in functional assays, 
lentiviral transfection of miR-1258 decreased heparanase expression and the in vitro 
invasive ability of brain metastatic breast cancer and lung cancer cells [Zhang L. et al., 
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2011; Liu H. et al., 2012]. In addition, stable expression of miR-1258 in brain metastatic 
breast cancer cells inhibited in vivo experimental metastasis [Zhang L. et al., 2011]. 
Despite several attempts in treating A204 and CME-1 cells with miR-1258 by transient 
transfection, we observed only a mild reduction of heparanase mRNA, which did not affect 
the protein levels. These findings suggested that miR-1258 is not relevant in the control of 
heparanase expression in our sarcoma models. 
As an alternative strategy to silence heparanase, we used commercially available siRNAs 
(siR04, siR05 and siR06). By this approach, heparanase was highly inhibited at mRNA 
level, and a partial down-regulation of the intracellular protein was also achieved, 
especially with siR04 and siR06. Moreover, these two anti-heparanase siRNAs were able 
to reduce extracellular secreted heparanase, as assessed by specific ELISA and enzymatic 
assays.  
The down-regulation effect of anti-heparanase siRNA on extracellular enzymatically active 
heparanase was in agreement with the observed inhibition of wound healing and Matrigel 
invasion capacity of both sarcoma cell lines. Vlodavsky and his group, in fact, 
demonstrated that heparanase secreted and retained at the cell surface is mainly responsible 
for the protein pro-invasive effect in vitro and is a major determinant in the control of 
tumour angiogenesis and metastasis [Goldshmidt
a
 O. et al., 2002]. Thereby, these findings 
suggest that heparanase RNAi may represent an exploitable strategy to counteract sarcoma 
progression. In line with our results, it has been recently reported that the invasive ability 
of A204 and CME-1 cells was reduced using small molecule heparanase inhibitors [Madia 
V.N. et al., 2018; Messore A. et al., 2018]. In addition, Cassinelli and collaborators showed 
a decrease of cell invasive ability and soft agar colony formation using other heparanase 
inhibitors, i.e., the HS mimetics SST0001 and supersulfated low molecular weight heparin 
[Cassinelli G. et al., 2013; Cassinelli
b
 G. et al., 2016; Cassinelli G. et al., 2018] in various 
sarcoma models, including CME-1. Interestingly, these effects were more marked than 
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those observed in the present study. This might be related to the double action of HS 
mimetics that inhibit heparanase and compete for HS-binding molecules. Thus, they can 
inhibit cell signaling also by blocking ligand-induced HS-dependent activation of cell 
surface receptors [Cassinelli
a
 G. et al., 2016] (Figure 5.1). 
 
Figure 5.1. HS mimetics mechanism of action. 
(A) Double action of HS mimetics, which inhibit heparanase and prevent the binding of bioactive molecule 
to HSPG. (B) HS mimetics block the activation of signaling pathways mediated by RTKs and heparanase 
released HS binding molecules. 
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It has been shown that intracellular heparanase is localised in the cytoplasm, mostly in 
lysosomes, and in the nucleus, where it exerts a multiplicity of functions [Goldshmidt
b
 O. 
et al., 2002; Zester A. et al., 2004; Shubert S.Y. et al., 2004; Nobuhisa T. et al., 2007]. 
Thus, we analysed the intracellular heparanase in subcellular fractions to investigate 
whether it was differently modulated by RNAi in specific cellular compartments. By 
western blotting and IF staining, the two mature forms of heparanase were found to 
segregate differently, with the latent 65 kDa heparanase localised mostly in the nucleus and 
the 50 kDa active form in the cytoplasm, the latter concentrated in spots likely 
corresponding to lysosomes. Heparanase in these two cellular compartments was not 
substantially affected by gene silencing, whereas, as expected, the primary transcript 
product, pre-proheparanase, was reduced by the siRNA. It was previously demonstrated 
that heparanase accumulates in a stable form within the lysosomes, where the acidic 
microenvironment provides suitable conditions for storage and optimal enzymatic activity 
[Goldshmidt
b
 O. et al., 2002]. It was also previously reported that, according to our 
findings, both the latent and the active heparanase forms are present in the nucleus, where 
the enzyme has been proposed to influence gene expression [Schubert S.Y. et al., 2004; 
Purushothaman A et al., 2011]. Our data indicate that heparanase is also present in the 
nucleus in a stable form resistant to siRNA-mediated silencing. 
Heparanase role in the tumour aggressive phenotype has been ascribed in part to its 
expression enhancing effect on genes that participate in angiogenesis and cell motility, e.g., 
VEGF, MMP-9, uPA/uPAR, TF, FGF-1 and -2 [Purushothaman A. et al., 2008; Cohen-
Kaplan V. et al., 2008; Nadir Y. et al., 2006; Madia V.N. et al., 2018; Messore A. et al., 
2018]. Heparanase can influence gene expression through indirect and direct mechanisms. 
An enzyme-independent signaling function has been described to activate protein kinases 
(e.g., Akt, Src) ultimately inducing the transcription of genes [Fux L. et al., 2009]. Nuclear 
heparanase enzyme activity has been implicated in the loss of syndecan-1 which activates 
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HAT activity and expression of genes, such as VEGF and MMP-9, promoting aggressive 
tumour behaviour [Purushothaman A. et al., 2011]. In the present study, siR06-mediated 
heparanase silencing was found to reduce expression of angiogenesis-related proteins such 
as TF, CXCL16 and CD26 in A204 and CME-1 cells, and of FGF-1 in A204 cells. Only 
mild inhibition of other factors previously described as regulated by heparanase such as 
VEGF, uPA and PDGF-AA was detected by protein array, suggesting that they could be 
regulated by the nuclear heparanase fraction which was not affected by gene silencing. In 
fact, the HS mimetic heparanase inhibitor SST0001 was previously shown to down-
regulate these molecules in A204 cells [Cassinelli G. et al., 2013]. 
Overall, these experiments demonstrated that heparanase silencing by siRNAs down-
regulates the secreted protein and inhibits invasiveness of sarcoma cells. Prolonged 
exposure to RNAi is likely to be needed to achieve the down-regulation of heparanase 
stored in lysosomes and nuclei. 
The second aim of this thesis was the optimisation of a delivery system for small nucleic 
acids (i.e., miRNA and siRNA) to target heparanase in STS cells. There is a great interest 
in the delivery of nucleic acids for therapeutic purposes, with the development of 
innovative approaches designed to reach the tumour site. The in vivo delivery of RNAi 
molecules has shown many challenges, because nucleic acids have poor stability (half-life 
lower than 10 min), off-target effects, and inefficient cellular entry when administered 
systemically [Juliano R.L., 2016]. In this context, nanotechnology offers a potent tool for 
the development of drug delivery systems with the ability to carry and protect such 
payloads. In fact, nanoparticles have been shown to enhance in vivo targeting properties, 
pharmacokinetics, half-life and bioavailability of therapeutic nucleic acids [Tatiparti K. et 
al., 2017]. In addition, the high versatility of nanoparticle formulations can in principle 
permit the co-encapsulation of different therapeutics and the transferability of this 
technology to various diseases.  
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Here, we used different nanodelivery platforms which, in principle, should be endowed 
with high versatility allowing, after a successful set up, the use of miRNA or siRNA to 
specific targets in different tumour types. 
The first nanoparticles examined in this study, HNPs, consisted of hybrid nanogel particles 
with a silica core covered with a polymeric shell responsive to pH shift, able to buffer and 
swell in acidic pH [Khaled S.Z. et al., 2016]. The hydrogel shell, due to its high 
hydrophilicity and elastic consistency, resembles living tissues and allows the release of 
the payload in a controlled manner. In fact, under specific physiopathological conditions 
(i.e., pH) the hydrogel swells and the payload is released mainly by diffusion [Ratner B.D. 
and Hoffman A.S., 1976; Hamidi M. et al., 2008]. However, the use of the sole hydrogel is 
limited by poor stability. For this reason, hybrid nanoparticles, consisting of a hydrogel 
shell (PDEAEM/PEGMA/TEGDMA) conjugated with a solid core (i.e., silica), were used 
to enhance the stability without affecting the biocompatibility and environmental 
responsiveness of the polymer [Yang J. et al., 2013]. 
The increase in size and the acquisition of a positive charge by HNPs under acidic 
conditions is known as “proton sponge effect”. We exploited this feature to load a siRNA. 
In fact, at acidic pH the structure of the HNP hydrogel was looser, allowing the 
incorporation of siRNA, and the positive charge acquired by the hydrogel determined the 
electrostatic binding with the siRNA. The pH-responsiveness also allowed endo-lysosomal 
escape. Indeed, the evaluation of in vitro effect of HNPs indicated that they were 
internalised in endosomes and accumulated in late endosomes and lysosomes, whose pH is 
gradually more acidic. The lowering of pH induced the swelling of HNPs that broke out 
from the endo-lysosomal membrane releasing their content into the cytoplasm. 
After the characterisation of the physico-chemical properties of HNPs, it is key to examine 
in vitro biological effects. As expected, we observed that HNPs were devoid of toxic 
effects, i.e., they did not impair the viability of A204 cells up to a precise concentration 
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(0.1 ng/cell). Cell treatment with this HNP concentration resulted in optimal 
internalisation, a phenomenon subsequent to interaction of the particles with the cell 
membrane, as supported by SEM images. In spite of the apparent lack of toxicity of HNPs 
at 0.1 ng/cell, a 3 h exposure to the nanoparticles with cell harvesting 24 h after treatment 
resulted in a marked cell cycle perturbation with increase of the S phase cell fraction and 
decrease of the G2/M phase cells. This observation suggests that cells slow down 
proliferation upon treatment with HNPs. However, given that no effect on cell viability 
was observed upon 72 h exposure to 0.1 ng/cell HNPs, it is likely that the cell cycle 
perturbation is a transient and reversible effect. This interpretation is in line with the 
observed slowing down of the cell migration capability, an effect that was also reversible. 
The subsequent in vitro evaluation of HNPs effects carried out by fluorescence microscopy 
tracking acidic organelles, showed a partial accumulation of HNPs in endo-lysosomal 
vesicles 3 h after treatment, implying that the remaining fraction of HNPs was in the 
cytoplasm. At a later time (i.e., 72 h), HNPs were mainly localised in acidic vesicles as 
supported by Pearson’s correlation values. These results imply that nanoparticle 
localisation in subcellular compartments is a dynamic process. In fact, a re-organisation of 
the vesicular compartment was also evidenced in endothelial cells, in which at 72 h after 
treatment HNPs were incorporated in vesicles presenting features of multilamellar bodies, 
as shown by TEM, suggesting that they will be extruded [Parodi A., Arrighetti N. et al., 
submitted]. In fact, multilamellar body formation has also been reported as the main source 
of exosomes, suggesting that cells constituted these vesicular formations around HNPs to 
extrude them within exosomes [Denzer K. et al., 2000]. It is conceivable that nanoparticles 
internalised in tumour cells undergo the same phenomenon; these findings support the 
hypothesis that the observed alteration of cell cycle and migration were due to the presence 
of nanoparticles free into the cytoplasm. Moreover, the restoration of physiological cell 
function may be a consequence of the sequestration of HNPs in multilamellar bodies. 
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To achieve efficient siRNA delivery, besides having proper subcellular localisation of 
nanoparticles, it is fundamental to obtain siRNA release. Although, under our in vitro 
experimental conditions, HNPs appeared to be able to release a fluorescent siRNA, 
functional studies with an anti-heparanase siRNA failed to achieve heparanase silencing. 
We hypothesised that the polymeric hydrogel shell of HNPs was not able to protect the 
siRNA functionality. Thus, we exploited a different polymer, polyethylenimine (PEI), 
already investigated for nucleic acid delivery [Kwok A. and Hart S.L., 2011; Buchman 
Y.K. et al., 2013]. We conjugated the PEI to the silica core with the aim to protect siRNAs 
from degradation. However, these modified nanoparticles also failed to deliver positive 
results in terms of heparanase silencing.  
When tested in vivo, HNPs had a prolonged circulation time. Indeed, 2 h after 
administration, the nanoparticles were still detectable in the tumour by IVM. During this 
time, the siRNA was maintained attached to the nanoparticles throughout the experiment. 
The prolonged circulation time shown by these nanoparticles is advantageous for the 
accumulation of the therapeutics at the tumour site obtained through the enhanced 
permeability and retention effect. 
Nevertheless, given the disappointing results obtained in vitro with HNPs, we decided not 
to pursue the HNPs and to evaluate a different platform based on biomimetic nanoparticles 
(i.e., leukosomes) that was already under investigation at the HRMI.  
Biomimetic nanoparticles are expected to substantially advance the current paradigm used 
for particle targeting and shielding relying on synthetic routes (e.g., functionalisation with 
antibodies, peptides or hydrophilic polymers). Biomimetic nanoplatforms may allow the 
delivery and sustained release of a myriad of therapeutics to tumour tissues. The 
technology is based on the synergistic combination of nanotechnology and cancer cell 
biology. 
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Leukosomes are liposome-like nanoparticles obtained by the complexation of leukocyte 
membrane proteins, extracted from purified circulating leukocytes, and synthetic 
biocompatible phospholipids. Membrane proteins protect leukosomes from immune 
response recognition and favour the adhesion and margination to the endothelium 
[Molinaro R. et al., 2016]. In previous studies, leukosomes were shown to exhibit a 
predisposition to target inflamed endothelium and accumulate at tumour sites exhibiting 
intrinsic anti-inflammatory properties [Corbo C. et al., 2017; Martinez J.O. et al., 2018]. 
Besides, leukosomes have a structure and composition similar to those of exosomes, which 
are natural carriers of nucleic acids [Valadi H. et al., 2007]. Owing to their exosome-like 
structure, leukosomes undergo the same internalisation mechanisms, such as fusion with 
cell membrane, endocytosis or receptor mediated internalisation [McKelvey K.J. et al., 
2015] (Figure 5.2). Based on these favourable features, we decided to test leukosomes for 
siRNA delivery. Leukosomes were first synthesised with the well-established TLE method 
and then loaded with the siRNA using the transfection reagent Exo-Fect. In this way, 
leukosomes by avoiding endo-lysosomal entrapment might release their cargo into the cell 
cytoplasm, where siRNAs accomplish their inhibitory function. 
 
Figure 5.2. Exosome internalisation mechanisms. 
 (A) Ligand-receptor mediated; (B) fusion with cell membrane  (C) endocytosis [van Balkom B.W. et al., 
 2011]. 
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In vitro evaluation of the biological effects of leukosomes indicated that, similarly to 
HNPs, they did not affect cell viability after long-term exposure (i.e., 72 h) and that they 
are internalised efficiently producing a mild perturbation of the cell cycle. The analysis of 
the siRNA-leukosome trafficking in tumour cells showed that these biomimetic 
nanoparticles avoid the endo-lysosomal compartment and suggested that a fraction of 
siRNA was free in the cytoplasm, showing that indeed the small nucleic acid could be 
released and made available to interact with the target. Although this biomimetic platform 
was considered optimised for siRNA delivery, the results that we obtained in functional 
studies with an anti-heparanase siRNA indicated that the delivered siRNA was somehow 
inactivated. Interestingly, we observed a high colocalisation of fluorescent siRNA and 
lysosomes. To investigate whether siRNA sequestration was the reason for the lack of 
efficacy, we compared the fluorescent analysis of leukosome/siRNA with those of 
lipofectamine RNAiMAX/siRNA, the standard method for in vitro transfection. The 
comparison showed a similar amount of siRNA retained into lysosomes, so we excluded 
that this was the reason why heparanase expression was not inhibited with leukosomes 
transfection. Thus, we hypothesised that siRNA was compromised during the loading or 
delivery phases. 
As the first synthesised leukosomes were negatively charged, and this could interfere with 
the loading of siRNA, in turn negatively charged, we developed a second type of 
leukosomes carrying a positive charge, ascribable to specific phospholipids. Further 
experimental effort supported the view that an incorrect encapsulation of the siRNA, 
deposited onto the leukosomes surface, instead of being encapsulated into them, was also 
the reason for our failure to silence heparanase with this alternative type of leukosome. 
To overcome this issue, a new generation microfluidic approach, NanoAssemblr, was used 
for leukosome synthesis as it allows the encapsulation of siRNA during the synthesis 
phase, preventing the use of Exo-Fect. Since in this case, heparanase silencing was also not 
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obtained, we hypothesised that the leukocyte proteins within the leukosome membrane 
were somehow compromising the siRNA stability. To verify this hypothesis we also tested 
siRNA-liposomes without achieving heparanase silencing.  
In additional experiments, we used PEI to protect siRNA during the loading of both 
leukosomes and liposomes, as previously shown in literature [Kwok A. and Hart S.L., 
2011]. However, an appropriate formulation of these nanoparticles for delivery of 
functional siRNA was not obtained. 
Finally, although in vivo testing in mice xenografted with A204 cells evidenced promising 
features of leukosomes, i.e., ability to accumulate at primary tumour and metastatic sites, 
leukosomes appear to require further optimisation before being considered suitable for 
delivery of small nucleic acids. 
Taken together, as far as nanoparticles are concerned, the results obtained during this thesis 
project support the view that, once the physico-chemical properties of nanoparticles are 
optimised, additional efforts will be needed before formulations useful for in vitro and, 
ultimately, in vivo delivery of RNAi molecules will be obtained. In this regard, besides the 
evaluation of the internalisation and subcellular distribution, it appears to be mandatory to 
address siRNA functionality maintenance. 
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6.CONCLUSIONS & FUTURE 
PERSPECTIVES 
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To identify a heparanase RNAi molecule effective in rhabdoid tumour and synovial 
sarcoma models, we tested a previously described heparanase miRNA, miR-1258, and 
commercially available validated siRNAs. Whereas miR-1258 did not produce a 
substantial reduction of heparanase expression by transient transfection in our sarcoma cell 
lines, the siRNAs effectively down-regulated expression and enzymatic activity of secreted 
heparanase. These effects were reflected in inhibition of sarcoma cell invasiveness and 
anchorage-independent growth, supporting the pro-metastatic role of secreted heparanase. 
In contrast, intracellular fractions, including lysosomal and nuclear heparanase, appeared 
to be resistant to transient siRNA silencing suggesting that their down-regulation likely 
requires a prolonged cell exposure to RNAi. This aspect needs further investigation. 
The two delivery nanoplatforms tested in this thesis work, HNPs and biomimetic 
leukosomes, showed promising features in terms of in vivo targeting to the tumour and 
metastatic sites. However, their application for siRNA delivery still needs adjustments 
specifically addressing how to preserve the functionality of RNAi molecules.  
After further optimisation, these innovative platforms may represent versatile tools 
available to hit various targets in different tumour types. 
The results presented here may provide a starting point for future investigations. 
The heparanase compartmentalisation evidenced in cell fractionation studies indicated a 
high stability of the protein in lysosomes and nuclei. This aspect should be deeply 
investigated in order to clarify the role of the enzyme in those compartments, specifically 
in relation to the suggested implication of heparanase in autophagy and gene transcription. 
Indeed, a better understanding of these functions is highly relevant in view of the 
therapeutic targeting of heparanase. The use of repeated transfections or stable silencing 
will be fundamental to enable the reduction of heparanase in all sub-cellular compartments. 
Conclusions 
 
 
150 
Heparanase silencing reduced the expression of some angiogenesis-related factors as 
shown by protein array analysis. The validation of these effects using different techniques 
(i.e., real-time and western blotting) will be required to confirm their dependence on 
heparanase.  
The heparanase/HSPG axis modulates a multiplicity of pathways in both tumour and 
microenvironment that have not been completely clarified. To elucidate the specific effects 
induced by this axis inhibition on downstream pathways in sarcoma, it may be useful to 
compare the effects achieved using different inhibitory approaches, for example siRNAs, 
small molecules or HS mimics. The identification of specific pathways altered by the 
heparanase/HSPG system will be useful for the rational design of new combinatorial 
treatments to counteract sarcoma progression.  
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